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A B S T R A C T
Background
This review focuses on non-dispensing services from pharmacists, i.e. pharmacists in community, primary or ambulatory-care settings,
to non-hospitalised patients, and is an update of a previously-published Cochrane Review.
Objectives
To examine the effect of pharmacists’ non-dispensing services on non-hospitalised patient outcomes.
Search methods
We searched CENTRAL, MEDLINE, Embase, two other databases and two trial registers in March 2015, together with reference
checking and contact with study authors to identify additional studies. We included non-English language publications. We ran top-
up searches in January 2018 and have added potentially eligible studies to ’Studies awaiting classification’.
Selection criteria
Randomised trials of pharmacist services compared with the delivery of usual care or equivalent/similar services with the same objective
delivered by other health professionals.
Data collection and analysis
We used standard methodological procedures of Cochrane and the Effective Practice and Organisation of Care Group. Two review
authors independently checked studies for inclusion, extracted data and assessed risks of bias. We evaluated the overall certainty of
evidence using GRADE.
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Main results
We included 116 trials comprising 111 trials (39,729 participants) comparing pharmacist interventions with usual care and five trials
(2122 participants) comparing pharmacist services with services from other healthcare professionals. Of the 116 trials, 76 were included
in meta-analyses. The 40 remaining trials were not included in the meta-analyses because they each reported unique outcome measures
which could not be combined. Most trials targeted chronic conditions and were conducted in a range of settings, mostly community
pharmacies and hospital outpatient clinics, and were mainly but not exclusively conducted in high-income countries. Most trials had
a low risk of reporting bias and about 25%-30% were at high risk of bias for performance, detection, and attrition. Selection bias was
unclear for about half of the included studies.
Compared with usual care, we are uncertain whether pharmacist services reduce the percentage of patients outside the glycated
haemoglobin target range (5 trials, N = 558, odds ratio (OR) 0.29, 95% confidence interval (CI) 0.04 to 2.22; very low-certainty
evidence). Pharmacist services may reduce the percentage of patients whose blood pressure is outside the target range (18 trials, N =
4107, OR 0.40, 95% CI 0.29 to 0.55; low-certainty evidence) and probably lead to little or no difference in hospital attendance or
admissions (14 trials, N = 3631, OR 0.85, 95% CI 0.65 to 1.11; moderate-certainty evidence). Pharmacist services may make little or
no difference to adverse drug effects (3 trials, N = 590, OR 1.65, 95% CI 0.84 to 3.24) and may slightly improve physical functioning
(7 trials, N = 1329, mean difference (MD) 5.84, 95% CI 1.21 to 10.48; low-certainty evidence). Pharmacist services may make little
or no difference to mortality (9 trials, N = 1980, OR 0.79, 95% CI 0.56 to 1.12, low-certaintly evidence).
Of the five studies that compared services delivered by pharmacists with other health professionals, no studies evaluated the impact of
the intervention on the percentage of patients outside blood pressure or glycated haemoglobin target range, hospital attendance and
admission, adverse drug effects, or physical functioning.
Authors’ conclusions
The results demonstrate that pharmacist services have varying effects on patient outcomes compared with usual care. We found no
studies comparing services delivered by pharmacists with other healthcare professionals that evaluated the impact of the intervention
on the six main outcome measures. The results need to be interpreted cautiously because there was major heterogeneity in study
populations, types of interventions delivered and reported outcomes.There was considerable heterogeneity within many of the meta-
analyses, as well as considerable variation in the risks of bias.
P L A I N L A N G U A G E S U M M A R Y
Can services delivered by pharmacists improve patient health?
What is the aim of this review?
To test whether services provided by pharmacists improve patient health. We identified 116 studies to answer this question.
Key messages
Some services provided by pharmacists can have positive effects on patient health, including improved management of blood pressure
and physical function. The pharmacist services did not reduce hospital visits or admissions. Services delivered by pharmacists produced
similar effects on patient health compared with services delivered by other healthcare professionals.
What was studied in the review?
Pharmacists deliver a wide range of services to patients. We need to know which pharmacist services are effective in helping patients to
improve their health. This review included studies of pharmacist services for a wide range of conditions including high blood pressure
and diabetes. The review measured the effect of these services on benefits (improved health outcomes) as well as harms (unplanned
hospital admissions, adverse drug effects).
What are the main results of the review?
We found 116 relevant studies which involved 41,851 participants. Studies were conducted in 25 countries with the USA, UK, Canada
and Australia contributing most studies. Many were conducted in community pharmacies (chemist shops) and hospital outpatient
clinics. The studies compared services delivered by pharmacists with either usual care or with care delivered by other health professionals.
The studies were of overall high quality, although some had problems because they did not include all the relevant information needed
to assess quality.
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Of the 111 studies that compared pharmacist services with usual care, 47 studies reported the most important outcomes. Compared
with usual care, pharmacist services may reduce the percentage of patients whose blood pressure is outside the target range. It is
uncertain whether services delivered by pharmacists reduce the number of patients with glycated haemoglobin levels outside the target
range, because the certainty of the evidence is very low. Pharmacist services may make little or no difference to hospital attendance or
admissions or to adverse drug effects or to death rates. Pharmacist services may slightly improve physical functioning.
We found no studies comparing services delivered by pharmacists with other healthcare professionals that evaluated the impact of the
intervention on the six main outcome measures.
How up-to-date is this review?
We searched for studies that had been published up toMarch 2015. We ran top-up searches in January 2018 and have added potentially
eligible studies to ’Studies awaiting classification’.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pharmacists’ non-dispensing roles targeting non-hospitalised patients compared with the delivery of no comparable service for health problem or population
Patient or population: Health problem or populat ion
Setting: Outpat ient sett ings
Intervention: Pharmacist services target ing pat ients
Comparison: Delivery of no comparable service
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with the delivery of no
comparable service
Risk with Pharmacist ser-
vices targeting patients
% outside blood pressure
range
Study populat ion OR 0.40
(0.29 to 0.55)
4107
(18 randomised trials)
⊕⊕©©a,b,c,d
LOW
550 per 1000 328 per 1000
(261 to 402)
% outside HbA1c range Study populat ion OR 0.29
(0.04 to 2.22)
558
(5 randomised trials)
⊕©©©b,d,e,f
VERY LOW
782 per 1000 509 per 1000
(125 to 888)
Hospital at tendance/ ad-
mission
Study populat ion OR 0.85
(0.65 to 1.11)
3631
(14 randomised trials)
⊕⊕⊕©b
MODERATE
214 per 1000 188 per 1000
(150 to 232)
Adverse drug ef fects Study populat ion OR 1.65
(0.84 to 3.24)
590
(3 randomised trials)
⊕⊕©©b,g
LOW
139 per 1000 211 per 1000
(120 to 344)
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SF-36 Physical Funct ioning The mean SF-36 Physical
Funct ioning was 53.2
MD 5.84 higher
(1.21 higher to 10.48
higher)
- 1329
(7 randomised trials)
⊕⊕©©b,g
LOW
Mortality Study populat ion
137 per 1000 111 per 1000 (81 to 150) OR 0.79 (0.56, 1.12) 1980 (9 randomised trials) ⊕⊕©©b,g
LOW
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io; MD: Mean dif ference
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the evidence by one level because of serious inconsistency.
bWe downgraded the evidence by one level because of serious indirectness of evidence.
cWe downgraded the evidence by one level because of suspected publicat ion bias.
dWe upgraded the evidence by one level because of the magnitude of the ef fect.
eWe downgraded the evidence by two levels because of very serious inconsistency.
fWe downgraded the evidence by two levels because of very serious imprecision.
gWe downgraded the evidence by one level because of serious imprecision.
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B A C K G R O U N D
The roles of pharmacists in patient care have expanded from the
traditional tasks of dispensing medications and providing basic
medication counselling to working with other health profession-
als and the public. This has led to greater involvement of phar-
macists across full health systems including in community phar-
macies, general medical practices and hospitals. Recent systematic
reviews have identified benefits of pharmacist-provided services in
terms of patient outcomes and have included the effect of phar-
macists in low-income countries (Pande 2013), targeting patients
with specific conditions (Greer 2016; Koshman 2008) and risk
factors (Altowaijri 2013; Charrois 2012) at specific stages in their
journey of care (Mekonnen 2016; Walsh 2016) and with specific
services (Hatah 2014; Jokanovic 2017). This systematic review
focuses on services provided by pharmacists to non-hospitalised
patients, i.e. individuals living in community or ambulatory-care
settings, with any clinical condition. The previous version of this
review (Nkansah 2010) included interventions to influence pa-
tient outcome and healthcare professional behaviour. Due to the
high numbers of new eligible studies that were identified for this
update, the review was split and this current version includes only
trials which report the effect of pharmacist interventions on pa-
tient outcome.
Description of the condition
Wecover awide range of health conditions in this review, including
chronic diseases, e.g. hypertension, diabetes, asthma. In addition,
the patient populations varied, e.g. hospital outpatients, people
living in the community.
Description of the intervention
A range of single or combined interventions (Michie 2014) can
be delivered by pharmacists to improve patient outcomes. These
can include medication reviews to assess the safety and effective-
ness of current medication regimens and to identify medicines
which need to be stopped or treatment which should be started.
Pharmacists can provide educational interventions to improve pa-
tients’ knowledge of the medicines, and persuasive techniques to
encourage them to use their medications effectively. Pharmacist-
led interventions can also train and enable patients to administer
their medication to optimise their health outcomes.
How the intervention might work
Different interventions can achieve their effect by different mech-
anisms of action. For example, education-based interventions
(Michie 2014) could provide patients with the knowledge they
need to use their medicines effectively and thereby achieve im-
proved health outcomes, e.g. lowered blood pressure, improved
glycated haemoglobin management. During medication reviews,
pharmacists could identify medicines which are likely to cause
harm which could then be stopped, thereby reducing adverse
events arising including unscheduled hospital admissions.
Why it is important to do this review
This systematic review focuses on non-dispensing services pro-
vided by pharmacists to non-hospitalised patients. Health systems
in many countries struggle to meet patients’ healthcare needs. In-
novative services are therefore needed to increase capacity and
optimise patient outcomes. Pharmacists are society’s experts on
medicines and medicines are the most commonly-used therapeu-
tic intervention. The optimal use of medicines should enhance
patient outcome and minimise medicine-related harm. It was im-
portant to undertake this review because large numbers of trials
have been conducted to explore the effect of pharmacist services
on the health outcomes of non-hospitalised patients and these data
needed to be synthesised to derive evidence of their effectiveness
compared with usual care, as well as compared with similar ser-
vices delivered by other health professionals. This is an update of
previous versions of this review (Bero 1995; Beney 2000; Nkansah
2010).
O B J E C T I V E S
To examine the effect of pharmacists’ non-dispensing services on
non-hospitalised patient outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials. Both patient-randomised and clus-
ter-randomised trials were eligible for inclusion. We did not re-
strict by language or publication status.
Types of participants
Any individual who received services from outpatient pharma-
cists. Pharmacists included community pharmacists, pharmacists
working in other primary care settings, e.g. general medical prac-
tices, as well as pharmacists who provide services to hospital out-
patients. We included studies where pharmacists delivered services
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to outpatients in a clinic attached to a hospital or a day hospital.
We excluded studies involving services to hospital inpatients or
residential care facilities. We included studies if the patients were
recruited as inpatients or at discharge, but where the interven-
tion was conducted in an outpatient setting. Any health condition
could be included. We included study participants of any age.
Types of interventions
The types of interventions we included were any services delivered
by pharmacists other than drug compounding or dispensing. We
included interventions if they sought to improve patient health
through the use or cessation of medication. We included multi-
disciplinary interventions if either (a) the multidisciplinary team
was led by a pharmacist or (b) most (> 50%) of the intervention
was delivered by pharmacists. This latter criterion excluded inter-
ventions where the pharmacist played only a minor role in the
intervention.
We excluded some intervention types that have recently been ad-
dressed in Cochrane and other systematic reviews (e.g. Sinclair
2004), and all health promotion interventions, as well as inter-
ventions which were solely focused on medication adherence and
automated care programmes.
We made two types of comparison:
• Pharmacist services targeting non-hospitalised patients
compared with the delivery of no comparable service for the
health problem or population.
• Pharmacist services targeting non-hospitalised patients
compared with services delivered by other health professionals
for the health problem or population.
Types of outcome measures
We included a broad range of outcome measures associated with
health, service utilisation and healthcare-related harm.We selected
commonly-used objective outcomes to facilitate comparison and
meta-analysis. Outcomemeasure selectionwas informed by guide-
lines and discussionwith clinicians with expertise in specific condi-
tions. For example, we sought national or international guidelines
to identify the clinical outcomes most frequently used in disease
management.Where no clear evidence was available to inform our
decision-making process, we consulted one or more clinicians to
determine the most meaningful outcome measures used in every-
day practice. For completeness, we have included trials which ful-
filled the above inclusion criteria but which did not present data
on the outcome measures of interest.
Main outcome measures
We evaluate six main outcome measures in this review: percentage
outside blood pressure range as defined by the study authors; per-
centage outside glycated haemoglobin (HbA1c) range as defined
by the study authors; hospital attendance/admission; adverse drug
effects; SF-36 physical functioning (Ware 1989); and mortality.
We present these outcomes in Summary of findings for the main
comparison.
Other outcome measures
We also include other frequently-reported outcome measures in
meta-analyses when available e.g. systolic and diastolic blood pres-
sure, glycated haemoglobin.
Search methods for identification of studies
Previous versions of this review involved both automated searches
based on key terms and manual searches of relevant journals and
conference abstracts. In this update, we included all studies in-
cluded in previous versions that met the revised inclusion crite-
ria, as well as all studies identified from a new electronic database
search.
Electronic searches
We conducted systematic searches in the following databases to
March 2015, without language restrictions:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, issue 2) via Ovid;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, issue 2) via Ovid;
• Cochrane Health Technology Assessment database (HTA;
2015, issue 2) via Ovid;
• Cochrane NHS Economic Evaluations Database
(NHSEED; 2015, issue 2) via Ovid;
• MEDLINE (Ovid) (including Epub Ahead of Print, In-
Process & Other Non-Indexed Citations) (1946 to 2015)
• Embase (Ovid) (1974 to 2015)
• CINAHL (EBSCO) (1981 to 2015)
• ProQuest Dissertations & Theses Global (including UK &
Ireland) (1861 to 2015)
We present search strategies in Appendix 1.We translated non-En-
glish publications prior to data extraction. We ran top-up searches
in 2018 and added potentially eligible studies to ’Studies awaiting
classification’.
Searching other resources
We also searched:
• ongoing or unpublished trials in the International Clinical
Trials Registry Platform (ICTRP) ( apps.who.int/trialsearch/),
and in ClinicalTrials.gov, US National Institutes of Health (
NIH) ( clinicaltrials.gov/).
We followed Cochrane recommendations for additional search
methods by:
• Reviewing reference lists of all included studies and relevant
systematic reviews.
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• Contacting authors of relevant studies/reviews to clarify
reported published information (as described above) and to seek
unpublished results/data.
Data collection and analysis
Selection of studies
Two review authors (MdBa, CS) independently assessed trials for
inclusion in the review. We screened the titles/abstracts to elimi-
nate obviously irrelevant studies. We retrieved the full text of each
potentially relevant article and combined multiple reports on the
same study. We assessed the full-text articles against the inclu-
sion criteria. If the two primary assessors did not reach agreement
through discussion, we consulted a third study author (MCW).
We reassessed studies included in the previous version of this re-
view for continued eligibility for inclusion in the update.
Data extraction and management
Review author pairs (MdBa, CS and PR, AW) independently ex-
tracted data from all newly-identified studies. We extracted data
using a modified version of the EPOC Data Extraction Checklist
(EPOC2017a). To streamline the data collection process, we built
a data entry database using the Epi Info platform (Epi Info 2010)
available for reference/use on figshare.com research repository (De
Barra 2016). We contacted study authors for additional material
if necessary. A third assessor (MCW) resolved any discrepancies.
We re-assessed studies included in the previous version of this re-
view for continued eligibility for inclusion in the update. We ex-
tracted additional data from studies included in the previous re-
view that met the eligibility criteria for this update. We captured
details on the content, format and delivery of the intervention.
For newly-identified studies, where necessary we contacted study
authors. We also extracted data for the clinical condition targeted,
the number of participants and their demographics, outcomemea-
sures, setting and country. We also retrieved the type and number
of pharmacists involved.
Assessment of risk of bias in included studies
Two review authors (MdBa, CS) independently assessed the risks
of bias of all studies eligible for the review, using the Cochrane
’Risk of bias’ tool (Chapter 8, Cochrane Handbook for Systematic
Reviews of Interventions (CochraneHandbook)) (Higgins 2011).We
resolved discrepancies by discussion. We scored performance bias
as low risk if the personnel delivering the intervention were blind
to allocation, or if it was unlikely that intervention delivery sys-
tematically differed from the described methods due to knowl-
edge of allocation. We scored detection bias as low risk if the as-
sessor was blind to the participant’s condition or if the outcome
involved little or no subjective estimation of true outcome level
(e.g. low density lipoprotein (LDL) measures or hospitalisations).
Where the assessor was not blinded and the outcome assessment
involved subjective estimation (e.g. quality-of-life measures, man-
ual sphygmomanometer, ’falls’ where these were undefined), we
scored risk of detection bias as high. We assessed attrition bias
using the holistic approach to judging recommended in Section
8.13 of the Cochrane Handbook (Higgins 2011). Studies with dif-
ferential attrition bias < 10% were low risk if total attrition was <
80% and the causes for missing data appeared similar across study
arms. Studies that reported intention-to-treat analyses were scored
low risk. We describe the ’Risk of bias’ characteristics for included
studies in the Characteristics of included studies table.
Measures of treatment effect
Where data were reported at multiple time points, we used data
reported at 12 months (or the closest time point to 12 months).
Continuous outcomes
We extracted a combination of baseline and final-score data for
continuous outcomes. We included final-score data if available,
with the mean difference (MD) in final scores used as the measure
of treatment effect. If only data from change scores were available,
we used these in the meta-analyses.
Binary outcomes
For binary outcomes, we used the odds ratio (OR) as the measure
of treatment effect. We framed the outcomes so that an event was
negative rather than positive, so that ORs less than one always
favour the pharmacist group.
Overall effect size
We calculated a standardised effect size for each study (see ’Main
outcome measures’).
For continuous outcomes, we calculated the standardised mean
difference (SMD) (also known as Hedges’ g) to represent the dif-
ference between groups on a standardised scale. For binary out-
comes, we calculated the log odds ratio, using the method rec-
ommended in the Cochrane Handbook 9.4.6 to convert this to an
SMD by multiplying it by 0.5513 (Chinn 2000; Higgins 2011).
We transformed effect sizes if necessary so that values less than
zero always favour the pharmacist group.
Although we used a mixture of final scores and change scores
for continuous outcomes, following the advice of the Cochrane
Handbook 9.4.5.2 we did not do this for the SMD outcome. If a
study only reported change scores for the planned outcome, then
we chose a different outcome if possible, or we dropped the study
from the SMD analysis.
We could not calculate effect sizes for every study. For example,
this situation arose if no useable quantitative data were available
or if only medians were available.
Meta-analysis outcomes
We undertook meta-analyses of the six main outcome measures.
We included these six outcomes in the GRADE assessment. We
present a full list of all outcomes in Appendix 2.
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Unit of analysis issues
We include both patient-randomised and cluster-randomised trials
in this review. We used the guidance in the Cochrane Handbook
6.4.4 when incorporating cluster-randomised trials in the meta-
analyses (Higgins 2011). We reduced the effective sample sizes of
cluster-randomised trials by dividing by the design effect, 1 + (M-
1)*ICC, where M is the average cluster size in the intervention
arm and ICC is the intraclass correlation coefficient. As no trial
in the review reported ICCs, we used an estimated ICC of 0.06
based on De Vera 2014, that had identified reported ICCs in trials
of pharmacist interventions.
Dealing with missing data
If trials reported means without standard deviations (SDs), we
used a variety of approaches to estimate standard deviations, in-
cluding their derivation from 95% confidence intervals (CIs) and
from reported standard errors. If no measure of variability was
available, we imputed standard deviations using the average stan-
dard deviation of the other trials within the review. We did this for
four outcomes: systolic blood pressure; diastolic blood pressure;
SF-36 Physical Functioning; and Asthma Control Questionnaire
(ACQ). For some binary outcomes, we estimated numerators and
denominators from reported percentages. For one trial, (Bernsten
2001), we estimated denominators using dropout rates which had
been reported on a country-by-country basis. We imputed stan-
dard deviations for the following outcomes measures (n = num-
ber of trials): systolic blood pressure (13); diastolic blood pressure
(10); SF-36 (3); and glycated haemoglobin change (1). We esti-
mated numerators from reported denominators and percentages
for seven studies.
Assessment of heterogeneity
We examined heterogeneity usingChi2 tests, and used the I2 statis-
tic to quantify the effect of heterogeneity on the results; I2 > 50%
reflects ’substantial’ heterogeneity and > 75% ’considerable het-
erogeneity (Cochrane Handbook 9.5.2 (Higgins 2011)).
Assessment of reporting biases
We assessed the presence of publication bias by visual inspection
of funnel plots (by NWS) for each meta-analysis.
Data synthesis
We conducted standard meta-analyses for all outcomes which had
been reported by at least two trials. We chose a random-effects
model because of the expected between-study heterogeneity. For
continuous outcomes, we pooled only trials reporting the same
outcome using the same units, although there was often variation
in the types of intervention assessed. We pooled mean differences
using the inverse variance approach (Higgins 2011). Three out-
comes (blood glucose, total cholesterol and LDL cholesterol) were
reported using a mixture of units (mmol/l or mg/dl), so we used
conversion formulae (Diabetes UK; Rugge 2011) to convert these
to mmol/l. We included a mixture of trials that reported final
scores as well as studies that reported change from baseline.
We combined binary data using the Mantel-Haenszel approach.
For some binary outcomes, we pooled trials where the exact defi-
nitions varied: e.g. the proportion outside a stated range for blood
pressure or glycated haemoglobin, with the specific range some-
times varying between trials.We also included an outcome for hos-
pital attendance/admission which included hospital admission, re-
hospitalisation or emergency admission, depending on the trial.
For three-arm trials, we created two groups (intervention versus
control) using appropriate pooling formulae. For some trials, we
pooled two intervention arms, and for others two control arms. In
some cases, this resulted in a composite arm of two rather differ-
ent intervention groups, although both met the review inclusion
criteria. There were no trials with four or more arms.
Summary of findings
We assessed the certainty of the evidence using the GRADE ap-
proach, i.e. the five GRADE considerations (trial limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
(Guyatt 2008).We usedmethods and recommendations described
in Section 8.5 and Chapter 12 of theCochrane Handbook (Higgins
2011) and the EPOCworksheets (EPOC 2017b). One review au-
thor (NWS) assessed the certainty of the evidence and a second
author (MCW) then reviewed and confirmed these assessments.
We created two ’Summary of findings’ tables for the main inter-
vention comparisons and included the following important out-
comes:
• Percentage outside target blood pressure range
• Percentage outside target glycated haemoglobin range
• Hospital attendance/admission
• Adverse drug effects
• SF-36 Physical Functioning
• Mortality
Subgroup analysis and investigation of heterogeneity
We had planned no subgroup analyses a priori, and performed
none. We assessed heterogeneity using the I2 statistic (see above).
Sensitivity analysis
We had planned no sensitivity analyses a priori, and performed
none.
R E S U L T S
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Description of studies
Results of the search
We retrieved 1903 records after de-duplication from the electronic
searches and excluded 1657 citations based upon a screen of the
title and abstract. We reviewed the full text of 246 records and
identified 116 for inclusion in this review (Table 1), 87 of which
we identified for this update (Figure 1). One three-arm trial (
Hay 2006) could be included in both comparisons. The top-up
searches, conducted in January 2018, identified 2277 citations
after de-duplication, of which 331 were classified as > 90% chance
of being a randomised trial by the classifier (EPOC 2017a). Of
these, we added 95 to Studies awaiting classification.
Figure 1. Study flow diagram.
Included studies
Participants
Trials were conducted in 24 countries with the USA (42), UK
(13), Canada (11) and Australia (10) contributing most of the
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studies (n = 76 (66%)). Studies were also included from Spain (5),
Brazil (4), Jordan (3) and Sweden (3), with two studies each from
Belgium, Chile, China, Colombia, India, Iran, Thailand and the
United Arab Emirates (UAE). Single studies were included from
Denmark, Hong Kong, Iraq, Malaysia, Malta, the Netherlands,
Nigeria, and Portugal. In addition, one study was multi-centred
with countries participating across Europe. The total number of
randomised participants was 41,851; this ranged from 21 to 6000
participants per trial (median = 198). A wide range of clinical con-
ditions and medicine-related behaviours were targeted (Appendix
2), including hypertension (27), diabetes (20), asthma and/or
chronic obstructive pulmonary disease (COPD) (14), depression
(7), cardiovascular disease (5), heart failure (5), and cholesterol/
lipid management (4). In addition, some studies targeted specific
patient populations, e.g. those with multiple conditions (receiv-
ing multiple medicines) (9), general medicines management (in-
cluding managing potential risk/harm) (10), older participants
(4). Few studies included pain management (2), epilepsy (2) or
metabolic syndrome (2), and single studies targeted HIV, cancer,
arthritis, bipolar disease and osteoporosis.
Interventions
The studies were conducted in a range of settings. The most com-
mon settings in which the pharmacists delivered their interven-
tions were community pharmacies and primary care practices or
clinics, hospital outpatient clinics and specialist clinics. Other set-
tings included the patient’s home including telephone follow-up,
as well as community settings. The categorisation of the delivery
setting was problematic due to the variation of terminology used
across studies and countries. Fifty-one studies involved one par-
ticipating site, 61 involved multiple sites, and for four studies the
number of participating sites was unclear.
The average duration of intervention (i.e. first interaction to last
interaction)was 7.4months (standard deviation: 5.6) and involved
an average of 5.6 (standard deviation: 5.6) healthcare provider-
patient interactions, including phone calls. Face-to-face interac-
tion between the pharmacist and the patient was involved in 108
studies and was combined with telephone contact in 36 studies, or
with printed materials in 45 studies. Many studies used combina-
tions of interactions. In general, the interventions were poorly de-
scribed with non-specific definitions and vague descriptions, and
lacked detail.
Most interventions targeted one of two of the following types of
behaviour:
1. Suboptimal prescribing targeted by medication reviews, home
monitoring to derive better data for future prescriptions, rational-
isation of prescriptions, identification and resolution of medicine
discrepancies, as well as contact with prescribers to modify pre-
scriptions.
2. Suboptimal use of prescribed medication targeted by interven-
tions to improve medicine use through a variety of methods in-
cluding education, synchronisation of medicine refills, provision
of compliance devices and patient follow-up.
For study details see the Characteristics of included studies table.
Outcomes
Of the 116 trials, 76 were included in meta-analyses. The 40
remaining trials were not included in the meta-analyses because
they each reported unique outcome measures which could not be
combined. In total, 73 trials were eligible for the comparison of
pharmacist-led service and usual care, and three for pharmacist-
led service with other healthcare professional.
Excluded studies
We eliminated 152 studies. The main reasons for exclusion were
that the interventions were not delivered predominantly by a
pharmacist or that they targeted hospitalised patients. Three
studies were excluded for specific reasons, as presented in the
Characteristics of excluded studies.
Risk of bias in included studies
We present the results of the ’Risk of bias’ assessment in Figure
2 and Figure 3. Thirteen studies (11.2%) had no identifiable
biases (Green 2008; Malone 2001 Margolis 2013; McAlister
2014;Olesen2014; Peterson 2004; Rothman 2005; Sarkadi 2004;
Simpson 2011; Stewart 2014; Tannenbaum 2014; Tommelein
2013; Wu 2006).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
12Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We determined the risk of selection bias associated with random
sequence generation to be low in 75 trials, high in three trials and
unclear in 38 trials. We determined that risk of selection bias due
to allocation concealment was low in 59 trials, high in six trials
and unclear in 51 trials.
Blinding
We determined that risk of performance bias due to blinding of
participants was low in 49 trials, high in 30 trials and unclear in 37
trials. We determined that risk of detection bias due to blinding
of personnel was low in 62 trials, high in 36 trials and unclear in
18 trials.
Incomplete outcome data
We determined that risk of attrition bias was low in 79 trials, high
in 29 trials and unclear in 8 trials.
Selective reporting
We determined that risk of bias was low for ’incomplete reporting
of data’ in 105 trials, high in five trials and unclear in six trials.
Other potential sources of bias
We assessed the risk of specific biases as ’unclear’ in many trials,
due to incomplete reporting.
Effects of interventions
See: Summary of findings for the main comparison
Pharmacists’ non-dispensing roles targeting non-hospitalised
patients compared with the delivery of no comparable service for
health problem or population
Comparison 1: Pharmacist services targeting patients
versus usual care
Seventy-three trials compared pharmacist services targeting pa-
tients versus usual care for which useable data were available that
could be included in one or more meta-analyses. We performed
meta-analyses for 15 outcomes. Trials could be included in more
than one meta-analysis if they presented relevant data. For most
meta-analyses there was no clear evidence of funnel plot asymme-
try, although only a few included more than 10 trials.
Percentage outside blood pressure range
Eighteen trials (4107 participants) evaluated whether blood pres-
sure fell outside a specified range (Analysis 1.1). These trials used
a mixture of systolic and diastolic blood pressure and a variety of
target ranges, but we used systolic blood pressure in our analysis
if both were reported. The results indicate that those in the phar-
macist groups may be less likely to have blood pressure outside
the target range (OR 0.40, 95% CI 0.29 to 0.55, low-certainty
evidence; I2 = 81%). The asymmetric pattern shown in the funnel
plot for this meta-analysis could be an indication of publication
bias.
Percentage outside glycated haemoglobin range
We are uncertain whether pharmacist services improve the per-
centage of patients outside the glycated haemoglobin target range
(5 trials, N = 558, OR 0.29, 95% CI 0.04 to 2.22, very low-cer-
tainty evidence, I2 = 92%) (Analysis 1.2).
Hospital attendance/admission
Pharmacist services probably lead to little or no difference in hos-
pital attendance or admissions (14 trials, N = 3631, OR0.85, 95%
CI 0.65 to 1.11, moderate-certainty evidence, I2 = 44%) (Analysis
1.3).
Adverse drug effects
Pharmacist services may make little or no difference to adverse
drug effects (3 trials, N = 590, OR 1.65, 95% CI 0.84 to 3.24,
low-certainty evidence, I2 = 52%) (Analysis 1.4).
SF-36 physical functioning
Pharmacist services may slightly improve physical functioning
(measured by the SF-36) (7 trials, N = 1329, MD 5.84, 95% CI
1.21 to 10.48, low-certainty evidence, I2 = 84%) (Analysis 1.5).
Mortality
Pharmacist services may make little or no difference to mortality
(9 trials, N = 1980, OR 0.79, 95% CI 0.56 to 1.12, low-certaintly
of evidence, I2 = 13%) (Analysis 1.6).
Other outcomes
Other effects for HbA1c
MeanHbA1cwas 0.77 units lower for those receiving a pharmacist
intervention (15 trials, N = 2298, MD −0.77, 95% CI −0.97
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to −0.58, I2 = 77%) (Analysis 1.7). Patients in the pharmacist
groups tended to have lower fasting blood glucose than those in
control groups (8 trials, N = 1349, MD −1.17 mmol/l, 95% CI
−1.71 to −0.63, I2 = 74%) (Analysis 1.8).
Continuous measures of blood pressure
Thirty-one trials (N = 5939) and 32 trials (N = 6003) were in-
cluded in themeta-analyses of diastolic and systolic blood pressure,
respectively. On average, there was evidence that pharmacist inter-
ventions reduced diastolic blood pressure by −3.50 points (95%
CI −5.44 to−1.56) and systolic blood pressure by −5.96 points
(95% CI −7.35 to −4.57) compared with usual care (Analysis
1.9; Analysis 1.10). In both analyses, there was evidence of statis-
tical heterogeneity (I2 = 94% and 74%, respectively).
Lipids
Overall, patients in the pharmacist groups tended to have lower
total cholesterol (7 trials, N = 1592, MD−0.35 mmol/l, 95% CI
−0.56 to −0.13, I2 = 77%) (Analysis 1.11). There was little or
no difference for LDL cholesterol (6 trials, N = 854, MD −0.14
mmol/l, 95% CI −0.30 to 0.02, I2 = 56%) (Analysis 1.12).
Respiratory function
A small number of trials were included in the meta-analyses for
each of three respiratory outcomes: FEV1 (3 trials, N = 291), peak
flow (2 trials, N = 460) and dyspnoea (2 trials, N = 820). There
was no evidence of an effect of the pharmacist intervention on any
of these outcomes: FEV1: MD 0.11, 95% CI −0.01 to 0.23, I
2 = 0%; Analysis 1.13; Peak flow: MD: 3.36, 95% CI −0.36 to
7.09, I2 = 0%; Analysis 1.14; Dyspnoea: OR 0.90, 95% CI 0.68
to 1.20, I2 = 0%; Analysis 1.15.
Comparison 2: Pharmacist services targeting patients
versus other healthcare professionals
Five trials compared pharmacist services targeting patients versus
care provided by healthcare professionals, for which useable data
were available that could be included in one ormoremeta-analyses.
We performed meta-analyses for two outcomes and calculated an
overall standardised effect size for five trials included in the meta-
analysis.
Percentage outside blood pressure range
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on the percentage outside blood pres-
sure range.
Percentage outside glycolated haemoglobin range
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on percentage outside glycolated hae-
moglobin range.
Hospital attendance/admission
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on hospital attendance/admission.
Adverse drug effects
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on adverse drug effects.
SF-36 physical functioning
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on SF-36 physical functioning.
Mortality
We did not find any studies comparing pharmacists’ non-dispens-
ing roles targeting non-hospitalised patients with other healthcare
professionals that reported on mortality.
Other outcome measures
Comparedwith other healthcare professionals, pharmacist services
were not associated with differences in systolic blood pressure (3
trials, N = 1238, MD 1.31, 95% CI −6.22 to 8.84, I2 = 94%)
(Analysis 2.1) and diastolic blood pressure (2 trials, N = 959, MD
−1.36, 95% CI −4.30 to 1.59, I2 = 86%) (Analysis 2.2).
D I S C U S S I O N
Summary of main results
We included 116 randomised trials in this review, most of which
(n = 111) compared pharmacist services with usual care, with the
remaining five comparing pharmacist services with those delivered
by other health professionals.
Compared with usual care, we are uncertain whether pharmacist
services improved the percentage of patients outside the glycolated
haemoglobin target range (very low-certainty evidence). Pharma-
cist services maymake little or no difference to hospital attendance
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or readmission (moderate-certainty evidence) or to adverse drug
effects (low-certainty evidence). Pharmacist services may, how-
ever,reduce the percentage of patients whose blood pressure is out-
side the target range (low-certainty evidence) and may also slightly
improve physical functioning (low-certainty evidence).
We did not find any trials comparing pharmacists’ non-dispensing
roles with services delivered by other health professionals that as-
sessed the percentage of patients outside blood pressure or glyco-
late haemoglobin target range, hospital attendance and admission,
adverse drug effects, physical functioning or mortality.
In addition to the main outcomes discussed above and reported
in the Summary of findings for the main comparison, we also in-
clude secondary outcome measures. We did not assess these sec-
ondary outcomes using GRADE for certainty of evidence. Com-
pared with usual care, pharmacist services achieved reductions in
systolic and diastolic blood pressure of −5.96 mmHg and −3.50
mmHg, respectively. A reduction in systolic blood pressure of 5
mmHg is associated with a 34% reduction in stroke and 21% re-
duction in ischaemic heart disease (Law 2003), and as such, the
results also suggest that these effects are clinically relevant. Fur-
thermore, compared with usual care, pharmacist services achieved
reductions in glycolated haemoglobin, fasting blood glucose and
total cholesterol. Conversely, pharmacist services made little or no
difference to low density lipoprotein levels or respiratory function,
compared with usual care.
Most trials were conducted in anglophone high-income countries,
and results should therefore be interpreted with caution for their
relevance to lower-income countries. The aim of many trials was
to achieve improved control of hypertension and blood glucose,
which could have led to falls, postural hypotension and hypogly-
caemia; these potential harms were not assessed. This review there-
fore does not comment on the potential harms of the pharmacist
services evaluated by the included trials.
Overall completeness and applicability of
evidence
We searched multiple sources of data to identify eligible trials,
performing duplicate, independent data extraction for all compo-
nents. Evidence of potential publication bias was demonstrated in
Analysis 1.1 (% outside blood pressure range). The original re-
view used a mainly narrative approach and only three small meta-
analyses were possible. The larger number of trials in this update
allow a wider range of quantitative meta-analyses. We calculated
effect sizes for many of the included trials, enabling standardmeta-
analyses to be conducted.
As expected, we detected substantial heterogeneity in most of the
meta-analyses undertaken, possibly due to variation in interven-
tions tested and definitions used. Using GRADE, we downgraded
all outcomes to moderate certainty due to high risks of bias, with
some outcomes being further downgraded due to high levels of
heterogeneity.
The pharmacist services were poorly described and thus limit the
ability to replicate these interventions for future trials or for service
delivery. The use of checklists for reporting interventions, such as
Template for Intervention Description and Replication (TiDieR)
(Hoffman 2014) should enhance completeness of reporting and
replicability of future service evaluations. There was little or no
discussion of the mechanisms of action by which the pharma-
cist services were hypothesised to improve patient outcomes. The
Behaviour Change Technique Taxonomy and Behaviour Change
Wheel (Michie 2014) have been used to categorise the active in-
gredients or behaviour change techniques (BCTs) of interven-
tions and to identify interventions likely to achieve the desired
behavioural goal. The use of taxonomies and frameworks for de-
veloping and evaluating interventions could provide clarity about
the anticipated or intended mechanisms of action of pharmacist
interventions. The effectiveness of pharmacist interventions could
be diminished if their recommendations on prescribed medicines
need to be actioned by a third party, e.g. a doctor. In some coun-
tries, however, pharmacists are able to prescribe and to directly
effect any changes in prescribed medicines to enhance patient out-
comes. Few trials in this review included or reported whether the
participating pharmacist(s) were qualified prescribers.
Certainty of the evidence
With the trials included in the analysis of pharmacist interven-
tions compared with usual care, the certainty of the evidence is
very low or low for most of the outcomes. This is mainly explained
by major heterogeneity in study populations, types of interven-
tions delivered and reported outcomes. Three trials were included
in the meta-analyses of pharmacist interventions compared with
interventions delivered by healthcare professionals, with very low
certainty of the evidence. Evidence is limited on whether phar-
macist-led services achieve equivalent patient outcomes compared
with other healthcare professional provision.
Potential biases in the review process
The extensive searches performed by the EPOC team are likely
to have identified most or all relevant trials. Duplicate, indepen-
dent screening and data extraction processes minimised bias and
reduced error, although incomplete descriptions of study proce-
dures and interventions complicated this task. Publication biases
and strategic selection of outcomes may also have led to an infla-
tion of the estimated effect size.
Agreements and disagreements with other
studies or reviews
The results of this systematic review generally concur with those
of other reviews of pharmacist services conducted in different set-
tings or with different health conditions or patient populations,
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which report mixed evidence of the benefit of pharmacy interven-
tions (Altowaijri 2013; Charrois 2012; Greer 2016; Hatah 2014;
Jokanovic 2017; Koshman 2008; Mekonnen 2016; Pande 2013;
Walsh 2016). An earlier Cochrane Review (Glynn 2010) of inter-
ventions to improve hypertension suggested that pharmacist-led
interventions showed promising results. In this updated review,
patients who received pharmacist-led services were less likely to
have blood pressure outside the target range compared with pa-
tients receiving usual care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results need to be interpreted cautiously because there was
major heterogeneity in study populations, types of interventions
delivered and reported outcomes.There was considerable hetero-
geneity within many of the meta-analyses as well as considerable
variation in the risks of bias.
This review demonstrates that pharmacist services have varying
effects on patient outcomes compared with usual care. Some ser-
vices appear to have little effect whilst others have the potential to
improve important outcomes on a scale which is clinically impor-
tant.
There was little or no difference between the effectiveness of in-
terventions that were pharmacist-led compared with the same in-
tervention being delivered by other healthcare professionals. This
is an important finding in terms of role substitution, with particu-
lar implications for costs. For example, if pharmacists can achieve
similar effects compared with doctors, service delivery by the for-
mer is likely to cost less than the latter. However, we did not ex-
amine costs and resources required for delivering interventions, so
the cost effectiveness of these services remains to be established.
Implications for research
The development of future pharmacist services should be informed
by existing knowledge about effective intervention design and de-
velopment. Further research is required to help identify which
components of an intervention are more effective and under what
conditions. We also need a deeper understanding of why certain
interventions but not others are effective in some clinical domains,
and why certain interventions only work in some populations or
settings but not in others. These factors may explain the high het-
erogeneity often observed in this review.
There is a need for better alignment between health priorities
and the clinical topics and behaviours selected and targeted by
pharmacist-led services.Whilstmost of the included trials targeted
non-communicable diseases, thereby reflecting the global burden
of disease, a number of conditions identified as future priorities
were under-represented in this review (WHO 2011), e.g. HIV,
Alzheimer’s Disease, mental health conditions, and cancer.
There is now an abundance of research evaluating pharmacist ef-
fectiveness. Future trials should better describe research methods
as well as intervention and comparator interventions delivered, in
order to enhance the certainty of the evidence and the replicability
of interventions. The potential harms of these services should also
be explored. High-quality economic evaluations of these services
should assist policy-makers in deciding on investing in these ad-
ditional pharmacy services.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adibe 2013a
Methods Randomised trial
Participants 220 patients with diabetes (intervention 110; control 110)
2 urban tertiary teaching hospitals
Nigeria
Year of study: Not stated.
Interventions In the pharmaceutical care (PC) group, pharmacists set priorities for patient care, assessed
educational needs, identified drug-related problems, developed a PC plan in collabora-
tion with the patient and the doctor, implemented, monitored and reviewed the plan.
Nurses organised patients, conducted point-of-care testing, counselled patients,and re-
inforced the information given to the patients during training sections. Physicians pro-
vided the visitation/appointment schedule for the patients, prescribed laboratory tests,
and implemented changes in medications
4 sessions of 90 to 120 minutes
Duration 12 months
Outcomes Health-related Quality of Life (HRQoL)
Notes Funding source: Science and Technology Education Post Basic (STEP-B) through the
University of Nigeria
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to groups by using online “random sequence gen-
erator”
Allocation concealment (selection bias) Low risk Quote “Allocation was also sorted through online “random se-
quence generator” which was set in a 2-column format: the first
column was priori designated to the intervention group (55 pa-
tients) and the second column to the control group (55 patients)
” (per hospital 220 total)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk No mention of participant blinding
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Assessors were not blinded and a self-report outcome for
HRQoL used
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Adibe 2013a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Attrition bias or loss during follow-up was also a serious threat
but was avoided by using an intention-to-treat design.” Between
group attrition < 10%
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Adler 2004
Methods Randomised trial
Participants 533 patients with depression and/or dysthymia (intervention: 268; control: 265)
9 Eastern Massachusetts primary care practices
USA
Year of study: Not stated.
Interventions Pharmacists assessed a range of variables; medication history, medication regimen for
drug issues, drug efficacy and toxicity, education about depression including symptoms
and antidepressants, encouraged anti-depressant therapy and maintained strong thera-
peutic communication with patients. This was tailored towards the patient’s needs in
accordance with depression guidelines. Pharmacists spent 70 minutes per patient across
a 6-month period; minimal intervention was to be 9 appointments over 18 months
Outcomes Modified Beck Depression Inventory (mBDI) at 6 months
Notes Funding source: National Institute of Mental Health under grant RO1 MH56214
Conflict of interest: None stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by a “computerised coin-flip” built into the screener
Allocation concealment (selection bias) Low risk Randomisation is post-enrolment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Outcome are self-reported and no blinding of personnel or par-
ticipants
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Non-blinded patients acted as their own assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
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Adler 2004 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Albsoul-Younes 2011
Methods Randomised trial
Participants 253 hypertension patients (intervention: 131; control: 122)
General hospital
Amman, Jordan
Year of study: March to November 2009
Interventions Patients met with a pharmacist for 20 - 30 minutes before seeing their physician each
month for 6 months. Pharmacists took information on medication history, encour-
aged compliance, adherence to pharmacological and non-pharmacological therapy and
responded to questions. They also educated the patients about healthy lifestyle using
education materials and self-monitoring of BP. Recommendations were offered to the
physician, with notes about cost-effective drug choices
Outcomes Reduction in systolic blood pressure (SBP) at 6 months; Reaching goal BP (SBP < 140
mmHg, diastolic BP < 90mmHg; for diabetic patients it was SBP < 130mmHg, diastolic
BP < 80 mmHg)
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by ’coin tossing’
Allocation concealment (selection bias) Low risk Randomisation is post-enrolment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Quote: “Patients were not informed of their study allocation,
neither were the physicians, nor the nursing team” but the per-
sonnel were aware
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Personnel and possibly patients were aware of allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate 97%.
Selective reporting (reporting bias) Low risk All outcomes reported
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Albsoul-Younes 2011 (Continued)
Other bias Low risk None identified
Ali 2012
Methods Randomised trial
Participants 46 participants with type 2 diabetes (intervention 23; control 23)
2 branches of a pharmacy chain in Hertfordshire
United Kingdom
Year of study: February 2008 and July 2009.
Interventions Intervention group received a pharmaceutical care package with regular monitoring and
consultations with the community pharmacist for 12 months. Pharmacists carried out a
targeted medicine use review (if required) and lifestyle modification counselling with a
referral to a general practitioner or other healthcare professional where appropriate
Patients were seen by the pharmacist every month for the first 2 months, and then every
3 months a total of 6 appointments
Duration 12 months
Outcomes HbA1C
Blood glucose
Diabetes Quality of Life
Notes Funding source: UKDepartment of Health. Equipment fromMerek Sharp and Dohme
Conflict of interest: No party had involvement in the design, conduct or analysis or
preparation of the manuscript. However, Professor Robinson from Merck Sharp and
Dohme Ltd helped in the analysis andmanuscript preparation but received no consulting
fee
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted by a computer-generated ran-
domised list held by the researcher at the School of Pharmacy,
eliminating the potential influence of pharmacists on the ran-
domisation
Allocation concealment (selection bias) Unclear risk No relevant information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Differences in implementation of the intervention are legitimate
parts of the intervention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Assessors (participants/self-report) were not blind to interven-
tion but HbA1c is an objective measure
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Ali 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants missing. Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All main outcomes reported
Other bias Low risk None
Amariles 2012
Methods Randomised trial
Participants 714 patients with cardiovascular disease or who were at risk (intervention: 356; control:
358)
Multi-site across 13 Spanish regions. 60 community pharmacies invited and 40 phar-
macists performed assessments, suggesting that 40 of the 60 pharmacies participated
Spain
Year of study: September 2006 to June2007.
Interventions Intervention reviewed drug and clinical records, assessing health problems with current
drug therapy, aim for drug therapy outcomes, and educate about cardiovascular risk,
prevention and relevance to patient. There were 5 flexible appointments across 32 weeks
Outcomes Diastolic blood pressure at 8 months
Systolic blood pressure at 8 months
Total cholesterol at 8 months in mg per dL
Notes Funding source: Funded in part by RocheDiagnostilcs. EmilioGarcía-Jiménez employed
by Stada Laboratory
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a computer-generated randomisation schedule
Allocation concealment (selection bias) Unclear risk Quote: “Each pharmacy entered into the study when the phar-
macist submitted by fax or email the record of the first patient
who fulfilled the inclusion criteria. Once the study’s coordina-
tor verified the fulfilment of the inclusion criteria, he randomly
assigned 1 of the mentioned 50 groups to the pharmacy, pro-
viding it with a sequence of 20 codes (ONE or ZERO) that de-
termined which patient was assigned to the intervention group
or the control group.”
Unclear if the study co-ordinator knew the participants alloca-
tion to control or intervention before he decided if they met
criteria
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Amariles 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Quote: “Due to the nature of the intervention, participant blind-
ing was not possible. There was no “placebo” treatment, and
after randomization, patients were informed of their group as-
signments.”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk BP is measured by pharmacist aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate 90%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Andres 2007
Methods Randomised trial
Participants 112 participants with type 2 diabetes (intervention 58; control 56)
144 community pharmacies in the province of Pontevedra
Spain
26 pharmacists
Year of study: February 2003 to March 2004.
Interventions Drug knowledge was assessed by pharmacists using the “Dáder” method (a process for
pharmacist follow-up of patients who are receiving medication)
Compliancewithmedicationwas assessed using amodifiedMorisky-Greenquestionnaire
Every 3 months
Duration 12 months
Outcomes HbA1C
Notes Published in Spanish
Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information of randomisation procedure provided
Allocation concealment (selection bias) Unclear risk No relevant information found
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Andres 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk In this complex intervention, the personnel are unlikely to have
been blinded; implications for performance bias are unclear
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk HBA1c is unlikely to be biased by outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout rate. Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All main results reported
Other bias Low risk None
Armour 2007
Methods Randomised trial
Participants 396 asthma patients (intervention 191; control 205)
Recruited from 50 pharmacies
New South Wales, Queensland and Victoria, Australia.
Year of study: November 2004 to July 2005
Interventions Pharmacy Asthma Care Program intervention included targeted counselling and asthma
education,medication and lifestyle issues, review of inhaler technique, drug-related prob-
lems, goal setting and review, and possible GP referral. This was developed through 3
visits across a 6-month period, plus an optional visit at 3 months
Outcomes Forced Expiratory Volume (FEV1) at 6 months
Mean change in FEV1 from baseline
Asthma severity at 6 months
Notes Funding source: Australian Department of Health and Ageing as part of the Third
Community Pharmacy Agreement
Conflict of interest: None stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Low risk Quote: “Pharmacists were not informed as to group allocation;
both groups were informed that they were providing an asthma
care service involving spirometry. Pharmacies were asked to re-
cruit up to 10 subjects from their customers.”
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Armour 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Quote: “Pharmacists were not informed as to group allocation;
both groups were informed that they were providing an asthma
care service involving spirometry.”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Participants were unblinded and this may have influenced mea-
surement of FEV
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall competion rate 91%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Barbanel 2003
Methods Randomised trial
Participants 24 patients with asthma (12 intervention group, 12 control group)
Community pharmacy in Tower Hamlets, East London
United Kingdom
Year of study: Not stated.
Interventions Pharmacists reviewed inhaler technique, provided personal education on a variety of
asthma-related topics and followed up with patients with weekly telephone calls, vs usual
care.
Length of intervention - 45 to 60 minutes initial education session and weekly telephone
calls
Number of interventions - 12 during 3 months
Outcomes Improvement in asthma symptoms based on North of England asthma symptom scale
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “They were then randomised using sealed envelopes to
intervention or control groups”.
Unclear how random sequence generated
Allocation concealment (selection bias) Low risk Patients were randomised using sealed envelopes to intervention
or control groups
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Barbanel 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel unblinded but all differences likely to be legitimate
parts of intervention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Participants were not blinded. Main outcome was subjective
measure
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Only 1 outcome measured, which is reported
Other bias Low risk None
Bernsten 2001
Methods Cluster-randomised trial
Participants 2454 general/elderly patients (Intervention 1290; Control 1164) (86 control sites and
104 intervention sites)
Community pharmacies in Denmark, Germany, The Netherlands, Northern Ireland
(co-ordinating centre), Portugal, Republic of Ireland and Sweden
Year of study: Not stated.
Interventions Community pharmacists provided pharmaceutical care to patients in the intervention
group including patient assessment, identification of actual and potential drug-related
problems (e.g. poor compliance, poor knowledge, adverse drug reactions). Data sources
included (i) the patient (by informal questioning); (ii) the patient’s general practitioner
(GP); and (iii) pharmacy-held records. Pharmacy interventions included: (i) educating
the patient about drug regimen andmedical condition(s); (ii) implementing compliance-
improving strategies such as drug reminder charts; and (iii) rationalising and simplifying
drug regimens in collaboration with the patient’s GP
Continuous process
Duration 18 months
Outcomes Hospitalisations over past 18 months
Notes Funding source: European Commission, under the BIOMED 2 programme for medical
research, funded the coordination of this multicentre study
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Half of the recruited sites were randomly assigned as control
sites and half as intervention sites and, where possible, con-
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Bernsten 2001 (Continued)
trol and intervention sites were matched as closely as possi-
ble according to size (e.g. total number of patients served),
situation (e.g. city centre vs village) and type (e.g. owned by
a single proprietor vs part of a national chain)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Not stated but unlikely due to intervention pharmacist train-
ing
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Hospitalisations are an objective measure
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% but, large changes in sample
size due to some arms only running for 6 or 12 months
Selective reporting (reporting bias) Unclear risk Major results are reported. Unclear why some results pre-
sented by country and some averaged across all
Other bias Unclear risk Intervention was not the same across all countries
Quote: “Each country adapted the manual, translating and
modifying sections where appropriate, according to differing
national practices.”
Blalock 2010
Methods Randomised trial
Participants 186 elderly participants (intervention 93; control 93).
100 community pharmacies from the same chain, located in North Carolina
USA
Year of study: Not stated.
Interventions Quote “Intervention was a face-to-face medication consultation conducted by a commu-
nity pharmacy resident. The pharmacist reviewed the patient’s medications and identi-
fied potential problems in their drug therapy. Special attention was given to medications
that have been found to increase the risk of falling, with an emphasis on Central Nervous
System (CNS)-active medications using structured algorithms. Control group received
no medication consultation. Participants in both groups received a packet containing
2 brochures on the prevention of falls developed by the Centers for Disease Control
and Prevention (What You Can Do to Prevent Falls and Check for Safety: A Home Fall
Prevention Checklist for Older Adults).”
1 45-minute meeting
Duration 12 months
Outcomes Number of falls
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Blalock 2010 (Continued)
Notes Funding source: National Center for Injury Prevention and Control at the Centers for
Disease Control and Prevention (R49 CE000196)
Conflict of interest: The authors wish to acknowledge Joseph T. Hanlon, PharmD,
and Cathleen S. Colón-Emeric, MD, for their assistance with the development and
refinement of the algorithms used in this study. The authors have indicated that they
have no other conflicts of interest regarding the content of this article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Random assignments will be based on a list of random
numbers generated using statistics software package”
Allocation concealment (selection bias) Low risk Quote “620 envelopes will be prepared such that each envelope
includes a card on which either ’Experimental Group’ or ’Con-
trol Group’ is written. The envelopes will be sealed and arranged
sequentially, by the list of random numbers.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Protocol states that participants were blinded but pharmacists
were not
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote “To monitor data quality, all data collection instruments
will be reviewed by a research assistant immediately upon their
return by study participants. In cases where participants have
missed items or provided incomplete, illegible, or ambiguous
information, the research assistant will follow-up with the par-
ticipant by telephone to obtain the needed information. The
research assistants will be blinded to participants’ experimental
group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High attrition rate but reported as intention-to-treat analysis.
Between group attrition < 10%
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Bogden 1998
Methods Randomised trial
Participants 95 hypertensive patients (intervention 49; control 46).
Single hospital outpatient clinic
USA
Year of study: Not stated.
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Bogden 1998 (Continued)
Interventions Both control and intervention arms included strategy and treatment planning with a
physician. Intervention patients also received recommendations from a pharmacist for
half an hour before each physician visit. 3 visits over 6-month period
Outcomes Diastolic Blood Pressure (DBP) at 6 months
Systolic Blood Pressure at 6 months
% of patients who achieved target blood pressure goals of less than 140 mm Hg for
systolic blood pressure and less than 90mmHg for diastolic blood pressure in the control
and intervention groups
Notes Funding source: Queen’s medical Centre, Honolulu. research Centres in MinoritiesIn-
stituions Aard(P20 RR11091) from the National Institutes of Health
Conflict of interest: Not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomised by odd/even last digits of social security number
Allocation concealment (selection bias) Low risk Due to randomisation type no influence of allocation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Participants were not told to which group they were allocated
but would most likely know due to the study procedures
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk BP measured by blinded nurses
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall competion rate 92%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Bond 2000
Methods Randomised trial (by medical practice)
Participants 3074 patients on repeat medications (intervention 1614; control 1460)
Health professionals (delivering intervention): 62
Practices: 19
University-affiliated setting
Medical practices in Grampian, United Kingdom
Unit of analysismismatch corrected (randomised by practice, analysed by patient; analysis
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Bond 2000 (Continued)
accounted for clustering effect)
Year of study: 1995 - unclear.
Interventions Pharmacist dispensed repeat prescriptions following a protocol to check whether items
were required, or patients were experiencing side effects or drug interactions, vs usual
care
Length of the intervention: not clear
Number of interventions: 12 during 12 months
Outcomes Death rate
Adverse drug reactions
Hospital admissions
Notes Funding source: Grampian Health Board
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to either the control or interven-
tion group using random-number tables
Allocation concealment (selection bias) Low risk Random-number tables were used.
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel unblinded, but there appears to be
little potential for bias in implementation of
repeat prescriptions
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unblinded and may or may not have influ-
enced assessment of outcome variables (ad-
verse drug problems)
Incomplete outcome data (attrition bias)
All outcomes
High risk Large number of missing patients. Large be-
tween group attrition >40%
Selective reporting (reporting bias) Low risk Main outcomes were reported
Other bias Low risk None
Borenstein 2003a
Methods Randomised trial
Participants 197 hypertensive patients (intervention; 98 control)
2 main offices of one medical practice of general internists and internal medicine sub-
specialists affiliated with a large community hospital
USA
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Borenstein 2003a (Continued)
Year of study: 1996 to 1998
Interventions The intervention was made up of visits by pharmacist who assessed adherence to anti-
hypertensive drugs, side effects, patient habits in accordance with guidelines as well as
education about lifestyle modifications. Also follow-up visits with physicians for treat-
ment plans. On average there were 8 provider interactions over a 12-month period
Outcomes Systolic blood pressure at 12 months
Number achieving blood pressure goals at 12 months
Notes Funding source: Not specificed.
Conflict of interest: Not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear what method of randomisation was used
Allocation concealment (selection bias) Unclear risk Unclear if patients or personnel were aware of allocation during
recruitment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP measurement has low risk of performance bias.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unclear regarding method of BP measurement and whether as-
sessor was blind to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk 99/635 and 98/637 completed. Between group attrition < 10%
but overall attrition >80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Bosnic-Anticevich 2010
Methods Randomised trial
Participants 52 patients with either asthma or chronic obstructive pulmonary disease (intervention
26; control 26)
8 community pharmacies
Sydney, Australia
Year of study: Not stated.
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Bosnic-Anticevich 2010 (Continued)
Interventions Intervention was given written, verbal and demonstrated instructions on how to use an
inhalation device. This education occurred once and was assessed monthly
Outcomes Number achieving full-technique score (8/8) at 4 months
Notes Funding source: Not specified.
Conflict of interest: None stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by means of computer
generated random group allocation, prior to study commence-
ment.”
Allocation concealment (selection bias) Low risk Computer-generated random group allocation, prior to study
start
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Participants were blinded to allocation, but the experimenter
was not. This may have led to differences besides those specified
in the protocol
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Subjective outcome, with researchersmeasuring and conducting
analysis not appearing to be blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however, High (~20%) overall
attrition which was related to perception of value
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Very small sample size
Boyd 2013
Methods Randomised trial
Participants 500 patients starting a new medicine for asthma/chronic obstructive pulmonary disease,
type 2 diabetes, hypertension or antiplatelet/anticoagulant treatment (interventioon 250;
control 250)
Community pharmacy
United Kingdom (England)
Year of study: Not stated.
Interventions Patients randomised to the intervention arm received theNewMedicines Service (NMS)
. The NMS includes patient engagement, intervention and follow-up
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Boyd 2013 (Continued)
Outcomes Unclear. Medication adherence is one of the outcomes for analysis
Notes No useable quantitative data
Funding source: Department of Health Policy Research Program
Conflict of interest: Not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomised 1:1 into 1 of the 2 study arms stratified by
drug/disease group within each pharmacy, using the statistical
software
Allocation concealment (selection bias) Low risk Quote: “sequentially numbered tamper-proof opaque sealed en-
velopes containing details of allocation group” used
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unclear until exact methods and outcomes published
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Main outcome: self-reported adherence
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Results not yet reported
Selective reporting (reporting bias) Unclear risk Results not yet reported
Other bias Unclear risk Results not yet reported
Brook 2003
Methods Randomised trial
Participants Patients with depression: 135 (intervention 64; control 71)
Health professional (delivering intervention): 19
Practice: not clear
Community pharmacy
The Netherlands
Year of study: April 2000 to April 2001.
Interventions Pharmacist coaching patients and take-home video, vs usual care
Length of the intervention: not clear
Number of interventions: 3 during 6 months
Outcomes Disease control assessed by self-rating 90-item (Hopkins) Symptom Checklist (SCL-90)
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Brook 2003 (Continued)
Notes Required 75 patients in arm to detect 13% difference in depression at significance level
of 0.05. No useable quantitative data
Funding source: Organon unconditionally sponsors International Health Foundation.
The study received an unconditional grant from GlaxoSmithKline
Conflict of interest: The study was carried out without interference of either of the
companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation occurred at patient level and with a 1:1 ratio,
using block randomisation to ensure equal numbers of interven-
tion and control patients by pharmacy
Allocation concealment (selection bias) Low risk Randomisation used “block randomization”. The whole sample
was randomised before delivery to the pharmacies. These forms
were precoded and delivered in sealed envelopes
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Quote: “Neither patients, nor pharmacists were blinded for
group assignment”
Unclear if this influenced intervention. Same pharmacists deliv-
ered both arms, therefore potential for contamination
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Subjective outcome in an unblinded trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk 1 outcome, appropriately reported
Other bias Low risk None
Bruhn 2013
Methods Randomised trial
Participants 193 participants with chronic pain (intervention (1) 70: intervention (2) 63: control 60)
6 general practices
United Kingdom
Year of study: March 201 to not stated.
Interventions The intervention was pharmacist medication review with and without prescribing
Control patients received usual care. Patients attended a face-to-face consultation with
the pharmacist at which a pharmaceutical care plan was agreed. The plan included
medical history, current conditions; known allergies and adverse drug reactions; relevant
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Bruhn 2013 (Continued)
laboratory results; pain-related medications prescribed in the previous 10 years; current
pain-related prescription medications; current symptoms; lifestyle issues, including units
of alcohol consumed each week; recommendations for changes to medication (if any)
; whether non-pharmaceutical treatments had been considered; and any other relevant
issues. In the prescribing arm, prescriptions for medicines were issued by the pharmacist.
Patients were followed up either by phone or face-to-face, at each pharmacist’s discretion
Outcomes Chronic Pain Grade intensity
Notes Funding source: Medical Research Council (grant ID: 85356).
Conflict of interest: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All participating pharmacists took part in a 2-day course up-
dating them about pain management. As part of the training,
participants defined and agreed the treatment algorithm they
would all use
Allocation concealment (selection bias) Low risk Patients returning completed questionnaires were randomised
by the researcher using a telephone randomisation service with
a random number allocation which ensured allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were necessarily unblinded, but this is unlikely to bias
the results
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Largely self-report and, as patients are unblinded, susceptible to
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition >10%.
Selective reporting (reporting bias) Low risk All main results reported
Other bias Low risk None
Capoccia 2004
Methods Randomised trial
Participants Patients with depression: 74 (intervention 41; control 33)
Health professional (delivering intervention): 2
Practice: 1
University-affiliated teaching clinic
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Capoccia 2004 (Continued)
Outpatient clinic in USA
Year of study: Not stated.
Interventions Pharmacist collaborating with primary care physicians (PCPs) to provide patient edu-
cation, antidepressant therapy adjustment, monitoring of adherence and adverse drug
reactions and prevention of relapse, vs usual care
Length of the intervention: 15 minutes
Number of interventions: 13 during 12 months
Outcomes Disease control using 20-item Hopkins Symptom Checklist (SCL-20)
Notes Not all patients completed 13 sessions
55 patients in each arm required to detect a difference of 28% in clinical improvement
rates at 0.05 significance level
Funding source: Aetna Quality of Care Foundation
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) High risk Not explicitly mentioned in paper
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unblinded, but likely that all personnel actions fall within pro-
tocol directions
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Assessors (participants/self-report) unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate 91%.
Selective reporting (reporting bias) Low risk Main outcomes reported.
Other bias Unclear risk Quote: “Data collection was conducted via telephone interviews
and thus subject to recall bias.”
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Carter 2008
Methods Randomised trial
Participants 243 hypertension patients (intervention 127; control 116)
5 primary care clinics (intervention 2; control 3).
Iowa, USA
Year of study: January 2004 to October 2006.
Interventions Intervention to address suboptimal medication regimens and poor medication adher-
ence; through strategy planning, adherence aids, and home monitoring. Encouraged to
attend 4 clinic meetings on top of baseline interview over 8-month period, with optional
additional visits or phone support
Outcomes Systolic and diastolic blood pressure (BP) at 4 and 9 months
Notes Funding source: National Heart, Lung, and Blood Institute (HL069801). Dr Carter
supported by the Center for Research in Implementation in Innovative Strategies in
Practice (CRIISP), Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development Service (HFP 04-149)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of clinics was performed using a table of random
numbers
Allocation concealment (selection bias) Unclear risk No information relevant to concealment of allocation provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Neither participants nor personnel were blinded. This may have
led to extra intervention changes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Two different research nurses were dedicated to patients
in either control sites or intervention sites to minimize contam-
ination.”, “Individual data elements were double-entered into
a database by a blinded data management team that included
data technicians, the data manager, and the biostatistician” and
“The 24-hour results were used as a blinded objective outcome
and were not made available to either the patient’s physician or
the clinical pharmacist until the patient completed the trial”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Typical/planned BP measures reported
Other bias Low risk None identified
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Castejon 2013
Methods Randomised trial
Participants 84 participants with diabetes and their support person (number allocated to each group
not stated)
Community organisation for under-served Latinos
Florida, USA
Year of study: January 2010 to November 2010.
Interventions 2 pharmacist-led counselling sessions on medication, nutrition, exercise, and self-care to
promote behaviour change every 2 weeks for 6 weeks and a follow-up clinical screening
3 months later
Session included the Pharmacist Assessment and Reinforcement of Diabetes Self-man-
agement (PARDS) (1) A 90-minute focused discussion group (FDG) on type 2 diabetes
knowledge, beliefs, and barriers and motivators to clinical and self-management; (2) a
video What is Diabetes (3) training in self-monitoring of blood glucose
Outcomes HbA1C
Notes Funding source: Centers for Medicare & Medicaid Services
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unblinded assessors
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk HBA1C, unlikely to be biased
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition > 10%. High attrition rate overall.
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
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Charrois 2006
Methods Randomised trial
Participants 71 participants with high-risk asthma (intervention 37; control 34)
Community pharmacies in 2 remote rural communities
Alberta, Canada
Year of study: Not stated.
Interventions Intervention patients received education on asthma (medications, inhaler technique,
written asthma education materials and development of action plan), Optimisation of
drug therapy and assessment of adherence with formal onward referral as needed to
respiratory therapist or physician
Follow-up at 2 weeks by telephone call and at 1, 2, 4 and 6 months
Duration: 6 months
Outcomes Number of hospitalisations, Asthma Control Questionaire
Notes Funding source: Canadian Institutes of Health Research, Institute of Health Economics,
UniversityHospital Foundation, andASTHMAStudy (Alberta Strategy toHelpManage
Asthma)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patient is randomised by an internet randomisation service
through the Epidemiology Coordinating and Research (EPI-
CORE) Centre, University of Alberta
Allocation concealment (selection bias) Low risk As 2 sites did not have internet access, sealed envelopes are pro-
vided for randomisation. To help ensure balance, randomisation
was done in blocks of 6 and stratified by site
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Performance of usual care may have been influenced by inter-
vention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Hospitalisation is an objective measure.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition > 10%, however, intention-to-treat
analysis seems to have been undertaken
Selective reporting (reporting bias) Low risk Main outcome measures reported
Other bias Unclear risk Contamination of the usual-care group may have occurred, as
the caregivers involved in the study were not blinded. As part of
the study implementation, we met with all local physicians
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Chisholm 2002
Methods Randomised trial
Participants 26 participants with renal transplants (intervention 14; control 12)
Tertiary teaching hospital clinics
USA
Year of study: Not stated.
Interventions Intervention patients received input from a clinical pharmacist including medication
review focused on controlling blood pressure, and (potential/actual) medication-related
problems. Recommendations for change communicated to nephrologists. For patients
more than 8 months post-transplant, there were pharmacist-led monthly telephone fol-
low-ups
Duration 12 months
Outcomes Systolic Blood Pressure, compliance rate
Notes Funding source: Carlos and Marguerite Mason Trust
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear. No description, although “prospectively randomised”
was stated
Allocation concealment (selection bias) Unclear risk No description
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unblinded, but with objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk The clinic nurse was blinded as to which patients were in the
intervention or control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 dropouts. Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
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Choe 2005
Methods Randomised trial
Participants Patients: 80 (intervention 41; control 39) with diabetes
Professional (delivering intervention): unclear
Practices: 1
University-affiliated internal medicine clinic
Michigan, USA
Year of study: Not stated.
Interventions Pharmacist evaluated/modified therapy, educated on diabetes management and compli-
cations, performed screening processes and telephone follow-up, vs usual care.
Pharmacist discussed therapeutic recommendations with the primary care physicians, vs
usual care
Length of intervention: 1 hour
Number of interventions: unclear number in 12 months, with another 12 months of
follow-up
Outcomes HbA1c
Notes Follow-up for HbA1c measurement was 13.6 months for intervention group and 14.9
months for control group
Funding source: University of Michigan College of Pharmacy
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation within each stratum was simple: because the
study was small, randomisation was done by hand, drawing
numbers from a container that included “0” for the control
group or “1” for the intervention group
Allocation concealment (selection bias) Unclear risk Unit of randomisation by patient; drew numbers (0 or 1) from
a container
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unblinded complex intervention. No interaction in control
group
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unblinded trial, but main outcomes are unlikely to be biased
due to objective outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Few outcomes, all reported
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Choe 2005 (Continued)
Other bias Low risk None
Chrischilles 2014
Methods Randomised trial
Participants 294 participants with acute coronary syndrome (intervention (1) 97; intervention (2)
100; control 97
A community health facility, a community hospital, and a local Arc (a national commu-
nity-based organization advocating for and serving people with intellectual and devel-
opmental disabilities)
Iowa, USA
Year of study: Not stated.
Interventions Intervention was self-management/health promotion workshops led by a trained facili-
tator and pharmacist-led medication management compared with a 3rd arm (usual care)
. The intervention programme consisted of 8 weekly 2-hour workshops. For the purpose
of this review, we included only the self-management/health promotion workshops led
by a trained facilitator and pharmacist-led medication management
Outcomes Mean symptoms
Notes Funding source: This publication was supported by Grant Number 5R01DD000107
from The Centers for Disease Control and Prevention
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 3 people were randomised at a time using sealed envelopes that
contained the assignment order that had been randomly pre-
assigned by computer. The envelopes were prepared by an indi-
vidual not involved in the interventions or data collection
Allocation concealment (selection bias) Low risk 3 people were randomised at a time using sealed envelopes that
contained the assignment order that had been randomly pre-
assigned by computer. The envelopes were prepared by an indi-
vidual not involved in the interventions or data collection
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded and allocation may have influenced the subjective
outcome, mean symptoms
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded and subjective outcome ofmean symptoms reported.
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Chrischilles 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition > 25%, however, complete data avail-
able for 96% participants
Selective reporting (reporting bias) Low risk Major results reported. Some post hoc analysis
Other bias Low risk None
Clifford 2005
Methods Randomised trial
Participants Patients: 180 (intervention 92; control 88)
Professional (delivering intervention): unclear
Practices: 1
University-affiliated internal medicine clinic
Australia
Year of study: February 2001 to November 2002
Interventions Pharmacist assessed patients’ drug regimen and clinical parameters, developed therapeu-
tic plan, provided patient education about diet, exercise, compliance and home-glucose
monitoring, and forwarded patient information (medication lists, laboratory results,
goals) to primary care pharmacists, vs usual care.
Length of intervention: 5 to 30 minutes (average 15 minutes)
Number of interventions: 8 in 12 months (face-to-face meetings at baseline, 6, and 12
months; 6-weekly intervals by phone)
Outcomes HbA1c
Fasting plasma glucose, blood pressure, serum lipids, urinary albumin-to-creatinine ratio
Notes Funding source: The Raine Foundation, University of Western Australia, funded the
FDS. R.M.C. was the recipient of a National Health and Medical Research Council of
Australia PhD scholarship
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A subset of patients was randomised to the intervention or usual
care by consecutive allocation
Allocation concealment (selection bias) High risk Quote: “randomised...by consecutive allocation”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were not blinded but all differences in behaviour be-
tween control and intervention arm appear to be legitimate parts
of the intervention
57Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Clifford 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Assessors unblinded, but the main outcome does not allow for
significant detection bias. HbA1c is an objective measure
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall competion rate >90%
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
Cody 1998
Methods Randomised trial (by patient)
Similar control site: NOT CLEAR
Participants Community pharmacies of the Kaiser Permanente (number per group unclear)
Patients: 6000
Pharmacies: 9
USA
Year of study: January 1993 to February 1995.
Interventions Comparison of 3 models
Control model: usual care before 1992 in California
California statemodel (1992)which requires outpatient pharmacist to counsel all patients
who receive new or changed prescription about directions for use, the importance of
compliance, proper storage, and relevant precautions and warnings
Kaiser Permanente (KP) model that focuses on a more comprehensive pharmacist con-
sultation and other elements of pharmaceutical care on selected high-risk patients
Duration: 23 months
Outcomes Quality of life (SF-36)
Notes Funding source: Kaiser Permanente Medical Care Program
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “random assignment study”
Allocation concealment (selection bias) Unclear risk Not explicitly described; appears to have
been performed by a central randomised
scheme/computer system
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Cody 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Large complex intervention with non-
blinded personnel
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Mailed survey, assessor is participant: A
non-blinded study with subjective out-
come - HRQoL
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall attrition rate > 50%.
Selective reporting (reporting bias) Low risk Few outcomes, all reported
Other bias Low risk None
Cordina 2001
Methods Randomised trial
Participants 152 participants with asthma (intervention 86; control 66)
Community pharmacies
Malta
Year of study: Not stated.
Interventions Intervention patients received community pharmacy-led verbal counselling, an educa-
tional video, an information leaflet, and subsequent monitoring with reinforcement; The
education included pathology, avoidance of triggers, use of inhaled drugs and peak flow
meters, inhaler technique (verbal, written and video materials). Monitoring included
patient-completed diary cards of peak expiratory flow (PEF) (morning and evening) and
symptoms. Community pharmacists reviewed monthly when the patients collected their
asthma drugs. Pharmacists received information on the patient’s best peak flow value,
smoking history, comorbidities, drug allergies, and prescribed drugs. There was referral
to the asthma clinic as needed. Recommendations for treatment changes were made to
the patient’s physician
Duration: 12 months.
Outcomes SF-36
Living with Asthma Questionnaire (LWAQ)
PEF
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
59Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cordina 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk States “random” but no mention of method of randomisation
Allocation concealment (selection bias) Unclear risk The pharmacist at each site was invited to participate in the study
and was informed of the allocation of control or intervention
status
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Quote: “Given the nature of the intervention, patients,
providers, and the case manager were not blinded to the inter-
vention.”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded assessors: SF-36 and LWAQ are high risk as they are
subjective
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however, high attrition rates
across groups
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
De Castro 2006
Methods Randomised trial
Participants 71 hypertensive patients (intervention 34; control:37)
Specialist clinic
Porto Alegre, Brazil
Year of study: Not stated.
Interventions Intervention designed Dader method; obtain pharmacotherapeutic history, identify and
challenge problems, and lifestyle changes to treat hypertension. Control received similar
cognitive tests but focused only on drug-related problems. 24-week programme
Outcomes Diastolic and systolic blood pressure (BP) at 4 months
24-hour systolic BP at 24 weeks
Notes Funding source: FAPERGS, FIPE-HCPA, CNPq
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The random allocation was done in blocks of 8 patients each and
stratified by gender through a computer-generated sequence
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De Castro 2006 (Continued)
Allocation concealment (selection bias) Low risk The random allocation was done in blocks of 8 patients each and
stratified by gender through a computer-generated sequence
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Mentions double-blinding, but unclear if this was successful.
Patient was blinded
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Blinding unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Di Donato 2014
Methods Randomised trial
Participants 302 participants with hypertension (number per group not stated)
Community pharmacy chain stores
USA
Year of study: January 2012 to June 2012
Interventions Pharmacists synchronised all medication (re)fills, including antihypertensive medication
(s), prior to the date when the next refill was due and pharmacists checked for any
medication changes. At the point of refill pharmacists measured patient blood pressure
Duration: 4 months
Outcomes Systolic blood pressure
Diastolic blood pressure
% within target blood pressure
Notes Funding source: TheRedCross PharmacyResidency Program is fundedby aCommunity
Pharmacy Residency Expansion Project grant from the National Association of Chain
Drug Stores Foundation. This study was supported by HoMedics, Inc. through product
donation
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were enrolled at six retail locations and ran-
domized by research staff into three groups based on enrollment
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Di Donato 2014 (Continued)
order: control, medication synchronization, or education”
This may be less effective than true random allocation.
Allocation concealment (selection bias) High risk Quote: “Patients were enrolled at six retail locations and ran-
domized by research staff into three groups based on enrollment
order: control, medication synchronization, or education. Ran-
domization occurred at the patient level, and within each phar-
macy. ”
Investigators could foresee assignment:
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Most of the outcomes were objective and should be immune to
strong bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Used an electronic blood pressure measure
Incomplete outcome data (attrition bias)
All outcomes
Low risk Statistical analyses were conducted by a ’per protocol’ approach
(i.e. patients lost to follow-up were excluded).
Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
Doucette 2009
Methods Randomised trial
Participants 78 diabetic patients (intervention 36; control 42)
7 community pharmacies
Iowa, USA
Year of study: Not stated.
Interventions Discussions regarding medication, clinical goals, self-care and recommendations for fu-
ture medication, across 4 quarterly visits
Outcomes Systolic and diastolic blood pressure change scores
Low density lipoprotein cholesterol (LDL-C) (mg/dL) (change from baseline)
HbA1C (%) (change from baseline)
Notes Funding source: Community Pharmacy Foundation.
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Doucette 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar dropout in both groups
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Edwards 2014
Methods Randomised trial
Participants 200 participants with cancer (intervention 100; control 100)
Cancer Centre
Newfoundland, Canada
Year of study: Not stated.
Interventions The intervention patients received a visit from the seamless care pharmacist (SCP) prior
to the initiation of chemotherapy. The visit included medication history reconciliation.
The SCP checked medication against established regimen protocols, including a drug
interaction check, recalculation of the dose, and verification of pertinent laboratory val-
ues. The patient’s hospital pharmacist, oncology nurse, and attending physician received
copies of the report. The SCP counselled the patient on their treatment, identified and
resolved any drug-related problems. Patients were followed up by phone 2 days post-
chemotherapy to identify/resolve drug-related problems
Duration: unclear
Outcomes
Notes Control group outcomes not presented
No useable quantitative data
Funding source: Funded through unrestricted research grants from Pfizer, Amgen, and
Roche
Conflict of interest: None stated
Risk of bias
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Edwards 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised 1:1 to the intervention group or the
control group in the clinical trials department using a random-
number generator
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unclear
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) High risk No clear statement of outcomes
Other bias High risk Outcomes not presented. Length of study not stated
Farsaei 2011
Methods Randomised trial
Participants 174 patients with type 2 diabetes (intervention 87; control 87)
Isfahan Endocrine & Metabolism Research Center (IEMRC) outpatient clinic
Iran
Year of study: April 2008 to January 2009
Interventions The intervention group received 2 pharmacist-delivered educational sessions. The ses-
sions included oral anti-hyperglycaemic medications, adherence, self-care management,
diabetes diary log and pill box usage. Patient’s glycaemic control in the intervention
group was followed for 3 months through either telephone or face-to-face interviews
with the pharmacist. A questionnaire containing patient demographics and lab results
(HbA1c and fasting blood glucose) was filled by the pharmacist for each patient in the
intervention group and advice was given according to her/his concerns about diabetes
control
Patients were phoned or seen weekly for 3 months.
Duration 3 months
Outcomes % achieving target HbA1c
Mean HbA1c
Fasting blood glucose
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Farsaei 2011 (Continued)
Notes Funding source: This study was funded from Isfahan University of Medical Sciences
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly selected among eligible patients
whomet inclusion-exclusion criteria and then allocated into two
groups: intervention and control.”
Allocation concealment (selection bias) Unclear risk No mention of concealment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were not blinded, but different staff educated control
and intervention participants
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Non-blinded assessment, but bias unlikely to influence HBA1c
Incomplete outcome data (attrition bias)
All outcomes
High risk 59 of 87 intervention completed the trial, 86 of 87 control.
Between group attrition > 30%
Selective reporting (reporting bias) Low risk All main outcomes reported
Other bias Low risk None
Faulkner 2000
Methods Randomised trial
Participants 30 participants with congestive heart disease (CHD) (intervention 15; control 15)
Patients were recruited from a hospital coronary care unit (but setting for intervention
was domiciliary)
USA
Year of study: Not stated.
Interventions Intervention patients were phoned weekly. Emphasis was placed on the importance of
therapy in reducing the risk of recurrent cardiac events. Patients were questioned about
when and where prescriptions were filled, how they paid for their prescriptions, potential
side effects, overall well-being, and specific reasons for noncompliance when applicable
Duration: 12 weeks
Outcomes Total cholesterol
Low density lipoprotein (LDL)
High density lipoprotein (HDL)
Triglycerides
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Faulkner 2000 (Continued)
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised to telephone contact or no telephone
contact using a computer-generated list of random numbers
Allocation concealment (selection bias) Unclear risk Unclear if allocation concealed.
Patients were randomised to telephone contact or no telephone
contact using a computer-generated list of random numbers
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Potentially unblinded but objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unclear if blinded assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% completion rate.
Selective reporting (reporting bias) Unclear risk Main outcomes reported
Other bias Low risk None
Finley 2003
Methods Randomised trial
Participants 125 patients with depression (intervention 75; control 50)
Professional (delivering intervention): 2
Practice: 1
Outpatient clinic in Kaiser Permanente Medical Center
San Rafael, USA
Year of study: Not stated.
Interventions Pharmacist managed medication regimens, conducted in-clinic and telephone follow-
ups, and educated patients about medications and disease state, vs usual care.
Length of the intervention: 30-minute initial clinic visit, “brief ” second and third clinic
visits, 5- to 10-minute telephone calls
Number of interventions: 3 clinic visits + 5 telephone follow-ups during 6 months
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Finley 2003 (Continued)
Outcomes Brief Inventory for Depressive Symptoms (BIDS) score
% patients with ≥ 50% reduction in BIDS score
% patients achieving remission (BIDS score < 9)
% patients with reduction in Work and Social Disability Scale (WSDS) score
Notes Pharmacistsmet weekly with a psychiatrist (“psychiatricmentor”) to present newpatients
and provide updates on other patients; the psychiatrist was also available for consultations
as needed.
Study was powered to detect compliance outcomes only.
Funding source: Sidney Garfield Memorial Fund
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly assigned to the collaborative
care model or back to usual care in a 3:2 ratio”
Allocation concealment (selection bias) Low risk Used “sealed envelopes”, no mention of whether envelopes were
opaque
After the patients completed a brief survey to assess baseline
depression severity (Brief Inventory for Depressive Symptoms
(BIDS)) and functional impairment (Work and Social Disability
Scale (WSDS)), the investigators opened a sealed envelope that
determined study
group assignment (intervention vs usual care)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Providers were aware of intervention, but all differences between
control and intervention arm are integral to the intervention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Assessors (participants/self-report) were unblinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rates. Between group attrition >20%.
79% of intervention and 50% of control participants returned
the survey
Selective reporting (reporting bias) Low risk All results reported
Other bias Unclear risk Potential for seasonality due to 6 months only
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García-Cárdenas 2013
Methods Randomised trial
Participants 65 pharmacices and 373 patients with asthma (intervention 208; control 165)
Community pharmacies
Spain
Year of study: November 2010 to June 2011.
Interventions Patients visited pharmacy at least 3 times according to need. The pharmacists recorded
patient demographic details, and assessed asthma control, medication adherence and
inhaler technique. Patients were educated using verbal instructions, physical demonstra-
tion and written information about inhaler use. Adherence was explored with the Beliefs
about Medicines Questionnaire and Health Beliefs Model
Duration: 6 months
Outcomes % patients achieving correct inhaler technique, Asthma Control Questionnaire
Notes Funding source: The study was funded by the AstraZeneca Foundation, who did not
interfere with the study design, collection statistical analysis, interpretation of the data
and writing of the manuscript, nor in the decision to submit this manuscript for publi-
cation
Conflict of interest:The study was funded by the AstraZeneca Foundation, who did
not interfere with the study design, collection statistical analysis, interpretation of the
data and writing of the manuscript, nor in the decision to submit this manuscript for
publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pharmacies were the unit of randomisation and were assigned by
an independent researcher after they agreed to participate in the
study to either intervention (IG) or control group (CG) using a
computer-generated list of random numbers with ratio 1:1
Allocation concealment (selection bias) Low risk Pharmacies were the unit of randomisation and were assigned by
an independent researcher after they agreed to participate in the
study to either intervention (IG) or control group (CG) using a
computer-generated list of random numbers with ratio 1:1
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Quote: “Given the nature of the intervention pharmacists or
patients could not be blinded.” Outcomes are at high risk of bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Mostly self-measured or measured by the pharmacists. Oppor-
tunity for bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
68Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
García-Cárdenas 2013 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None
Garção 2002
Methods Randomised trial
Participants 100 hypertensive patients (intervention: 50; control: 50)
1 community pharmacy
Maxial, Portugal
Year of study: April 2000 to September 2000.
Interventions Individualised intervention based on health promotion by pharmacist
Monthly visits for 6 months
Outcomes Systolic and diastolic blood pressure (BP) at 9 months
BP in target range at 6 months
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No randomisation technique described
Allocation concealment (selection bias) Unclear risk Allocation not described
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Uncear if blinded or consequences of non-blinding
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Study pharmacist was not blinded and took all measures.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
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Gattis 1999a
Methods Randomised trial
Participants 181 patients with heart failure or left ventricular dysfunction (intervention 90; control
91)
General cardiology faculty clinic
Durham, North Carolina, USA
Year of study: October 1996 to July 1997.
Interventions Pharmacists for intervention patients offered therapeutic recommendations to their at-
tending physician and discussed changes in to drug therapy with patients. 3 follow-
up phone calls to talk through issues with drug therapy, answer questions and identify
clinical events. All 4 interactions over 6 months
Outcomes All-cause mortality and non-fatal heart failure
Notes Funding source: American Society of Health Systems Pharmacists Research and Educa-
tion Foundation, Duke Clinical Research Institute
Conflict of interest: Not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Allocation occurred after randomisation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk No blinding; unclear if this influenced delivery or other factors
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Non-blinding unlikely to affect all-cause mortality or heart fail-
ure
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition rate unclear
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Endpoint was not the same for all participants, median of 6
months. Unclear how this would affect the results
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González-Martin 2003
Methods Randomised trial
Participants 21 patients with asthma (intervention 11; control 10)
Professional (delivering intervention): not clear
Practice: 1
Outpatient paediatric clinic affiliated with Catholic University
Chile
Year of study: Not stated.
Interventions Pharmacist educated patients on medication therapy and inhaler use using asthma ex-
planatory booklet and prescribed medications brochure, vs usual care.
Length of the intervention: 30 minutes
Number of interventions: 3 during 9 weeks
Outcomes Paediatric asthma quality of life questionnaire (PAQLQ) score: emotions, activities,
symptoms domains
Spirometry testing: Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1)
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the child was assigned at random to one of the two
groups of the study”
Allocation concealment (selection bias) Unclear risk Allocation procedure not described
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Same unblinded personnel administered both intervention and
control arms
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Assessors were not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the trial.
Selective reporting (reporting bias) Low risk Few outcomes, all reported
Other bias Low risk None
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Goodyer 1995
Methods Randomised trial
Participants 100 patients > 70 years (intervention 50;control 50)
Outpatient clinics of the Medicine for Elderly Department at Charing Cross Hospital
United Kingdom
Year of study: Not stated.
Interventions Verbal counselling on the correct use of medication + medication calendar and informa-
tion leaflets
Length of intervention: 3 domiciliary visits over a 6- to 12-week period
Outcomes Compliance (pill count) defined as the%of the number that should have been consumed
Patient knowledge
Exercise test (distance in 6 minutes and distance until breathless)
Clinical assessment
Nottingham Health Profile
Breathlessness when performing different activities
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly allocated to intervention or
control groups”
Allocation concealment (selection bias) Unclear risk Allocation procedure not described explicitly
No information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Personnel were not blinded. Unclear if this caused bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “clinical assessments [were] carried out by a physicians
blinded to group allocation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
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Green 2008
Methods Randomised 3-armed trial
Participants 778 participants with hypertension: (Intervention (1) 202; intervention (2) 209; control
207
Setting is 10 primary care medical centres
USA
Year of study: Not stated.
Interventions In the 2 intervention groups patients also received a self-management support interven-
tion (home blood pressure monitor and training and a web-based service) in addition
to usual care. In one of the intervention groups, a clinical pharmacist provided care
management support by a single telephone call and subsequently the internet which
provided a template for BP monitoring, current medication, a patient-selected lifestyle
goal, recommended medication changes and follow-up plan. Communication thereafter
was 2-weekly by the web
Duration: 12 months
Outcomes Systolic blood pressure (BP)
Diastolic BP
Quality of Life
Notes Funding source: This research was funded by a grant from the National Heart, Lung,
and Blood Institute of the National Institutes of Health (NIH): Grant R01-HL075263;
Electronic Communications and Blood Pressure Monitoring (e-BP)
Conflict of interest: Dr Ralston received grant funding from Sanofi-Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Within these two groups, we randomly assign se-
quential blocks of three, six, or nine to the three interven-
tion groups. Each study coordinator at a given centre is
provided packets of nine envelopes from each of the two
systolic blood pressure groups and told to take the first en-
velope from the top of the given blood pressure group to
balance intervention assignment within centre and blood
pressure groups”
Allocation concealment (selection bias) Low risk Quote: “Within these two groups, we randomly assign se-
quential blocks of three, six, or nine to the three interven-
tion groups. Each study coordinator at a given centre is
provided packets of nine envelopes from each of the two
systolic blood pressure groups and told to take the first en-
velope from the top of the given blood pressure group to
balance intervention assignment within centre and blood
pressure groups”
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Green 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Main outcomes are objective.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Recorded blood pressure taken by research assis-
tant blinded to subject’s intervention group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition overall. Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All major results reported
Other bias Low risk None
Hammad 2011
Methods Randomised trial
Participants 199 patients with metabolic syndrome (intervention 112; control 90)
6 family medicine clinics at 1 university hospital
Amman, Jordan
Year of study: March 2009 to September 2009.
Interventions Met with both pharmacist and physician. Pharmacists provided medication counselling,
answered questions on self-monitoring, lifestyle choices, compliance with drug therapy.
Education materials were distributed discussing metabolic syndrome and increased risks.
Monthly visits across 3 months
Outcomes Systolic and diastolic blood pressure at 6 months
Fasting blood glucose (mg/dL)
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin-toss method
Allocation concealment (selection bias) Unclear risk Unclear if the recruiter knew the allocation status of the partic-
ipant during the consent process
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unblinded participants and personnel
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Hammad 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Blood pressure was measured monthly by assistant nurses who
were blinded to the patient’s study arm assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate >80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Hawes 2013
Methods Randomised trial
Participants 61 participants (intervention 24; control 37)
Academic medical centre
USA
Year of study: October 2009 to April 2011
Interventions Intervention group received a care transitions clinic visit with a clinical pharmacist 72
hours post-discharge. The visit included medication history, identifying and resolving
medication discrepancies, creating a current medication list and counselling on medica-
tion use. Discrepancies between the Best Possible Medication Discharge List (BPMDL)
and the discharge summary were identified and characterised
Outcomes Number of re-hospitalisations
Notes Funding source: Funding from the American College of Clinical Pharmacy Ambulatory
Care Practice and Research Network was used to provide compensation in the form of
a $15 gift card from a large retail store to subjects for study participation
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk During the first year of the study, 30 patients were enrolled
and a random number generator was used for randomisation.
Because of unequal allocationof patients to the study arms, block
randomisation with a block size of 4 was used for the second
year of the study, during which 31 patients were enrolled
Allocation concealment (selection bias) Unclear risk Insufficient Information
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Potential for bias (non-blinded)
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Hawes 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Seems unlikely. Rehospitalisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the trial.
Selective reporting (reporting bias) Low risk All reported
Other bias Unclear risk Baseline data not shown in full
Hawkins 1979
Methods Randomised trial
Participants 1148 diabetic or hypertensive patients (or both) (intervention 574; control 574).
Episodes of care: 12,918
Professionals (delivering intervention): 2
Practices: 1
Outpatient primary care clinic
Texas, USA
Year of study: March 1976 to August 1978.
Interventions Pharmacistmanagement of drug therapy (physiciannot involved) vs usual care (physician
only)
Pharmacists prescribed drugs and modified drug therapy as needed.
Length of intervention: 29 months
Outcomes Kept appointment rate
Follow-up clinic visits
Hospital admissions
Emergency Department visits
Compliance
Mean blood pressure
Blood sugar level
% of patients with decreased blood pressure
% of patients with decreased blood sugar levels
Notes Intervention was delivered by pharmacists who were assisted by trainees
Funding source: DHEW public health service grant
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were assigned randomly into three
groups”
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Hawkins 1979 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation procedure not described explicitly
No information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel (pharmacists and doctors) were aware of allocation
but all differences in implementation of the intervention are a
legitimate part of the intervention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Assessors were not blinded and the outcome blood pressure was
assumed to be measured manually
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition > 10%. High overall attrition.
Quote: “control groups experienced a significantly greater pa-
tient dropout rate and total attrition”
60.8% vs 48.8% completed
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Hay 2006
Methods Randomised 3-armed trial
Participants 325 patients with knee pain (enhanced pharmacy intervention 108; community phys-
iotherapy intervention 109; control 108)
15 general practices
North Staffordshire, England
Year of study: May 2001 to March 2004.
Interventions All participants were given a leaflet on knee osteoarthritis about self-help and exer-
cises. Enhanced pharmacy intervention aimed to optimise pharmacological pain con-
trol through drug therapy and reinforce self-help messages (6 sessions over 10 weeks)
. Community physiotherapy intervention, which was exercises led by musculoskeletal
community physiotherapists (3 - 6 sessions over 10 weeks). Control was just written
information (initial visit and 1 phone call 1 week later)
Outcomes WOMAC (WesternOntario andMcMaster Universities Osteoarthritis Index) pain score
at 12 months
Notes Funding source: Arthritis Research Campaign, North Staffordshire Primary Care Re-
search Consortium, and the Department of Health National Co-ordinating Centre for
Research Capacity Development. NEF funded by a primary care career scientist award
from the Department of Health and NHS R&D
Conflict of interest:None stated. The sponsors of the study had no role in the study
design, data collection,data analysis,data interpretation,or writing of the report
Risk of bias
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Hay 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random-number generator
Allocation concealment (selection bias) Low risk Quote: “We assigned each participant a unique study num-
ber, which corresponded with that on a sealed opaque en-
velope that contained information about participants’ al-
located treatment and was issued to the participant by the
study nurse.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk By necessity, participants and the health professionals de-
livering the interventions were not blind to allocation
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Study nurses and researchers who collected, entered, and
analysed data were unaware of treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate
>80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Hendrie 2014
Methods Randomised trial
Participants 245 participants with type 2 diabetes (intervention 119; control 126)
8 metropolitan community pharmacies
Perth, Western Australia
Year of study: May 2003- not stated
Interventions Patients in the intervention group received a pharmacist-led Diabetes Management Ed-
ucation Program (DMEP) Responses to the Diabetes Patient Assessment Questionnaire
(DPAQ) were entered into a pharmaceutical care software programme. Based on com-
puterised feedback, the developed personal treatment targets for the patient provided
patient education materials.The pharmacist followed up with patients at 1, 3 and 6
months, to review and monitor progress, and support adherence
Duration: 6 months
Outcomes SF-36
Notes Funding source: Not specified
Conflict of interest: None stated
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Hendrie 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “We paired them based on geographical location and the
socioeconomic status of the population served, and then ran-
domly selected one pharmacy in each pair to be in the inter-
vention (DMEP protocol) group, with the other assigned to the
control (standard care) group”
Randomisation technique not specified
Allocation concealment (selection bias) Unclear risk No relevant information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were not blinded, but differences in behaviour are le-
gitimate parts of the protocol. Separate personnel for interven-
tion and control groups
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk In the self-report outcomes, participants (assessors) were not
blinded to outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Quote: “Thirteen intervention group patients (18.6%) and 17
control group patients (18.9%) dropped out of the study for
various reasons.”
Selective reporting (reporting bias) Low risk All outcomes mentioned are reported
Other bias Low risk None
Hirsch 2014
Methods Randomised trial
Participants 667 participants with hypertension (intervention 339; control 328)
University general internal medicine clinic
California USA
Year of study: July 2010 to June 2012.
Interventions Quote “Intervention patients received 4 x 30-minute pharmacist visits (baseline, 3, 6,
and 9 months). The pharmacist assessed the patient’s knowledge of hypertension, cur-
rent treatment and treatment goals, self-monitoring behavior, medical and medication
history, and current medications. The pharmacist helped the patient to set individual
BP goals, reviewed and/or ordered laboratory tests, made adjustments to the antihyper-
tensive-medication regimen. Each visit was documented. During subsequent visits, the
pharmacist reviewed progress laboratory values, adherence, and self-monitoring behavior
and continued to make changes to the antihypertensive-medication regimen as needed.
A physician was always present in the practice and available for consultation as needed.”
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Hirsch 2014 (Continued)
Duration: 9 months
Outcomes % achieving target blood pressure
Systolic blood pressure (BP)
Diastolic BP
Notes Funding source:This research was funded by National Institutes of Health (NIH)/Na-
tional Heart, Lung and Blood Institute grant no. 1RC2HL101811-01 and by NIH grant
nos. UL RR031980 and UL1TR000100
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomly assigned, by a computer-gener-
ated random sequence, to either the intervention group or the
usual-care group
Allocation concealment (selection bias) High risk Intervention group participants were randomised before being
invited to participate. Control participants were not contacted as
no additional care/measurement took place. Many intervention
participants declined toparticipate, creating significant potential
for bias
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unlikely to affect, objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Quote: “In the PharmD-PCP MTM [intervention] group, the
pharmacistmeasured the blood pressure (BP) at the beginning of
each study visit, as was standard practice for all internal medicine
clinic patients, whereas the nursing staff measured BP in the
usual-care patients.”
Systematic differences in measurement likely to create detection
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition > 30%.
Selective reporting (reporting bias) Low risk All reported
Other bias High risk Additional inclusion criteria were applied to the intervention
group after randomisation.
Quote: “An additional inclusion criterion of having had a clinic
visit in the 6-month period before screening was applied to en-
sure that data from only patients who continued to receive pri-
mary care pharmacist care for at least 9 months after the index
visit were included.”
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Ho 2013
Methods Multi-centre randomised trial
Participants 253 participants with acute coronary syndrome (ACS) (intervention 129; control 124)
4 Veterans Affairs (VA) medical centres
USA
Year of study: July 2010 to March 2013.
Interventions The intervention comprised four components: 1. Quote “Medication reconciliation:
Within 7 to 10 days of hospital discharge, a pharmacist met/phoned patients to address
medication problems or adverse effects and reconcile differences in medications between
the pre-hospital and post-discharge regimens.The pharmacist also provided patients with
a pill box for those who did not have one and instructed the patient on how to fill the pill
box. 1 month later, the pharmacist called the patient to assess any interim new medica-
tions as well as adverse effects to medications and/or adherence issues, and synchronised
refill dates of cardiac medications. The pharmacist answered any other questions related
to medications, emphasising the importance of continuing to take medications as pre-
scribed. 2. Patient Education: At 1 week and 1 month post-discharge visit and thereafter
by automated voice messages and telephone calls a pharmacist provided education about
their medicines when requested by the patient
3. Collaborative Care: The pharmacist notified the patient’s primary care clinician and/
or cardiologist (if the patient had one) that the patient was enrolled in the adherence
intervention by having them co-sign the pharmacists’ initial enrolment note in the com-
puterised medical record. 4. VoiceMessaging: The voice messaging system contacted pa-
tients regularly with medication reminders (monthly) and medication refill reminders
(timed to refill due dates)”
Duration: 12 months
Outcomes % achieving target blood pressure
Systolic blood pressure (BP)
Diastolic BP
Mean Low Density Lipoprotein cholesterol
Notes Funding source: This study was funded by a Veterans Health Administration Health
Service Research&Development (HSR&D) Investigator Initiated Award (grant IIR 08-
302). Dr Bosworth was supported by a senior career scientist award (Research Career
Scientist Award VA HSR&D 08-027)
Conflict of interest: The funding agency had no role in design and conduct of the study;
in the collection, analysis, and interpretation of the data; or in the preparation, review,
or approval of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients with ACS were randomised using
blocked randomisation stratified by study site in a 1:1
ratio to intervention or usual care
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Ho 2013 (Continued)
Allocation concealment (selection bias) Low risk The allocation sequence was concealed until a patient
consented to participate and was generated centrally
using the graphical user interface implemented for the
study
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk The allocation sequence was concealed until a patient
consented to participate and was generated centrally
using the graphical user interface implemented for the
study
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “3 BP measurements were taken in standard
fashionby someone blinded to study group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was performed. Between
group attrition < 10%
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Holland 2005
Methods Randomised trial
Participants 872 elderly patients (intervention 437; control 435)
4 general hospitals and 6 community hospitals
Norfolk and Suffolk, UK
Year of study: October 2000 to December 2002.
Interventions Pharmacists made home visits to talk with patient and carers through self-medication,
drug adherence, symptoms of drug reactions. This was reinforced by a second visit
between 6 and 8 weeks later
Outcomes Euroqol (EQ)-5D at 6 months
Total number of emergency hospital readmissions in 6 months
Notes Funding source: :Research costs were funded by a project grant from NHS Eastern
Region R&D and the Academic Pharmacy Practice Unit of the University of East Anglia.
RH was funded by the MRC as a research fellow during this study. Excess treatment
costs were funded by Norfolk Health Authority, Norfolk SocNorfolk Health Authority,
contributed some funding towards this study
Conflict of interest: AL works for a primary care trust, which pays for healthcare services
and is interested in interventions to reduce unnecessary readmissions to hospital.The
trust’s predecessor part funded this study
Risk of bias
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Holland 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We used third party telephone randomisation based on
a computer generated sequence in blocks of varying length.”
Allocation concealment (selection bias) Low risk Quote: “We used third party telephone randomisation based on
a computer generated sequence in blocks of varying length.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Participants were told after randomisation the group to which
they had been allocated
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. overall completion rate >80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Hunt 2008
Methods Randomised trial
Participants 463 hypertensive patients (intervention 230; control 233).
9 community-based primary care clinics from primary care research network
Oregon, USA
Year of study: Not stated.
Interventions Intervention comprised physician-pharmacist collaboration following hypertension
management guidelines. Pharmacists reviewed medication, lifestyle habits, assessed vi-
tal signs and reactions, provided education, identification of barriers to adherence and
provided a regimen. Average of 7.2 total visits between pharmacists and physicians
Outcomes Systolic and diastolic blood pressure (BP) at 12 months
SF-36 (physical functioning) at 12 months
BP in range
Notes Funding source: Boehringer Ingelheim funded the cost of the educational mailings and
the conduction of the study
Conflict of interest: All data collection, analysis, and reporting were conducted by the
study investigators and the Providence research staff. The investigators report no other
conflict of interest
Risk of bias
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Hunt 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a computer-generated random sequence
Allocation concealment (selection bias) Low risk Using a computer-generated random sequence
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Participant blinding was not possible. Knowledge of allocation
may have influenced behaviour
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Blood pressure was assessed by registered nurses blinded to par-
ticipants’ randomisation allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% but overall attrition rate >40%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Jaber 1996
Methods Randomised trial
Participants Urban African-American patients with diabetes: 39 (intervention 17; control 22)
Health professionals: 1
Practices: 1
University-affiliated general medicine outpatient clinic
Michigan, USA
Year of study: Not stated.
Interventions Pharmacist provided diabetes education, medication counselling, instructions on dietary
regulation, exercise and home glucose monitoring, and evaluation and adjustment of
drug regimen, vs usual care.
Length of intervention: 4 months
Outcomes Quality of life
Fasting plasma glucose
Notes Funding source: Diabetes Research and Education Foundation and Upjohn
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Jaber 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were assigned to an intervention or
control group in a randomized, parallel design fashion and fol-
lowed over a 4-month period”.
Unclear how randomisation took place
Allocation concealment (selection bias) Unclear risk Allocation procedure not described explicitly. No information
provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were not blinded but all expected differences in be-
haviour are part of the intervention
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unclear if assessors were blind to allocation. Primary outcomes
were objective
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition > 10%.
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Jackson 2004
Methods Randomised trial
Participants Patients: 128 (intervention 60; control 68)
Health professional (delivering intervention): 1
Practice: 1
Home-based follow-up of patients discharged from Royal Hobart acute care teaching
hospital in
Tasmania, Australia
Year of study: Not stated.
Interventions Pharmacist conducted home visit to test international normalised ratio (INR) and edu-
cate patients about anticoagulant therapy using printed educational materials.
Pharmacist informed physicians about patients’ INR, recommended dosage adjustments
and implemented therapy changes, vs usual care.
Length of the intervention: 24 minutes
Number of interventions: 4 during 90 days
Outcomes Therapeutic INR on day 8 after discharge
Total, major, and minor bleeding complications within 90 days of discharge
Notes Funding source: National Institute of Clinical Studies (NICS) and the Royal Hobart
Hospital Research Foundation. Roche Diagnostics Pty Ltd (Australia) contributed INR
monitors and test strips
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Jackson 2004 (Continued)
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients who provided informed consent were allocated to either
an intervention (home monitoring; HM) or control (usual care;
UC) group, using a computer-generated list of random numbers
Allocation concealment (selection bias) Low risk Patients were home-based; allocation was probably adequately
concealed
All general practitioners were sent a personalised information
letter when their patient was discharged, indicating the group
that the patient was enrolled in and what follow-up they would
receive
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Personnel were aware of allocation and this may have influenced
treatment in ways not specified by protocol. In particular, GPs
caring from UC participants have altered treatment
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Theraputic INR; unclear in terms of objectivity
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition overall. Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Jahangard-Rafsanjani 2014
Methods Randomised trial
Participants 101 participants with diabetes (intervention 51: control 50)
Community pharmacy
Iran
Year of study: Not stated
Interventions Intervention group received a Pharmacist-DeliveredDiabetes Support Program compris-
ing 5 monthly visits with a telephone call between visits to reinforce treatment adherence
and resolve any therapy-related problems. Education was delivered on diet management,
physical activity, and diabetes complications. At the recruitment visit, patients were pro-
vided with a blood glucose self-monitoring device and the required test strips were sup-
plied for 1 month. Patients were trained how to use the device and were requested to
document blood glucose levels every other day in a rotating schedule (fasting, post-pran-
dial, before lunch, before sleep). Each patient was provided with a special logbook and
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Jahangard-Rafsanjani 2014 (Continued)
educational pamphlets for the diabetes medications. At each follow-up visit, medication-
related problems, self-care issues, and the logbook were discussed with the patient
Duration: 5 months
Outcomes HbA1c
Systolic blood pressure (BP)
Diastolic BP
Notes Funding source: Deputy of Research, Tehran University of Medical Sciences. (Project
ID: 90-04-156-16161)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence was generated based on a block ran-
domisation algorithm (1:1 allocation ratio; block size: 4), and 2
authors who were not involved in the recruitment process had
access to the randomisation list
Allocation concealment (selection bias) Low risk Randomisation sequence was generated based on a block ran-
domisation algorithm (1:1 allocation ratio; block size: 4), and 2
authors who were not involved in the recruitment process had
access to the randomisation list. The community pharmacist re-
quested an allocation order
using telephone calls after a patient signed the informed consent
form
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unclear if measurement of primary outcomes was blinded
HbA1c is an objective outcome.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unclear if measurement of primary outcomes was blinded
HbA1c is an objective outcome.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
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Jarab 2012
Methods Randomised trial
Participants 133ChronicObstructive PulmonaryDisease (COPD) patients (intervention 66; control
67)
1 hospital outpatient clinic, Royal Medical Services Hospital
Jordan
Year of study: January 2011 to July 2011.
Interventions Patients were educated about COPD and management of symptoms. They were assessed
for medication use, given an educational booklet with simple exercises. Motivational
interviewing was used to improve adherence to prescribed treatment. This intervention
was given once and assessed over 6 months
Outcomes Forced Expiratory Volume (FEV1) at 6 months
Hospital admissions for acute exacerbation during 6 months follow-up
Notes Funding source: Alzaytoonah University of Jordan
Conflict of interest: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study participants were randomly assigned to intervention and
control groups by aminimisation technique using statistical soft-
ware
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded assessment of most outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall competion rate >80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
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Khdour 2009
Methods Randomised trial
Participants 173 participants with Chronic Obstructive Pulmonary Disease (COPD) (intervention
86: control 87)
All participants recruited from an outpatient COPD clinic
Northern Ireland, UK
Year of study: October 2006 to May 2008.
Interventions An individualised face-to-face intervention for each COPD patient delivered by the
clinical pharmacist focusing on their prescribedmedication, adherence, inhaler technique
and symptom management. Patient understanding of indications and doses of each
medicine, inhaler use were checked and advice was provided on simple exercises for
patients to do at home (booklet also provided) and smoking cessation if relevant. A
customised action plan for acute exacerbations was developed for each patient. At each
6-monthly outpatient clinic visit patients received reinforcement of the education on
COPD and its treatment from the clinical pharmacist. In addition, follow-up telephone
calls by the clinical pharmacist to reinforce the education and motivate the patients
to achieve their goals were made at 3 and 9 months, i.e. between outpatient clinic
appointments
Duration: 12 months.
Outcomes Health-related quality of life (HRQoL)
St George’s Respiratory Questionnaire (SGRQ)
Forced Expiratory Volume (FEV1)
Notes Funding source: Chest Heart and Stroke (N. Ireland) for financial support
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation carried out using minimisation method
Allocation concealment (selection bias) Unclear risk Probably centrally allocated but a little unclear
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Quote: “For operational reasons, the researcher could not be
blinded to the group to which the patient belonged”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Quote: “Patients who had difficulty self-completing question-
naires, e.g. forgot reading glasses, had the questionnaires read
to them. If this occurred, a strict protocol was followed, i.e. the
questions were read to the patients and their answers sought
without any interpretation ”.
All of these outcome variables might be influenced by the out-
come assessors
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Khdour 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) High risk Lots of variables measured, not all reported.
Quote: “In addition to data collected by questionnaire, patients’
charts and computerised hospital records were consulted to ob-
tain information on: emergency department visits within the last
year, hospital admissions within the last year, FEV1, medication
and medication regimen, body weight and other concomitant
illness.”
Other bias Low risk None
Krass 2007
Methods Randomised trial
Participants 335 diabetic patients (intervention 176; control 159)
56 pharmacies (intervention 28; control 28)
4 regions of Australia
Year of study: March 2004 to September 2004.
Interventions Educated about self-monitoring and given meter for blood glucose, adherence support,
medication review, self-management and lifestyle. Individual goal-setting and homework
sheets to be completed by next visit
5 visits over 6 months
Outcomes Diastolic and systolic blood pressure
HbA1C
Notes Funding source: The Pharmacy Diabetes Care Program was funded by the Australian
Government Department of Health and Ageing as part of the Third Community Phar-
macy Agreement. Precision Link software from Abbott Diagnostics supported training
and individual pharmacists in this study
Conflict of interest: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States using Excel but does not say how
Allocation concealment (selection bias) Unclear risk Unclear how allocation concealment was conducted
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk No blinding. Unclear if it may have influenced performance
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Krass 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk HbA1c unlikely to be biased by non-blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate >80%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Kritikos 2007
Methods Randomised trial
Participants 48 participants with asthma (intervention (1) 16; intervention (2) 16; control 16)
6 community pharmacies
Sydney, Australia
Year of study: January 2005 to July 2005
Interventions Pharmacists delivered a single interactive Asthma Education Programme of 150 minutes
to small groups of participants (5 - 8), focusing on asthma management, asthma medica-
tion, inhaler use. Relevant written information was also provided. Detailed programme
guidelines, (which included the use of an educational resource kit Talk in A Box provided
by the Asthma Foundation of New South Wales), were prepared to guide pharmacists
through each session and enable standardised delivery of the programme
Duration: Single session
Outcomes Proportion with severe asthma, asthma quality of life
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Three pharmacies were randomly selected”; no more
info on randomisation and “subjects were not randomly se-
lected”
Allocation concealment (selection bias) Unclear risk Unclear if allocation concealed
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk No overlap in intervention delivery staff
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Kritikos 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Asthma severity is subjective and unclear about blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the trial.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Krska 2001
Methods Randomised trial
Participants 381 elderly patients (intervention 168; control 164; numbers were only given for those
that completed the study)
Number of participating practices unclear
Grampian, Scotland
Year of study: Not stated.
Interventions Pharmacists interviewed patients in their homes for medication use, use of health and
social services and to distribute prescribed medicines and a care plan; listing care issues,
output, planned actions and pharmacist input
2 interviews over 3 months.
Outcomes HbA1c
SF-36
Notes Funding source:
Conflict of interest:
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Following stratification by number of drugs, number
of cardiovascular drugs and the presence of a non-steroidal anti-
inflammatory drug other than low-dose aspirin on the repeat
prescription, patients were allocated randomly to intervention
or control.”
Therefore unclear about the actual method of randomisation for
each participant. Only states method for practice
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
High risk No blinding and self-reported outcome
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Krska 2001 (Continued)
All Outcomes/Outcome 1
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk No blinding and self-reported outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Lai 2013
Methods Randomised trial
Participants 198 participants with osteoporosis (Intervention 98; control 100)
A tertiary hospital osteoporosis clinic
Malaysia
Year of study: September 2005 to February 2009
Interventions Participants in the intervention group received a “pharmaceutical care package” which
included a one-to-one, individualised medication review, education on osteoporosis,
risk factors, lifestyle modifications, goals of therapy, side effects and the importance of
adherence, at months 0 (baseline), 3, 6 and 12, with monthly follow-ups by telephone
calls in between for the first 6 months, then every 3 months up to month 12. Materials
included a booklet and a personalised osteoporosis medication regimen
Duration: 12 months
Outcomes Quality of Life Questionnaire of the European Foundation for Osteoporosis
Notes Funding source: This project was funded by the Postgraduate Research Fund P0110/
2006B, University of Malaya and the Endocrine Research fund, University of Malaya
Conflict of interest: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Therefore, participants were first divided into whether theywere
on alendronate or risedronate, then randomly allocated to the
intervention group using the random digits table (98) while the
rest were allocated to the control group
Allocation concealment (selection bias) Unclear risk No information about concealment.
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Lai 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk No blinding of participants. Some potential for bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Quality of life is subjective and therefore categorised as high risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Lee 2006
Methods Randomised trial
Participants 159 elderly patients (intervention 83; control 76)
1 general hospital
Washington, USA
Year of study: June 2004 to August 2006.
Interventions Medication education, time-specific medication packs.
Meet with pharmacists every 2 months over a 6-month period
Outcomes Diastolic and systolic blood pressure at 14 months
Low density lipoprotein mg/dL
Notes Funding source: This study was partially funded by a competitive junior investigator
grant award from the American Society of Health-System Pharmacists Research and
Education Foundation, managed under the auspices of the TRUE Research Foundation
Conflict of interest: Dr Taylor reported receiving research grant and honoraria from Kos
Pharmaceuticals, honoraria from Pfizer Pharmaceuticals, Wyeth Pharmaceuticals, and
Merck KgA, and a consulting agreement with Alinea Pharmaceuticals.Drs Lee and Grace
reported no financial disclosures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Quote: “Allocation was concealed to both patients and the study
personnel who enrolled participants by central control of the
randomization sequence.”
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Lee 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk No blinding
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded measures of blood pressure
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and similar dropouts
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Lenaghan 2007
Methods Randomised trial
Participants 136 elderly patients (intervention 69; control 67).
1 community pharmacist and patients from 1 general practice
Norfolk, England
Year of study: Not stated.
Interventions 2 home visits by a community pharmacist discussing drug interactions, education of
medicines, removal of out-of-date drugs and assessment of need for adherence aid. Visits
were arranged to include the carer of the elderly patient. Pharmacists discussed any issues
with the general practitioner for possible changes to medication prescription
Outcomes Euroqol (EQ)-5D
Hospital admissions
All-cause mortality
Notes Funding source: The main author’s post was funded by NHS Executive Eastern Region
research funding
Conflict of interest: The medication review intervention was funded by Holt Medical
Practicewho hosted the research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomisation was carried out by a third party, and
was stratified by whether the patient lived alone.”
Allocation concealment (selection bias) Unclear risk Unclear if the person enrolling the participant was aware of
allocation
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Lenaghan 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Knowing they were in the intervention group may have resulted
in behaviour change
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Hospital readmissions, deaths etc. not likely to be influenced
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however overall completion rate
<80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Lenander 2014
Methods Randomised trial
Participants 209 participants with drug-related problems (intervention 107: control 102)
Primary care centre
Stockholm, Sweden
Year of study: September 2004 to not stated.
Interventions Intervention group received a medication review performed by a certified geriatrics phar-
macist, involving a standardised semi-structured questionnaire that allowed patient in-
teraction. Computerised patient records were checked for prescriptions, drug indica-
tions, and plans for evaluation. Drugs and dosages were evaluated to correlate with renal
function, good practice and the drug formulary. A patient-centred technique was used,
focusing on the patients’ answers to assess understanding of and concordance with drug
treatment. The patients were also asked about prescribers other than their GP, and use
of non-prescription and herbal drugs. Concluding pharmaceutical advice was given to
patients and entered into the computerised patient record
Duration: single session
Outcomes Total drug-related problems
Number of drugs
Healthcare use: hospitalisations
Notes Funding source: The trial was funded by Stockholm County Council, the Stockholm
Drug and Therapeutics Committee, and Apoteket AB
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Lenander 2014 (Continued)
Random sequence generation (selection
bias)
Unclear risk Unclear how randomisation occurred
Allocation concealment (selection bias) Low risk Seems to have happened before any non-standardised patient
contact (a letter)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk No interaction with pharmacist in control group
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Data were analysed by an independent certified geriatrics phar-
macist, blinded to patient group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%. however, high attrition (>30%)
overall
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Li 2014
Methods Randomised trial
Participants 117 participants with Chronic Obstructive Pulmonary Disease (COPD) (intervention
58: control 59)
Participants recruited from University hospital
China
Year of study: February 2012 to January 2014
Interventions Intervention group patients received pharmacist-led individualised education sessions
(20 - 30minutes each session, 5 - 6 sessions) on effective use of respiratory devices, patho-
physiology of the disease, interpretation of medical testing and rationale for medication.
Medication management records evaluated each participant’s preferences and analysed
possible barriers to medication adherence. Telephone calls (4 - 5 sessions) were made at
the midpoint between clinic visits. During telephone counselling, the pharmacist asked
about the patient’s treatment effects, clarified any misconceptions, explained the nature
of any side effects and reminded patients of their next clinical appointment
Duration: 6 months
Outcomes Health-related quality of life (HRQoL)
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
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Li 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The pharmacists were blinded to the randomisation codes,
which were computer-generated and sealed in envelopes labelled
with consecutive numbers
Allocation concealment (selection bias) Low risk The pharmacists were blinded to the randomisation codes,
which were computer-generated and sealed in envelopes labelled
with consecutive numbers
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded and with subjective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Low risk of bias in detection: surveys completed by participant
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%, however, high attrition overall
(~30% lost at 1-year follow-up)
Selective reporting (reporting bias) Low risk All major outcomes reported
Other bias Low risk None
Lopez 2006
Methods Randomised trial
Participants 134 participants with heart failure (intervention 70: control 64)
Patients recruited from 2 hospitals
Spain
Year of study: September 2000 to not stated.
Interventions Intervention group received a pharmacist-led programme comprising a face-to-face visit
at discharge and a follow-up phone call. At discharge information tailored to the patient
was provided on the main characteristics of heart failure (pathogenesis and symptoms),
diet and drug therapy. Verbal communication was complemented by written materials.
Monthly during the first 6 months of follow-up, and subsequently, every 2 months, a
telephone call was made to the patient’s home to reinforce the information provided
Duration: 1 year
Outcomes Number of hospital readmissions, EuroQol
Notes Funding source: This study (PI00/0665) was co-financed with a grant from the Health
Research Fund (Fondo de Investigación Sanitaria, FIS) and the European Regional De-
velopment Fund (ERDF)
Conflict of interest: Not stated
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patients were randomized to one of the two groups through
a randomisation software
Allocation concealment (selection bias) Low risk Neither the physician nor the nurse responsible for the patient
knew the allocation until the educational intervention, the day
of discharge
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Personnel not blinded
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Assessors unblinded. Number of hospital readmissions is an ob-
jective measure
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition >20%. High attrition overall (>40%).
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Losada-Camacho 2014
Methods Randomised trial
Participants 182 participants with epilepsy (intervention 70: control 74)
Outpatient with epilepsy and a referral centre
Colombia
Year of study: June 2010 to September 2012.
Interventions Intervention group received a pharmaceutical care programme consisting of
1. Monthly or bi-monthly interviews including medication review; treatment adherence
(importance of regular use, and provision of adherence aids e.g. amedication record, a pill
box, an alarm clock as a reminder of when medications should be taken); registration of
seizures and possible triggers based on a patient’s completed seizure journal); therapeutic
drug monitoring in accordance with the guidelines of the International League Against
Epilepsy. Importance of lifestyle was emphasised. A guide for patients with epilepsy
was sent by e-mail so that it could be discussed at face-to-face interviews and specific
brochures were delivered according to the needs of each patient
2.Monthly lectures on: Epilepsy in women,Quality of life and epilepsy, Pharmacological
and non-pharmacological treatment in epilepsy, Contraception, Fertility, Pregnancy and
childbirth, Sleep hygiene, Breastfeeding and home care, Menopause and bone health
and how to improve memory
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Losada-Camacho 2014 (Continued)
Duration: 6 months
Outcomes Quality of life in epilepsy inventory-31 scores
Notes Funding source: This study was funded by a competitive investigator grant award from
the Universidad Nacional de Colombia (Colombia) - Research Division of Bogotá (ref:
202010011419 Quipu Code)
Conflict of interest: The Universidad Nacional de Colombia had no role in the design
and conduct of the study, in the collection, analysis and interpretation of the data or in
the preparation, review or approval of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The random allocation sequence was generated by ballot papers
drawn from an urn without the principal investigator and the
co-ordinator knowing the results in advance
Allocation concealment (selection bias) Low risk The concealment was performed by placing the ballot papers
in individual, opaque, sealed envelopes, numbered sequentially,
which were handled exclusively by the study co-ordinator
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Quote: “Although the study was not blinded, it was explained to
the patients that due to the large number of patients, all could not
be served at the same time and therefore the studywas conducted
in two stages whose sequence was decided randomly, so they
could begin the process of pharmaceutical care immediately, or
do it six months after the second questionnaire session. In this
way the effect of knowing the group assigned was avoided and
those in the control group were rewarded for their participation
in the study programme by receiving PC after answering the
questionnaires the second time.
The study was blind to the neurologists. They were informed
that the RCT was taking place in the institution but did not
know which patients were participating in the trial. Due to the
study’s design, the principal investigator was not blinded to the
patients’ allocation.”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Although the study was not blinded, it was explained to
the patients that due to the large number of patients, all could not
be served at the same time and therefore the studywas conducted
in two stages whose sequence was decided randomly, so they
could begin the process of pharmaceutical care immediately, or
do it six months after the second questionnaire session. In this
way the effect of knowing the group assigned was avoided and
those in the control group were rewarded for their participation
in the study programme by receiving PC after answering the
questionnaires the second time.
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Losada-Camacho 2014 (Continued)
The study was blind to the neurologists. They were informed
that the RCT was taking place in the institution but did not
know which patients were participating in the trial. Due to the
study’s design, the principal investigator was not blinded to the
patients’ allocation.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however overall attrition > 20%
Selective reporting (reporting bias) High risk Multiple outcomes
Other bias Low risk None
Magid 2013
Methods Randomised trial
Participants 348 hypertensive patients (intervention 175; control 173)
10 primary care clinics
Colorado, USA
Year of study: Not stated.
Interventions Both groups were given education materials for managing high blood pressure. Inter-
vention group also received a home blood pressure (BP) cuff and training of use. They
were required to upload their BP 3 times a week for pharmacist review who would make
medication adjustments, review adherence and flag high reports. They would commu-
nicate this by phone or e-mail
Outcomes Diastolic and systolic BP
Achievement of BP goal at 6 months
Notes Funding source: Funded in part by the American Heart Association
Conflict of interest: None stated. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the American Heart Association
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random allocation sequence was computer-generated using
stratified randomisation with an allocation ratio of 1:1
Allocation concealment (selection bias) Low risk Quote: “The sequence was concealed from the patient until the
baseline visit.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk BP measurement has low risk of performance bias.
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Magid 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Patients in both groups returned for a clinic visit at 6
months, at which time they had their BP taken by a research
assistant blinded to study group assignment using the same stan-
dardized protocol that was used at the baseline visit.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall attrition rate >80%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Mahwi 2013
Methods Randomised trial
Participants 130 participants (intervention 65; control 65)
Diabetic Centre
Sulaimany, Iraq
Year of study: September 2010 to January 2011.
Interventions Pharmaceutical care. The intervention group was followed up for 3 visits. The interval
between each visit ranged from 5 to 6 weeks with continuous weekly telephone calls for
the follow-up
Duration: 15 - 18 weeks
Number of Interventions: 3 visits, every 5 - 6 weeks
Outcomes Fasting plasma glucose (FPG)
HbA1c
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “In this study, patients were divided into two groups by
simple randomization technique”
Unclear how this actually happened
Allocation concealment (selection bias) Unclear risk Quote: “In this study, patients were divided into two groups by
simple randomization technique”
Unclear if selection bias an issue
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Not stated but objective outcomes
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Mahwi 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Not stated but objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Malone 2001
Methods Randomised trial
Participants Patients at high risk for medication-related problems (≥ 3 of following criteria: (1) > 5
medications, (2) > 12 doses a day, (3) > 3 chronic medical conditions, (4) > 4 changes to
medication regimen over past year, (5) taking < 80% of medications based on pharmacy
refill records, (6) taking medication requiring therapeutic monitoring
Patients: 1054 (intervention 523; control 531)
Health professional (delivering intervention): 78
Practice: 9
Ambulatory care clinics in Veterans Affairs Medical Centers
USA
Year of study: Not stated.
Interventions Pharmacist reviewedmedical records, performed physical assessment and laboratory tests
to assess appropriateness of medication therapy, modified therapy as necessary, educated
patients, and made referrals to other health professionals, vs usual care
Length of the intervention: > 15 minutes for > 73% of patient contacts
Number of interventions: mean of 3.5 during 12 months
Outcomes Cholesterol
Health-related quality of life using SF-36 questionnaire
Notes Funding source: Pharmacia & Upjohn, Inc, under the direction of the VA/Pharmacia
& Upjohn Steering Committee
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Potential subjects for the study were identified and randomised
by the central co-ordinating centre at theUniversity of Colorado
Health Sciences Center
Allocation concealment (selection bias) Low risk Quote: “randomised by a central coordinating centre”
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Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unblinded, but participants saw different personnel.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unblinded, but lipid level measurement is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
Margolis 2013
Methods Randomised trial
Participants 450 participants with hypertension (intervention 228: control 222)
16 primary care clinics in an integrated health system
Minneapolis-St. Paul, Minnesota, USA
Year of study: March 2009 to not stated.
Interventions Pharmacist telemonitoring intervention with remote BP measurement
Intervention patients received home monitors that store and transmit blood pressure
(BP) data to a secure website through a modem. Pharmacists met with patients for 1
hour during which they reviewed the patient’s relevant history, covered general points
about hypertension, instructed them on using the home BP telemonitor system and the
individualised home BP goal (i.e. < 135/85 mmHg or < 125/75 mmHg for patients with
diabetes or kidney disease). 20 patients were instructed to transmit at least 6 BP mea-
surements weekly (3 morning and evening). During the first 6 months of intervention,
patients and pharmacists spoke every 2 weeks by phone until BP control was sustained
for 6 weeks, then frequency was reduced to monthly. During intervention months 7 -
12, phone visits were every 2 months. During telephone calls, pharmacists emphasised
lifestyle changes and medication adherence. They assessed and adjusted antihypertensive
drug therapy based on an algorithm using the percentage of home BP readings meet-
ing the goal. Pharmacists communicated with patients’ primary care teams through the
electronic medical record following each visit
Duration: 12 months intervention, 18 months follow-up
Outcomes Systolic BP
Diastolic BP
Notes Study is cluster-randomised by clinic, but all data after that is at patient level
Funding source: Grant received from the National Heart, Lung, and Blood Institute
(R01HL090965)
Conflict of interest: The sponsor had no role in the design and conduct of the study;
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collection, management, analysis and interpretation of the data; and preparation, review
or approval of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The 16 primary care clinics were randomised to either the usual
care (n = 8) or intervention (n = 8) arms. Clinics were blocked
by size and clinic-level baseline BP control in 2008 in order to
balance those factors across study arms. Patients were linked to
their primary care clinic by self-report and were assigned to the
intervention based on which clinic they attended, resulting in
228 patients assigned to TI and 222 patients assigned to UC
Allocation concealment (selection bias) Low risk All consenting patients and primary care providers were blinded
to the study design and intervention assignment of the clinics,
although each patient and their primary care provider were in-
formed of their treatment assignment after randomisation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Objective outcome measures. also,
Quote: “Research clinic coordinators were not blinded to clinics’
treatment assignments, but were trained to treat patients in both
study arms identically”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Research clinic coordinators were not blinded to clinics’
treatment assignments, but were trained to treat patients in both
study arms identically.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Quote: “To account for missing data on continuous outcomes
we usedmaximum likelihoodbased ignorablemethods that yield
valid inference when the outcome data are missing at random.
We conducted sensitivity analyses adjusting for race and hy-
pertension treatment, which showed some imbalance by study
group”
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Marques 2013
Methods Randomised trial
Participants 58 participants with depression (intervention 31: control 27)
Outpatient clinic of Alzira Velano Hospital
University of Alfenas, Brazil
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Marques 2013 (Continued)
Year of study: April 2010 to January 2012.
Interventions Patient Education using Dáder method
Intervention group patients were visited approximately every 30 days; the intervals be-
tween visits could be shorter according to the patient’s needs. These patients were given
verbal and written information about the treatment, and educational lectures about dis-
ease and treatment; interventions with the psychiatrist were performed as needed
Frequency: monthly
Duration: 3 months
Outcomes Beck depression Inventory (BDI)
Becks Anxiety Inventory (BAI)
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk According to the Dáder Method, the patients in the interven-
tion group were visited approximately every 30 days; the inter-
vals between visits could be shorter according to the patient’s
needs. These patients were given verbal and written information
about the treatment and educational lectures about disease and
treatment; interventions with the psychiatrist were performed
as needed
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded pharmacists conducted the intervention and control
arm interaction: bias possible
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Participants unblinded completed self-report measures. Bias is
likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias High risk Only 3 months, seasonality, also numbers differ between table
and flow chart
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Marra 2012
Methods Randomised trial
Participants 139 participants with osteoarthritis (OA): (intervention 73; control 66)
Community pharmacies
Metropolitan area of Vancouver, Canada
Year of study: Not stated.
Interventions Pharmacist-led or educator-led educational intervention
Quote “Intervention patients received one-on-one consultation with a pharmacist. Phar-
macists offered education, medication review, referral to a physiotherapist and a guided
exercise program
We provided education regarding counselling on the symptoms and other aspects of knee
OA. Patients were given the opportunity to participate in an Arthritis Self Management
Program
Each patient received personalised education from the physiotherapist for a personalised
regimen. Patients were told to avoid exercise during active symptom flares. Walking aids
were recommended when necessary. At the end of weeks three and six, the patients were
reassessed by the physiotherapist and the participant’s exercise recommendations were
adjusted as needed. Patients in the intervention group were recommended to attend at
least two physiotherapist-guided exercise sessions per month for a total of 12 sessions.”
Duration: 6 months
Outcomes WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)
Notes Funding source: This study was funded by a pilot grant from the Canadian Institutes
of Health Research/Canadian Arthritis Network New Emerging Team Grant (Tooling
Up for Early Osteoarthritis) and by peer-reviewed operating grants from the Michael
Smith Foundation for Health Research and the Canadian Arthritis Network. Dr. Marra
is a Health Services Scholar, supported by the Michael Smith Foundation for Medical
Research, and is a Government of Canada Research Chair in Pharmaceutical Outcomes.
Dr. Cibere is supported by a JW McConnell Family Foundation Scholar Award and a
CIHR Clinical Scientist Award. Dr. Tsuyuki is supported by the Merck Frosst/Aventis
Chair in Patient Health Management at the University of Alberta. Dr. Khan is a New
Investigator at the Canadian Institutes of Health Research
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk To randomise the pharmacies, values from a uniform (0,1) dis-
tribution were generated by the study statistician. Pharmacies
were randomized to provide either the intervention (21 phar-
macies) or usual care (21 pharmacies)
Allocation concealment (selection bias) Unclear risk Pharmacy-level randomisation most important here. Unclear
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded. Participants were informed whether they were to
receive the interventionor usual care after they provided consent.
Subjective outcomes subject to bias
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Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded. Participants were informed whether they were to
receive the interventionor usual care after they provided consent.
Subjective outcomes subject to bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All analyses were conducted using intention-to-treat principles.
Between group attrition < 10%
Selective reporting (reporting bias) Low risk All reported. 1 primary outcome
Other bias High risk Baseline differences
Mazroui 2009
Methods Randomised trial
Participants 240 diabetic patients (intervention 120; control 120)
1 hospital outpatient clinic
United Arab Emirates
Year of study: Not stated.
Interventions Intervention patients were educated on their illness and medication needs, risk of com-
plications, side effects and storage, healthy lifestyle, and self-monitoring. They were also
given a reinforcing leaflet of this information. 1 initial intervention contact with follow-
up assessments every 4 months for 1 year
Outcomes All measured at 12 months
Diastolic and systolic blood pressure (BP)
Fasting blood glucose mg/dL
HbA1c
Serum total cholesterol
SF-36 (physical functioning)
Notes Funding source: Not stated
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After recruitment, patients were randomly assigned to
one of two groups: intervention group or control group.”
Allocation concealment (selection bias) Low risk Allocation occurred after randomisation:
Quote: “After recruitment, patients were randomly assigned to
one of two groups: intervention group or control group.”
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Mazroui 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Much of the interaction with non-blinded personnel
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk No evidence of blinding and several subjective measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate >80%.
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
McAlister 2014
Methods Randomised trial
Participants 279 patients > 18 years who had an ischaemic stroke or transient ischaemic attack
confirmed by a stroke specialist at 1 of the 3 stroke prevention clinics (intervention 139:
control 136)
Edmonton, Alberta, Canada
Hypertension and cholesterol
Year of study: 2009 to 2012.
Interventions Intervention patients received intensive pharmacist-led case management, consisting
of monthly follow-up visits with the study pharmacist for 6 months, independent of
planned follow-up with the clinic or family physician. At each visit, the study pharmacist
monitored the patient’s BP and lipid levels and initiated and/or titrated antihypertensive
and/or hypolipidaemic therapy as appropriate. The study pharmacist followed treatment
algorithms consistent with Canadian national guidelines. The pharmacist emphasised
medication and lifestyle adherence with patients and their caregivers, using the cardio-
vascular risk profile as an educational aid. The pharmacist also sent a fax to the primary
care physician after each visit outlining the status of that patient’s atherosclerosis risk
factors and any therapy adjustments made
Duration: 6 months
Outcomes Systolic blood pressure
Low density lipoprotein
Notes Funding source: Finlay McAlister and Sumit Majumdar received salary support awards
fromAlberta Innovates Health Solutions. Finlay McAlister held the University of Alberta
Chair in Cardiovascular Outcomes Research. Sumit Majumdar held the Patient Health
Management Chair at the University of Alberta. Project-specific funding for this trial
was provided by the Heart and Stroke Foundation of Alberta, the Alberta Heritage
Foundation for Medical Research, and Knowledge Translation Canada
Conflict of interest: None of the funders had a role in the design of the study nor in the
conduct, analysis, interpretation or reporting of the study, nor access to the data
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Randomisation will be done centrally by computer-gen-
erated random numbers, and a secure internet-based allocation
method that ensures allocation concealment”
Allocation concealment (selection bias) Low risk Quote “Randomisation will be done centrally by computer gen-
erated random numbers, and a secure internet-based allocation
method that ensures allocation concealment. As this study is un-
blinded, variable sized blocked randomisation will also be used
to preserve allocation concealment.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk All objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “with blinded ascertainment of outcome”
Quote: “all outcomes were collected in an independent and
blinded manner by observers who were masked to baseline mea-
surements and group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis. Between group attrition = 10%.
Selective reporting (reporting bias) Low risk Major results reported as planned
Other bias Low risk None
Mehos 2000
Methods Randomised trial
Participants Patients with stage 1 or 2 hypertension: 41 (intervention 20; control 21)
Health professionals (delivering intervention): not clear
Practices: 1
Family medicine residency training clinic
Colorado, USA
Year of study: Not stated.
Interventions Patients received blood pressure monitors, blood pressure diaries and telephone contacts
by pharmacist to evaluate blood pressure and response to therapy, vs usual care without
blood pressure self-monitoring.
Pharmacist informed primary care health professionals of patients’ blood pressure results
and provided therapy recommendations, vs usual care.
Length of intervention: 30 minutes (initial visit)
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Mehos 2000 (Continued)
Number of interventions: initial visits and phone call follow-ups over 6 months
Outcomes Systolic, diastolic, and mean arterial blood pressure
Notes Funding source: Supported by the 1998-1999 Bristol-Myers Squibb Pharmacy Practice
Hypertension Program grant from the American Association of Colleges of Pharmacy
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were randomized using a deck of cards and
enrolled in either the intervention or control group”
Allocation concealment (selection bias) Unclear risk Quote: “Randomized using a deck of cards”.
Unclear how this concealed allocation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Participants were unblinded. BP measurement has low risk of
performance bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk BP has low risk of detection bias.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk BP and SF-36, both reported
Other bias Low risk None
Mehuys 2008
Methods Randomised trial
Participants 201 asthma patients (intervention 107: control 94)
Recruited consecutively in 66 randomly-selected pharmacies
Flanders, Belgium
Year of study: January 2006 to October 2006.
Interventions Intervention patients received a protocol defined intervention at the start of the study
and at 1- and 3-month follow-up
Session 1 consisted of personal education from the pharmacist about: correct use of the
inhaler device; understanding asthma; symptoms, triggers and early warnings; under-
standing asthma medication and difference between controller and reliever medication,
and smoking cessation (if relevant)
At sessions 2 and 3 the pharmacist advice was based on the patient’s asthma score: If
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Mehuys 2008 (Continued)
score was < 15 (“uncontrolled” asthma): immediate referral to general practitioner or
respiratory specialist. If score was 15 - 19 (“insufficiently controlled” asthma): review
inhalation technique and check controller medication adherence. If score > 20 (“well-
controlled” asthma): no specific advice was needed
Control group patients received usual pharmacist care.
Frequency: sessions at 0, 1 and 3 months
Duration: 3 months
Outcomes Asthma Control Test score
Nights with awakenings
Peak expiratory flow (PEF) morning and evening
Notes Both control and intervention group involved pharmacy care.
Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequence of allocation to control or intervention group was
predetermined by the investigators based on a randomisation
table generated with SPSS 14.0 software
Allocation concealment (selection bias) Low risk Serially-numbered, closed envelopes were made for each partic-
ipating pharmacy
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Diary data: high risk:
Quote: “treatment recording (i) nocturnal awakenings due to
asthma, (ii) the number of inhalations of rescuemedication (dur-
ing the day or night), and (iii) the best of 3 measurements of
peak expiratory flow (PEF) made with a Mini-Wright Standard
Peak FlowMeter in themorning and evening before medication.
PEF data are expressed as the percentage of maximum predicted
value based on patient’s sex,age, and height.”
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Self-measured
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%, however, overall attrition 25%
Reasons for dropout were personal reasons (15), withdrawal
from study of the pharmacist (2), relocation (2), lost to follow-
up (27) and other reasons (5)
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
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Milos 2013
Methods Randomised trial
Participants 374 elderly patients (intervention 185; control 189) ≥ 75 years, and living in nursing
homes or the community
4 pharmacists with at least 4 years’ experience of performing medication reviews
Skåne County, Sweden
Year of study: September 2011 to February 2012.
Interventions Pharmacists conducted a medication review for patients based on electronic medical
records without interaction. Recommendations were sent to the patient’s physician by
team rounds, written contact, personal contact or phone
Outcomes Drug-related problems
Number of patients with potentially inappropriate medications
Number of patients with unplanned admissions
All-cause mortality
Notes Funding source: The study was conducted with government funding for projects involv-
ing improvement of drug therapy in the elderly
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisationwas performedusing a random-number gen-
erator and stratified only for geographic area
Allocation concealment (selection bias) Low risk After inclusion, the pharmacist used closed, non-transparent en-
velopes to randomise the patient to 1 of 2 groups: control or
intervention
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unclear from information provided
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Drug-related outcomes (number of drugs, drug-related prob-
lems, etc.) unlikely to be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk None identified
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Murray 2007
Methods Randomised trial
Participants 314 participants with heart failure (intervention 122: control 192)
University-affiliated, inner-city, ambulatory care practice
Indiana University Medical Group, Indianapolis, USA
Year of study: February 2001 to June 2004
Interventions Patient education and medication distribution.
When medications were dispensed, the pharmacist provided patient-centred verbal in-
structions and written materials about the medications by using a previously-tested
schema for instruction. Each medication category was assigned an icon (for example, the
icon for ACE (angiotensin converting enzyme) inhibitors was a red ace of hearts). The
same icon appeared on the container label and lid and on the written patient instructions.
Written instructions were aimed at patients with low health literacy and contained an
easy-to-follow timeline to remind patients when to take their medications. The pharma-
cist monitored patients’ medication use, healthcare encounters, body weight, and other
relevant data by using a study database. Information about patients was communicated
as needed to clinic nurses and primary care physicians
Frequency: every 2 months
Duration: 9 months
Outcomes Mean Emergency Department visits
Mean hospital admissions
Notes Funding source: Grant Support: In part by National Institutes of Health grants R01
AG19105 and R01 HL 69399 (Dr. Murray, principal investigator) and AG01799 (Dr.
Brater, principal investigator; Dr. Murray, co-principal investigator)
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “We randomly assigned patients, without blocking or
stratification, to receive the pharmacy intervention or usual care
by using a univariate discrete distribution using pseudo-random
number generation.”
Allocation concealment (selection bias) Low risk Interviewers contacted a centralised data manager at the end
of each interview to determine the patient’s study assignment,
which was otherwise concealed
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Quote: “[Usual care participants] received their prescription ser-
vices from pharmacists who rotated through the study phar-
macy. These pharmacists had not received the specialized train-
ing provided by the interdisciplinary team to the intervention
pharmacist and did not have access to the patient-centered study
materials.”
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Murray 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote:“We assessed interviewer blinding by using a comput-
erised closeout protocol at the end of each interview that re-
quired interviewers to guess whether each patient was in the in-
tervention or usual care group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) High risk Health-related quality of life (HRQoL) and disease-specific out-
comes not reported
Other bias High risk Quote: “during the busiest times, patients in the intervention
and usual care groups may have been in the pharmacy at the
same time.”
Naunton 2003
Methods Randomised trial
Participants 136 elderly patients (intervention 57; control 64) 15 were excluded after randomisation
Patients were recruited from the RoyalHobartHospital (the onlymajor public hospital in
the southern regionofTasmania) a 400-bed acute care teachinghospital. Visits performed
by 1 pharmacist
Southern Tasmania, Australia
Year of study: November 2000 to ~ May 2001.
Interventions Patients were visited in their homes 5 days after discharge from hospital. The study
pharmacist checked medication adherence and offered additional supports if this was
not met. They also offered education about medication, management, compliance; they
also discussed queries and improved liaison with health services. A letter was composed
with the patient to present to their doctor
Duration: 13 months with 90-day follow-up.
Outcomes Number of patients with unplanned readmissions
All-cause mortality
Notes Funding source: Abbott Australasia Pharmacy Research Grant, through SHPA
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to either an intervention or con-
trol group by the study pharmacist (MN) responsible for con-
ducting the home visits, using a computer- generated list of ran-
dom numbers.”
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Naunton 2003 (Continued)
Allocation concealment (selection bias) High risk Allocation by study pharmacist
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Non-blinded and some potential for bias in interactions
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unplanned readmissions, deaths etc. not likely to be biased
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall completion rate <80%. Attition rate per group not re-
ported
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Obreli-Neto 2015
Methods Randomised trial
Participants 200 participants with hypertension or diabetes (intervention 100: control 100)
Primary Health Care Unit (PHCU)
Salto Grande, Sao Paulo state, Brazil
Year of study: October 2006 to October 2009.
Interventions Intervention patients received pharmaceutical care in addition to usual care. The phar-
maceutical care intervention consisted of individual follow-ups according to the Phar-
macotherapy Workup and educational group activities. The Pharmacotherapy Workup
was performed by 4 trained pharmacists. During the Pharmacotherapy Workup, inter-
ventions were provided which aimed to improve compliance with the pharmacother-
apy. Pharmaceutical care included the assessment of non-compliance, discussions about
the role of medication, suggestions to physicians regarding new drug regimens and the
preparation of special packages to provide a visual reminder that a medication was taken.
The pharmaceutical care programme was developed individually according to the needs
of patients. Educational group activities were also organised once every 6 months, with
groups of 20 patients. During these activities, adherence, the dangers of self-medication,
and the correct storage of medicines were discussed
Frequency: every 6 months
Duration: 36 months
Outcomes Systolic blood pressure (BP)
Diastolic BP
Fasting glucose
HbA1c
Notes Funding source: No separate funding was obtained for this study
Conflict of interest: None stated
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Obreli-Neto 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequences (100 patients each in
the intervention and control groups)
Allocation concealment (selection bias) Low risk Computer-generated allocation using medical record numbers
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk All objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk All objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk All major results reported
Other bias Low risk None
Okamoto 2001
Methods Randomised trial
Participants 330 patients with hypertension (intervention group 164; control group 166)
Health professional (delivering intervention): 1
Practice: not clear
Hypertension and general medicine clinics within a managed care facility
USA
Year of study: Not stated.
Interventions Hypertension care provided by pharmacist or general practitioner
Pharmacist managed treatment of patients with hypertension and obtained consent from
physicians for therapy changes vs usual care
Length of the intervention: not clear
Number of interventions: 5 during 6 months
Outcomes BP - systolic
BP - diastolic
Health-related quality of life using SF-36
Notes Funding source: Not specified
Conflict of interest: Not stated
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Okamoto 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “If eligible, patients were randomly assigned to one of
two groups.”
Allocation concealment (selection bias) Unclear risk Not explicitly described
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP measurement has low risk of performance bias.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unblinded study, but this seems unlikely to influence an auto-
mated BP measure
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
Olesen 2014
Methods Randomised trial
Participants 630 participants - elderly patients (intervention 315: control 315)
9 pharmacists
Aarhus, Denmark
Year of study: Not stated.
Interventions Intervention-group patients received a home visit by a pharmacist at the beginning of
the project. The pharmacist examined the medicines list to consider possible side effects,
interactions, and administration, then simplified the regimen, informed the patients
about medication, listened to questions concerning medication, provided information
leaflets, and motivated adherence. Participating pharmacists must have had some prac-
tical experience or courses in Medication Review. No further training or standardisation
was arranged. At 3, 6 and 9 months the same pharmacists telephoned the patients to
inquire about the patients’ condition and changes in the medicine, uncover problems
and answer questions. Pharmacists could consult the project physician if required. If
the physician agreed with the pharmacists concerns, the pharmacist contact the general
practitioner. There were no standardised criteria for severity of medication problems
Frequency: Baseline home visit. 3,6,9 months telephone review
Outcomes Number of hospitalisations
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Olesen 2014 (Continued)
Notes Funding source: This study was supported by the Danish Ministry of Health and the
Association of Danish Pharmacies
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A total of 945 envelopes (315per patient subgroup)was prepared
with each containing a study inclusion code. At the first home
visit by a project nurse, patients were asked to select one envelope
Allocation concealment (selection bias) Low risk A total of 945 envelopes (315per patient subgroup)was prepared
with each containing a study inclusion code. At the first home
visit by a project nurse, patients were asked to select one envelope
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk It was impossible to conceal the identity of patients in the phar-
maceutical care group since the procedures were complex and
involved the pharmacists and nurses. However, hospitalisations
were deemed to be an objective measure
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Objective outcomes collected from electronic records, hence un-
likely to be biased. Probably blinded assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None
Park 1996
Methods Randomised trial
Participants 64 patients with hypertension (intervention 32: control 32)
Health professionals (delivering intervention): 2 pharmacy residents
Practices: 2 (not studied at the same time)
2 sites of a chain pharmacy
Chicago, USA
Year of study: Ocotober 1993 to May 1994.
Interventions Oral and written education about hypertension, its treatments and risk factors to the
patients and recommendation to the physician if necessary
Length of the intervention: 15 to 30 minutes
Frequency of the intervention: 4 in 4 months
119Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Park 1996 (Continued)
Outcomes Blood Pressure
Compliance (pill count)
Health Status Questionnaire (HSQ)
Hypertension/lipid Form
Notes The intervention group and control group were different at baseline (in their systolic
blood pressure) but the authors did not provide the significance level of this difference
Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients meeting these criteria were randomly assigned
to either a control of a study group during the initial screening
visit”
Allocation concealment (selection bias) Unclear risk Allocation procedure not described explicitly
Unclear how randomisation occurred or if it was adequately
concealed
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP measurement has low risk of performance bias.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk BP measured manually by assessors aware of the participant’s
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk All major results reported
Other bias High risk Quote: “Patients populations varied between the two sites”
Paulos 2005
Methods Randomised trial
Participants 42 patients with hyperlipidaemia (intervention group 23; control group 19)
Health professional (delivering intervention): 1
Practice: 1
Community pharmacy
Chile
Year of study: Not stated.
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Paulos 2005 (Continued)
Interventions Pharmacist measured total blood cholesterol and triglyceride levels and educated patients
on cardiovascular disease, risk factors and appropriate medication use, vs usual care.
Length of the intervention: 20 to 25 minutes
Number of interventions: 5 during 4 months
Outcomes Total cholesterol levels
Triglyceride levels
% of patients with decrease in total cholesterol levels
% of patients with decrease in triglyceride levels
Notes Funding source: Roche Diagnostics, Santiago, Chile, provided support by providing
Accutrend GCT device and strips
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients admitted to the trial were randomly di-
vided into a control group and an intervention group”
Allocation concealment (selection bias) Unclear risk Randomisation and allocation process were not described.
No clear information
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Personnel were not blinded, same pharmacists delivered both
arms
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk The main outcome (cholesterol) is objectively measured.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Original sample size unclear
Selective reporting (reporting bias) Unclear risk Some outcomes reported (smoking) that seem unrelated to in-
tervention
Other bias Low risk None
Peterson 2004
Methods Randomised trial
Participants 94 patients with cardiovascular disease discharged from the hospital on statin therapy
(intervention 46; control 48)
Health professional (delivering intervention): 1
Practice: 1
Acute care teaching hospital (Royal Hobart Hospital)
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Peterson 2004 (Continued)
Tasmania, Australia
Year of study: April 2001 to October 2001.
Interventions Pharmacist conducted home visits to perform cholesterol measurements, assess medica-
tion regimen and educate patients about lipid-lowering drug therapy and dietary and
life-style modifications, vs usual care.
Length of the intervention: not clear
Number of interventions: 6 during 6 months
Outcomes Cholesterol level at follow-up (6 months)
Notes Funding source: Community Pharmacy Practice Research Grant, through the Guild/
Government (Community Pharmacy) Agreement and administered by the Common-
wealth Department of Health and Aged Care. Roche Diagnostics Australia provided
equipment
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients who provided written, informed consent were
allocated to either the intervention or control group, using a
computer-generated list of random numbers.”
Allocation concealment (selection bias) Low risk Quote: “Computer-generated list of random numbers”. “Pa-
tients who provided written, informed consent were allocated
to either the intervention or control group, using a computer-
generated list of random numbers”
This appears to be centralised allocation.
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Personnel were aware of allocation but it is difficult to see how
this might have directly influenced intervention, beyond proto-
col
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Assessors may have been aware of allocation, but this is unlikely
to have influenced outcome measurement (a machine read-off )
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
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Reid 2005
Methods Randomised Trial
Participants 532 patients with hypertension (intervention 266: control 266)
Hypertension Management Clinic
United Kingdom
Year of study: Augusut 2001 to May 2002.
Interventions Implementation of aHypertensionManagement Clinic using a treatment protocol based
on guidelines. The new Sheffield table was used to estimate cardiovascular risk in patients
treated with anti-hypertensive medication because of its applicability to this patient
group. The pharmacist discussed all changes to prescribed medication with the patient
and their general practitioner (GP), prior to alteration. Dose titration was undertaken by
the pharmacist without GP consultation. Details of the consultation including lifestyle
modification advice were documented in the patient records. Changes in medication
were entered on the practice computer system and prescriptions were signed by a GP.
Blood samples required to monitor treatment or evaluate cardiovascular risk were taken
by the pharmacist or nursing staff and patients requiring an electrocardiogram were
referred to nursing staff. Patients were allocated 15-minute appointments and attended
the clinic at intervals of 2 weeks to 3 months depending on BP control
Outcomes % patients achieving target
Notes Funding source: Lothian Primary Care Development Fund
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised sequentially, prior to study
inception, by the pharmacist into two groups.”
Allocation concealment (selection bias) Unclear risk Randomised before contact.
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unclear if patients were blinded.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unclear if assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however, large overall attrition
Quote: “Group 1 (n = 92) [intervention] Of 266 patients iden-
tified, 73 were excluded. A total of 193 patients were invited to
attend the clinic of whom 92 (47.7%) attended. Group 2 (n =
68) [control] Of 266 patients identified, 107 were excluded. A
total of 159 patients were invited to attend the clinic of whom
68 (42.8%) attended”. Unclear whether these patients received
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Reid 2005 (Continued)
the same offer
Selective reporting (reporting bias) Low risk Most key results presented
Other bias Low risk None
Rickles 2005
Methods Randomised trial
Participants 63 patients presenting with new antidepressant prescriptions (intervention 31; control
32)
Health professional (delivering intervention): 14
Practice: 8
Community pharmacies within a large managed care organization
Wisconsin, USA
Year of study: October 2001 to September 2002.
Interventions Pharmacist provided monthly telephone-based education on antidepressant use and goal
of therapy and monitoring of adverse effects and adherence, vs usual care
Length of the intervention: 19, 12, and 11 minutes for first, second, and third phone
call, respectively
Number of interventions: 3 during 3 months
Outcomes >50% improvement in depression symptomsmeasuredwithBeckDepression Inventory-
II (BDI-II)
Notes Past use of psychiatric medications was different between groups at baseline.
Study was powered to detect compliance outcomes only.
Funding source: Sonderegger ResearchCenter and predoctoral National Research Service
Award through the National Institute of Mental Health
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “When a patient was enrolled from that site, the re-
searcher would randomly select a number out of the envelope”
Allocation concealment (selection bias) Low risk Assignment sealed in an envelope; envelope not reported as
“opaque”. Experimenters had no knowledge of forthcoming al-
locations
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Experimenters were unblinded but given that control partici-
pants received no intervention (phone call) bias is unlikely
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Rickles 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Participants were unblinded and this may have influenced self-
reported responses
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk All major outcome reported
Other bias Unclear risk Despite randomisation, intervention patients were more likely
than usual-care patients to have a history of psychotropic med-
ication use
Rothman 2005
Methods Randomised trial
Participants 217 patients with type 2 diabetes (intervention 112, control 105)
North Carolina, USA
Year of study: February 2001 to April 2003.
Interventions The intervention included intensive educational sessions, evidence-based algorithms,
and proactive management of clinical parameters
Outcomes Systolic blood pressure (BP)
Diastolic BP
Notes Funding source: Robert Wood Johnson Clinical Scholars Program, the University of
North Carolina Program on Health Outcomes, the University of North Carolina Divi-
sion of General Internal Medicine, University of North Carolina Hospital Performance
ImprovementDepartment, University of NorthCarolina Pharmacy, the Vanderbilt Cen-
ter for Health Services Research, and the Vanderbilt Diabetes Research and Training
Center
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned patients to the intervention or control group
using a random-number generator
Allocation concealment (selection bias) Low risk Assignment was contained in sealed envelopes that were opened
by the study co-ordinator
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Not blinded but outcomes are objective
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Rothman 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Not blinded but outcomes are objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk All relevant reported at 12 months and baseline
Other bias Low risk Baseline differences
Quote: “The intervention patients were slightly older than the
control patients (P=0.05) and more likely to be African Amer-
ican (P=0.10).” “We tried to limit this concern by performing
adjusted analyses, and these findings were similar to those from
our unadjusted findings”
Rubio-Valera 2012
Methods Randomised trial
Participants 179 participants with depression (intervention 87: control 92)
13 pharmacies (34 pharmacists)
Gavó, a city situated in the province of Barcelona, Spain
Year of study: OCtober 2008 to not stated.
Interventions The intervention consisted of a series of educational interventions focused on improving
patients’ knowledge of antidepressant medication, including the importance of compli-
ance.Moreover, in patients with a sceptical attitude towards medication, the intervention
aimed to reduce stigma, reassure the patient about possible side effects, and stress the
importance of following GPs’ advice
Number of Interventions: initial visit plus single (?) follow-up
Number of follow-ups unclear
Outcomes Mean severity of depression
Health-related Quality of Life
Notes Funding source: Carlos III Health Institute Grant
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was generated at the patient level by a
computerized random-number generator following a permuted
block design.”
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Rubio-Valera 2012 (Continued)
Allocation concealment (selection bias) Low risk Quote: “To assure the concealment of allocation, every GP re-
ceives a set of 10 sequentially numbered, opaque, sealed en-
velopes containing patient assignment. Envelopes were gener-
ated by an external investigator and details of the series are un-
known to any of the GPs or pharmacists in the study.”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded participants and subjective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “Blinding of participants and pharmacists is not possible
because of the type of intervention. However, the assessment vis-
its and data analysis are conducted by independent and blinded
evaluators”
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition >20%
Quote: “Only 87 (95%) and 64 (74%) in the control and in-
tervention group, respectively, received the intervention as allo-
cated and were included in the PP analysis.”
Selective reporting (reporting bias) Low risk All major results reported
Other bias Low risk None
Sadik 2005
Methods Randomised Trial
Participants 221 patients with heart failure (intervention 109; control 112)
Health professional (delivering intervention): 1
Practice: 1
Outpatient clinic in Al-Ain Hospital
Al-Ain, United Arab Emirates
Year of study: Not stated.
Interventions Pharmacist providing patient education about heart failure medications and disease
management during clinic follow-up visits, printed booklet on heart failure, symptom
monitoring diary card.
Pharmacist discussed drug therapy with patients’ physicians, vs usual care
Length of the intervention: not clear
Number of interventions: 5 during 12 months
Outcomes Quote “At the 3-monthly outpatient clinics, both groups of patients were assessed as per
initial baseline assessments as follows: 2-min walk test (including time to walk 25 and 50
m), BP, body weight, pulse, FVC, quality of life questionnaires (MLHF questionnaire
and the SF36), questionnaire on symptoms and knowledge of, and compliance with,
prescribed medication and lifestyle advice. Medication knowledge was scored as a per-
centage value relating to the number of correct answers given to questions on name of
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Sadik 2005 (Continued)
prescribed medications, daily dosage, strength, purpose of each medication and signifi-
cant side effects. A score of <50% was deemed to be poor knowledge. In relation to com-
pliance with prescribed medications, patient self-report on missing doses or taking extra
doses of their medication, without medical advice to do so, was considered noncompli-
ance. Regarding compliance with lifestyle advice, questions on the following were asked
to each patient: dietary modification and sodium restriction, limitation of or abstinence
from alcohol, restricted fluid intake, not sleeping flat, taking mild to moderate exercise
and smoking cessation (if appropriate). Each parameter was awarded one mark.”
Notes Patientswere recruited from the hospital ward andhospital outpatient clinic; Intervention
took place in hospital outpatient clinic
Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation carried out using minimisation method
Allocation concealment (selection bias) Unclear risk Not explicitly described
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Personnel were not blinded to allocation. Unclear if/how this
may have biased results
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Baselinemeasurements were performed by a research pharmacist
with the exception of the 2-minute walk test and theFVC test,
whichwere performedbynursing staff or a pharmacy technician.
They were blinded to the group to which individual patients
had been assigned and received training on test administration
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Quote: “Two patients in each group died during the study; in
addition, three patients withdrew from the intervention group
and six from the control group during the study”
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
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Salazar-Ospina 2017
Methods Randomised trial
Participants 92 patients (intervention group 43; control 49)
Psychiatric clinic
La Ceja, Antioquia, Colombia
Year of study: November 2011 to June 2014.
Interventions Patients assigned to the intervention group received usual care, verbal and written coun-
selling about bipolar disease, and pharmaceutical care for 1 year from a specially-trained
pharmacist using the Dader Method
Outcomes Number of hospitalisations, emergency service consultations, unscheduled outpatient
visits, and clinical evaluation of symptomatology
Notes Funding source: This research was financed in part by Humax Pharmaceutical S.A.,
providing the PhD student with a salary and the written material used in this work
Conflict of interest: Salazar-Ospina received funding from Credito Beca Francisco José
de Caldas Scholarship for Doctoral Programs (528). González-Avendaño is an employee
of Humax Pharmaceutical. The other authors reported nothing to disclose
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Participants were randomized to intervention or con-
trol groups in sequential order, and they were followed for 12
months”
Allocation concealment (selection bias) High risk Given the allocation method, it is probable that staff knew to
which group the (potential) participant would be allocated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk The staff and patients understood allocation so blinding may
not have been achieved
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Biased assessment unlikely as outcome measure was hospitalisa-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk Main outcomes specified.
Other bias Low risk None
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Samtia 2013
Methods Randomised trial
Participants 348 participants with diabetes (intervention 178: control 170)
Selected diabetes clinics
Southern Punjab (Nishter Hospital Multan and DHQ Hospital Layyah),India
Year of study: March 2011 to not stated.
Interventions Patient education
Intervention group patients received predefined specialised care. The components of care
were: education of disease including short- and long-term complications; medication
adherence and its effects on glycaemic control; education about timing of medication
use in relation to food; education about dietary restrictions; education about sensory
changes including foot examination; the role of exercise in achieving glycaemic control;
the role of self-monitoring of blood glucose to achieve glycaemic control; education
about control of HbA1c values and fasting blood glucose; and smoking cessation. If
relevant
Frequency: every 4 weeks
Duration: 5 months
Outcomes Fasting blood glucose
HbA1c
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear how randomisation performed
Quote:“Patients were randomly assigned into control (n=170)
and intervention groups (n=178).”
Allocation concealment (selection bias) Unclear risk Unclear if allocation concealed
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk No blinding, but the intervention knowledge seems unlikely to
affect objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk No blinding, but the intervention knowledge seems unlikely to
affect objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Quote: “Almost all the patients included completed the study
(control group: 168/170 and intervention group: 174/178).”
Selective reporting (reporting bias) Low risk Main outcomes present
Note that before-and-after results reported rather than control
versus intervention or “difference in the difference”
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Samtia 2013 (Continued)
Other bias Low risk None
Sarkadi 2004
Methods Randomised trial
Participants 64 patients with diabetes mellitus Type II (intervention 33; control 31)
Health professional (delivering intervention): unclear
Practice: unclear
Community pharmacies in Sweden
Year of study: Not stated.
Interventions Pharmacist led an educational programme using a video, a dice game and a booklet
on diabetes management to promote dietary modifications, exercise and blood glucose
control and referred patients to health professionals in cases of unsatisfactory glucose
control, vs no intervention.
Length of the intervention: unclear
Number of interventions: 3 during 1 year; 1 year follow-up after intervention completion
Outcomes HbA1c at 12 months (end of study)
HbA1c at 24 months (follow-up)
Notes Pharmacist-led educational group had assistance from a diabetes nurse specialist on the
first 2 occasions; patients were self-referred to the programme
Funding source: Swedish Foundation for Health-care Sciences and Allergy Research
Grant No. V2000 225, the National Corporation of Swedish Pharmacies, and Uppsala
University. Funding for the first author, Anna Sarkadi from the Knut and Alice Wallen-
berg Foundation in Stockholm, Sweden, grant nr. KAW 2001.0303
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For those participants eligible for randomisation, the
informed consent sheet and the questionnaire were put into
an unmarked envelope, one for each participant. The identical
envelopeswere thenput into a box. Each time 20 complete sets of
participant items were collected, randomisation was performed.
An assistant mixed the envelopes in the box, took them out one
at a time, and randomly placed them into two
piles. A third person, acting as a witness, pointed out which pile
should be allocated to the intervention group and which pile to
the control group.”
Appropiate randomisation procedure
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Sarkadi 2004 (Continued)
Allocation concealment (selection bias) Low risk Quote: “An assistant mixed envelopes in a box, took them out
one at a time, and randomly placed them into two piles. A third
person, acting as a witness, pointed out which pile should be
allocated to the intervention group and which pile to the control
group”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk No-one was blinded, but HBA1c unlikely to be biased
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk No-one was blinded, but HBA1c unlikely to be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk 1 main outcome reported
Other bias Low risk None
Schneider 1982
Methods Randomised trial
Participants 40 patients with essential hypertension and congestive heart failure (intervention 20;
control 20)
Health professional (delivering intervention): 1
Practice: 1
Outpatient medicine clinic
University Hospital Clinic, Ohio State University, USA
Year of study: Not stated.
Interventions Pharmaceutical care
Pharmacist examined and evaluated patients during a clinic visit
Pharmacist communicated findings and suggestions to physician, vs usual care
Length of intervention: 12 months
Outcomes Systolic and diastolic blood pressure
% target blood pressure achieved
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Schneider 1982 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to a study or a control
group”
Allocation concealment (selection bias) Unclear risk Not explicitly described
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk The personnel (doctors and pharmacists) were not necessarily
unblinded and this may have influenced protocol implementa-
tion
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk BP mostly objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from all 40 patients presented.
Selective reporting (reporting bias) Low risk All outcomes mentioned in Methods appear in Results
Other bias Low risk None
Schneiderhan 2014
Methods Randomised trial
Participants 121 participants (intervention 61: control 60)
Metabolic syndrome/psychotic
3 community mental health clinic setting
Minnesota, USA
Year of study: February 2012 to January 2014
Interventions Pharmacist comprehensive medication management not described
Outcomes Taking antipsychotic medicines
Notes Funding source: Founded by Medica Foundation, Minneaplois, Minnesota and Peters
Institute of Pharmaceutical Care, College of Pharmacy, University of Minnesota, Min-
neapolis
Conflict of interest: Dr Scheniiderhan has received honoraria from the American Society
of Health System Pharmacists
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a block randomization schedule was used to ensure
balanced treatment assignment of subjects recruited at each site”
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Schneiderhan 2014 (Continued)
Allocation concealment (selection bias) Low risk Quote: “a block randomization schedule was used to ensure
balanced treatment assignment of subjects recruited at each site”
A centralised call-in system was used to inform the investigators
of the participant’s random group assignment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Intervention unclear
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Unclear who collected data; blinding unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%, however, overall attrition rate
>20%
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Sellors 2003
Methods Randomised trial
Participants 889 elderly patients (intervention 431; control:458)
48 physicians (intervention 24; control 24)
Ontario, Canada.
Year of study: August 1999 to ~ July 2000
Interventions Structured medication assessment by pharmacist with patient, which assessed needs,
drug-related problems and course of action. This was discussed with the physician, who
then indicate their recommendation intentions and plan. 5 months later physician-
pharmacist discussion of what recommendations have been implemented. 4months later
pharmacist phoned patient to discuss drug therapy
Outcomes SF-36 (physical functioning) at 12 months
Notes Funding source: Funding was provided by the Health Transition Fund, Health Canada,
and in kind support from the Department of Family Medicine, McMaster University,
and the Centre for Evaluation of Medicines, St. Joseph’s Healthcare, Hamilton, Ont
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
134Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sellors 2003 (Continued)
Random sequence generation (selection
bias)
Low risk The pair of physicians in each postal code area were randomly
allocated, in a concealed fashion, to the intervention or control
group, using a central telephone randomisation procedure based
on computer-generated random numbers
Allocation concealment (selection bias) Low risk Randomisation was conducted by a research team member who
was blinded to the practices’ identities
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Neither family physicians nor their patients were blinded to their
allocation group
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Unblinded and self-reported SF36
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Sidel 1990
Methods Randomised trial
Participants 284 elderly patients (intervention 141; control 143) who wereMedicare recipients living
in the study area
1 pharmacist
Norwood, New York City, USA
Year of study: Not stated.
Interventions Patient-specific packet containing information on prescription and medication, home-
visit explained this packet, could contact physicians if wanted, counselled patient about
drug use, encouraged adherence and checked for out-of-date medicine. At least 2 visits
by pharmacist across 6 x 1-month periods, with additional phone contact as necessary
Outcomes Total Ambulatory Care visits past 3 months (change scores) at 36 months
Notes Funding source: National Institute on Aging (P01AG03424 and R0 lAG08125)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Sidel 1990 (Continued)
Random sequence generation (selection
bias)
Low risk Assigned by randomised tables
Allocation concealment (selection bias) Low risk Separate people enrolled and randomised participants.
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Little information about blinding or probable consequences
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Little information about blinding or probable consequences
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however, overall high attrition
>20%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Silveira 2014
Methods Randomised trial
Participants 332 participants receiving care for HIV infection at the Service for Specialized Assistance
in HIV (SAEH) (intervention 166: control 166)
School of Medicine, in Pelotas, southern Brazil
Year of study: Not stated.
Interventions Pharmaceutical care using the Dáder method.
Quote “Intervention patients received structured counselling on their prescription regi-
mens, at the time of initial drug dispensing and at monthly refill visits. The key elements
of pharmaceutical care were: reviewing the prescription with the patient; reviewing a card
on which medications were colour-coded to facilitate recognition and reduce confusion
that might arise from complicated drug names; reviewing the schedule, length, and date
of the next appointment; reviewing the patient’s understanding of the prescription by
asking him/her to describe it for the pharmacist; and giving patients verbal information
on the expected side effects of their medications. Patients were instructed to call the
pharmacist if side effects occurred. After the counselling session, the pharmacist verified
that all components of the intervention had been delivered.”
Duration: 1 year
Outcomes Proportion of patients reporting adherence to ART. Proportion of patients with unde-
tectable viral load
Notes No extractable data.
Funding source: The University of California San Francisco and grants by the US Na-
tional Institutes of Health (NIH): Fogarty International Center (FIC) D43TW005799;
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Silveira 2014 (Continued)
National Institute for Mental Health (NIMH) P30MH062246, R25MH064712; and
the FIC AIDS International Training and Research Program (AITRP) D43TW000003
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consenting participants were randomised using a random-num-
ber table
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Non-blinded randomised controlled trial. Unsure of effect on
outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Self-reported main outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%
Selective reporting (reporting bias) Low risk Main outcomes reported
Other bias Low risk None
Simpson 2011
Methods Randomised trial
Participants 260 participants with diabetes (intervention 131: control 129)
Primary care clinics in Edmonton, Canada
Year of study: February 2006 to January 2009.
Interventions The intervention programme began with an in-person visit with a study pharmacist to
identify all prescription, nonprescription, complementary, and alternative medications.
Pharmacists measured the patient’s height, weight, heart rate, and blood pressure. Blood
pressure was measured according to the Canadian Hypertension Education Program
recommendations using an automated machine. Pharmacists then formulated guideline-
concordant recommendations to optimise medication management of blood pressure
and other cardiovascular risk factors. These recommendations were discussed with the
primary care physician who was responsible for authorising medication changes. The
pharmacist then worked independently with the patient to implement these changes
Frequency: Once at beginning of year
Duration: 1 year
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Simpson 2011 (Continued)
Outcomes HbA1c
Systolic BP
Diastolic BP
United Kingdom Prospective Diabetes Study (UKPDS) Risk Engine Score
Notes Funding source: Canadian Diabetes Association, the Institute of Health Economics, and
the Alberta Heritage Foundation for Medical Research
Conflict of interest:None of the agencies were involved in the design and conduct of the
study; collection, management, and interpretation of the data; and preparation, review,
or approval of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A central randomization service provided computer
generated random sequences stratified by the primary care clinic
for treatment allocation.”
Allocation concealment (selection bias) Low risk Quote: “Pharmacists, analysts, and investigators were unaware
of the block size and allocation sequence to preserve allocation
concealment”
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Unblinded participants, but little cause for concern here due to
objective outcomes
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Quote: “a randomized controlled trial with blinded ascertain-
ment of outcomes”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis. Between group attrition < 10%
Missing data were replaced by carrying the last observation for-
ward
Selective reporting (reporting bias) Low risk Main outcomes clearly specified and reported
Other bias Low risk None
Solomon 1998
Methods Randomised trial
Participants Patients with hypertension and/or chronic obstructive pulmonary disease (COPD) -
hypertension arm 133 (intervention 63; control 70); COPD arm 98 (intervention 43;
control 55)
Health professionals: not clear
Practices: 11
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Solomon 1998 (Continued)
Outpatient clinics at 10 Veterans Administration Medical Centers and 1 university hos-
pital in USA
Year of study: Not stated.
Interventions Pharmacist-provided clinical pharmaceutical care services vs usual care
Pharmaceutical care services included clinical management of hypertension and COPD
by standardised patient assessment activities, pharmacists’ involvement with the health-
care team, collaboration with physicians to develop patient-specific plan, patient educa-
tion on hypertension and COPD, counselling to address patients’ questions or concerns,
and regular patient assessments and care.
Length of intervention: approximately 60minutes for initial visits, 30minutes for follow-
up visits
Number of interventions: monthly visits over 6 months
Outcomes Blood pressure (hypertension arm)
Borg Scale (COPD arm)
Notes Intention-to-treat analysis not done (number of patients reported is number of patients
analysed; number of patients randomised not clear)
Funding source: Novartis Pharmaceuticals corperation, East Hanover, N.J
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “study assistants assigned the patients using a table of
random numbers”
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unblinded personnel, potential for bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Blood pressure measurement and interview may have been con-
ducted by an experimenter who was not blinded to patient al-
location
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Report describes “evaluable patients”. Unclear how many re-
cruited into trial
Selective reporting (reporting bias) Low risk All main results reported. Post hoc tests labelled as such
Other bias Low risk None
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Sookaneknun 2004
Methods Randomised trial
Participants 235 patients with hypertension (intervention 118; control 117)
Health professionals: not clear
Practices: 3
University-affiliated community pharmacy and 2 primary care units in Thailand (Ma-
hasarakham, Takonyarng village, Kharmrieng village)
Year of study: Ocotober 2002 to July 2003.
Interventions Pharmacist provided monthly consultation and blood pressure monitoring, vs usual care
Pharmacist mademedication regimen change recommendations to physicians after iden-
tifying drug-related problems
Length of the intervention: 30 to 50 minutes
Number of interventions: 6 (monthly) during 6 months
Outcomes Blood pressure
Notes Funding source: Research grant from Chiang Mai University, Thailand
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A simple randomization technique was used to assign
the patients to a treatment group and a control group.”
Unclear how randomisation occurred
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP measurement has low risk of performance bias.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk BP measured manually by assessors aware of the participant’s
allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many completed the trial
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
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Stewart 2014
Methods Randomised trial
Participants 60 pharmacies, 395 patients with hypertension (intervention 207: control 188)
Pharmacies frommetropolitan, regional and remote areas in three Australian states (Vic-
toria, Western Australia and Tasmania) were contacted by telephone and informed about
the project
Year of study: July 2009 to January 2010.
Interventions Pharmacist care
Patients in the Pharmacist Care Group received a package of interventions from the
pharmacist for enhancing their antihypertensive medication adherence, which includes:
a home blood pressure (BP)monitor with the capacity to store and download BP readings
to be used for discussion at 3- and 6-month follow-ups; training by the pharmacist on
self-monitoring of BP,motivational interviewing and education by the pharmacist to help
patients improve their medication adherence and achieve target BP; pharmacist-initiated
homemedicines review, dose administration aid and/or patientmedication profile, where
necessary; medication use review to identify and resolve possible medication-related
hypertension (e. g. due to non-steroidal anti-inflammatory drugs, cold preparations,
complementary medicines, etc); referral to a general practitioner when needed (e.g.
very high blood pressure); and refill reminders (by either text, telephone or mail) from
their pharmacist at a chosen number of days before their antihypertensive medication
dispensing is due
Outcomes Systolic BP
Diastolic BP
Notes Randomisation: 60 pharmacies recruited and randomised - 30 pharmacist care and 30
in control group. Five either withdrew or were withdrawn (1 intervention, 4 countrol)
Funding source: AustralianGovernmentDepartment ofHealth andAgeing (as part of the
Fourth Community Pharmacy Agreement through the Fourth Community Pharmacy
Agreement Research & Development Grants Program managed by the Pharmacy Guild
of Australia)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out at a central location using the
sealed opaque envelope technique
Allocation concealment (selection bias) Low risk The randomisation process was carried out by 1 of the investi-
gators using the ‘sealed envelope technique’
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Blinding unclear
Low risk for BP
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Stewart 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Low risk for BP and all other measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis performed. Between group attrition
< 10%
Selective reporting (reporting bias) Low risk All main results reported.
Many subgroup analyses reported in the Results but not in the
Methods
These subgroup data were not analysed in our meta-analyses.
Other bias Low risk None
Suppapitiporn 2005
Methods Randomised trial
Participants 360 diabetic patients (intervention 180; control 180)
King Chulalongkorn Hospital
Bangkok, Thailand
Year of study: January to Dcember 2004.
Interventions All participants received diabetic drug counselling by a pharmacist; 1) counselling alone;
2) diabetic booklet; 3) specialised medication containers; 4) diabetes education, booklet,
medication containers
Interventions were received at the initial visit and at 6-month assessment follow-ups
Outcomes HbA1c at 6 months
Notes Funding source: Not specified
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a simple randomisation was performed”.
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Not stated
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Suppapitiporn 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Not stated, but medical records were used to get outcomes so
unlikely to be biased
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Actual completion rate unknown.
Selective reporting (reporting bias) High risk Quote: “patient records used to obtain patients response to in-
tervention”
Other bias Low risk None identified
Tang 2014
Methods Randomised trial
Participants 124 participants with epilepsy (intervention 59: control 65)
Patients with epilepsy who were treated at the outpatient clinic of Neurology
Huashan Hospital, University of Fudan, Shanghai, China
Year of study: Not stated.
Interventions Education and behavioural intervention
Intervention patients were educated by a pharmacist according to the guidelines of the
American Society of Health-System Pharmacists about pharmacist-conducted patient
education and counselling. Patients receivedmonthly calls from the pharmacist and were
instructed about their medications and asked to adhere to their anti-epileptic medica-
tion. There was also a behavioural intervention based on cue-dose training therapy. The
medication schedule used in this programme was presented in the form of a table that
illustrated the daily medication therapy of patients with pictures of anti-epileptic medi-
cation, and it provided patients with cues to take their medications
Frequency: Monthly phone calls, initial education session, persistent cues
Duration: 6 months
Outcomes Seizure control (50% reduction from baseline), Quality of life
Notes Funding source: Not specified
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A list of 300 random numbers between 0 and 9 was generated
using a statistical package. The patients were numbered accord-
ing to the order in which they were recruited. Patients who had
received an even randomly-generated number were assigned to
group I, and patients who received odd numbers were assigned
to group II
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Tang 2014 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded study with substantial potential bias
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Seizure change: low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Tannenbaum 2014
Methods Randomised trial
Participants 303 elderly patients on benzodiazepines (intervention 148: control 155)
The study included 30 community pharmacies (cluster units)
Montreal, Canada.
Year of study: 2010 to 2012.
Interventions Written educational material to facilitate benzodiazepine withdrawal
The patient empowerment intervention consisted of an 8-page booklet based on social
constructivist learning and self-efficacy theory. The intervention comprised a self-assess-
ment component about the risks of benzodiazepine use, presentation of the evidence
for benzodiazepine-induced harms, knowledge statements designed to create cognitive
dissonance about the safety of benzodiazepine use, education about drug interactions,
peer champion stories to augment self-efficacy, suggestions for equally or more effective
therapeutic substitutes for insomnia or anxiety or both, and stepwise tapering recom-
mendations. The intervention asked participants to discuss the de-prescribing recom-
mendations with their physician or pharmacist or both. The intervention was person-
alised according to the participant’s pharmacy profile to include the name of the specific
benzodiazepine the participant was taking. The intervention was mailed to the inter-
vention group within 1 week of group allocation while the usual care (wait list) group
received the educational tool 6 months following group allocation
Duration: 6 months
Outcomes Discontinuation of benzodiazepine use
Notes Funding source: Canadian Institutes of Health Research
Conflict of interest: Mr Martin received a bursary from the Michel Saucier Endowed
Chair in Pharmacology,Health,and Aging of the Faculty of Pharmacy of the Universitéde
Montréal, and Drs Tannenbaum and Ahmed were clinician scientists funded by the
Fonds de Recherche en Santé de Quebec
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Tannenbaum 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A statistician, blinded to pharmacy and cluster size, generated a
random allocation sequence using computer-generated random
digit numbers
Allocation concealment (selection bias) Low risk Up until the point of randomisation, neither the research assis-
tant, the cluster representative (the pharmacist), nor the client
knew the allocation of the clusters. After randomisation, only
the research assistant was aware of treatment allocation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Pharmacists and participants were not informed, and remained
unaware of the fact that there was another group in the study;
nor were they informed of the procedures for the other arm
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk 1 investigator and 1 research nurse, blinded to group alloca-
tion, independently assessed outcomes according to a prespeci-
fied protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Taveira 2011
Methods Randomised trial
Participants 88 participants with diabetes (intervention 44: control 44)
Eligible patients were identified by a combination of review of the Providence VAMC
electronic medical record system and referral by primary care providers
USA
Year of study: December 2006 to not stated.
Interventions A multidisciplinary education and pharmacist-led intensive behavioural and pharmaco-
logical group intervention
Intervention patients attended 4 once-weekly sessions of 2 hours, followed by 5 monthly
booster sessions with approximately 4 to 6 participants in each session. Each session
consisted of 2 parts: i) education and ii) behavioural and pharmacological interventions
for hypertension, hyperlipidaemia, hyperglycaemia and tobacco use. The education por-
tion included interactive lectures provided by a nurse, nutritionist, or the clinical phar-
macists who were certified in diabetes education. Each session focused on 1 or 2 self-
care behaviours, such as goal setting, to promote health and problem-solving for daily
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Taveira 2011 (Continued)
living or integration of psychosocial adjustment to daily life. At each session, food logs
were reviewed by the pharmacist and participants were reminded of their nutrition goals.
Participants prepared healthy food choices during these sessions and were advised of the
availability of nutrition programmes. The pharmacological and behavioural intervention
was conducted by a clinical pharmacist certified in diabetes education who performed a
group assessment to determine the degree to which patients felt they could manage the
daily aspects of diabetes care through discussion and use of the Perceived Competence
for Diabetes Scale. Each participant was provided with a cardiovascular risk report card
containing medical history, current medications, vital signs, and laboratory test results.
Medications for blood pressure, cholesterol, diabetes, and tobacco cessation were initi-
ated or titrated based on previously established treatment algorithms. Each group mem-
ber was provided with individualised homework for medication changes and a behaviour
change goal, such as exercise recommendations, dietary modifications, and blood glucose
or blood pressure monitoring. A clinical pharmacist used theory-based counselling and
reinforcement to change outcome expectations and to increase behaviours that would
improve diabetes self-care behaviours such as increasing physical activity and healthy
eating. Demonstration and coaching to increase self-efficacy for self-care skills, such as
monitoring of blood glucose and logging daily dietary intake, were also performed
Number of Interventions: 4 once-weekly sessions of 2 hours, followed by 5 monthly
booster sessions held in a classroomwith approximately 4 to 6 participants in each session
Outcomes HbA1C
Systolic BP
Low density lipoprotein-cholesterol (LDL-C)
Notes Funding source: AmericanCollege of Clinical Pharmacy Astra-ZenecaHealthOutcomes
Research Award (Dr. Taveira), American Society of Health System Pharmacists and
Education Foundation Federal Services Research Grant Program (Dr. Cohen), and VA
HSR&D Merit Review Award IAB 06-269 (Drs. Taveira, Cohen, and Wu)
Conflict of interest: None stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to the intervention arm or standard
care arm using simple coin toss randomisation
Allocation concealment (selection bias) Unclear risk No relevant information
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Unclear if participants were blinded
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Unclear if assessors were blinded, but HbA1C is an objective
measure
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Taveira 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Unclear risk Most outcomes were reported
Other bias Low risk None
Taveira 2014
Methods Randomised trial
Participants 200 patients at cardiovascular risk (group intervention 72; individual intervention 73;
control 55)
1 primary care clinic
USA
Year of study: October 2003 to December 2006.
Interventions Group medical intervention: 4 visits of 120 minutes held every 3 months for 12 months.
Patients were encouraged to bring social support, educated about healthy lifestyles, be-
havioural and pharmacological interventions for hyperglycaemia, hypertension and dys-
lipidaemia. Provided with individualised cardiovascular risk report card which was up-
dated at each session. Individualised homework given for medication changes, goals and
self-monitoring and phone contact as needed
Individual intervention: 30-minute visits once every 3months for 12months. Assessment
of medication adherence, blood pressure, vital signs with reference to nutritionist or
therapist as necessary
Outcomes Failure to maintain guideline goals was defined as an HbA1c > 7% (> 53 mmol/mol)
Outcomes presented as differences in failure rates rather than end point scores
Notes Funding source: Supported byMerck and Co. Inc. DiseaseManagement Grant Program,
Providence VA Medical Center, University of Rhode Island College of Pharmacy
Conflict of interest: None reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Unblinded personnel and patients may have influenced be-
haviour
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Taveira 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk HBA1c unlikely to be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Taylor 2003
Methods Randomised trial
Participants 81 patients enrolled; 69 high-risk patients reported (intervention 33; control 36)
3 community-based family medicine clinics affiliated with the University of Alabama
School of Medicine-Tuscaloosa
Alabama, USA
Year of study: December 1998 to not stated.
Interventions Intervention received usual care alongside pharmacotherapeutic interventions by a phar-
macists. Meeting with pharmacist 20 minutes before physician; identifying and prevent-
ing problems related to drug therapy. Pharmacist made recommendations to physicians
and provided drug and disease information. Written materials and devices to improve
compliance were provided
Outcomes SF-36 (physical functioning) at 12 months
Notes Funding source: ASHP Research and Education Foundation
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Quote: “Patients were randomly assigned to a control group or
an intervention group”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Patients and personnel not blinded and potential for perfor-
mance bias exists
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Taylor 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk SF-36 with no blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Tommelein 2013
Methods Randomised trial
Participants 734 participants with chronic obstructive pulmonary disease (COPD) (intervention 371:
control 363)
170 community pharmacies
Belgium
Year of study: December 2010 to not stated.
Interventions Patients in the intervention group received a 2-session intervention; 1 session at the
start of the study and 1 at 1 month. All interventions were given during one-to-one
counselling sessions. To support interventions, pharmacists were provided with infor-
mation leaflets on COPD, demonstration inhaler units and a list of practical solutions
to specific nonadherent behaviour. Session 1 at baseline included structured patient ed-
ucation (verbal and written form) about COPD pathophysiology, medication dose and
Inhalation technique. The importance of treatment adherence, possible side effects, self-
management (e.g. lifestyle advice) and smoking cessation were covered. The follow up
session at 1 month covered the same topics and discussed changes to adherence
Duration: 15 - 25 minutes
Outcomes Medical Research Council Dyspnoea Score, Euroqol (EQ)-5D utility score (scale -0.18
to 1)
Notes No extractable outcomes except for EQ-5D.
Funding source: Ghent University, Liège University and GlaxoSmithKline (protocol
number of the grant 114684)
Conflict of interest: Dr Brusselle reportedtohavereceivedagrantfromGlaxoSmithKline;is
a member of the board for AstraZeneca, BoehringerIngelheim, GlaxoSmithKline and
Novartis; has received payment for lectures at AstraZeneca, BoehringerIngelheim,Chiesi,
GlaxoSmithKline,MerckSharp&Dohme,Novartis, Pfizer andUCB.DrRemon reported
to have
received grants from IOF fund, FWO Vlaanderen and IWT; has received royalties from
Tibotec/Biovail. Dr Van Bortel reported that he has been a consultant at the Drug Re-
search Unit Maastricht; is employed by the Ghent University; has received royalties con-
cerning educational pharmacological books; has received payment for travel accommo-
dations concerning expenses unrelated to the trial from Daiichi-Sankyo and Servier
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Tommelein 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central Web-based randomisation system, created by an inde-
pendent investigator. As the interventionwas educational, blind-
ing of pharmacists was not possible
Allocation concealment (selection bias) Low risk To conceal assignment, pharmacists performed allocation
through a central Web-based randomisation system, created by
an independent investigator. As the intervention was educa-
tional, blinding of pharmacists was not possible
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Patients were not told the study group to which they were as-
signed
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Low risk: participant-completed measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Tsuyuki 2002
Methods Randomised trial
Participants 675 cardiovascular risk patients (intervention 344; control 331)
54 community pharmacies
Alberta and Saskatchewan, Canada.
Year of study: 1998 to 2000.
Interventions Pharmacists interviewed patients to determine modifiable cardiovascular risk factors and
give education using a brochure. Pharmacists sent recommendations to physicians and
encouraged patients to make an appointment. During 5 follow-up sessions either by
phone or in personover 16weekperiod, further education and suggestionswere provided,
as well as checking adherence and whether patients had seen their physician
Outcomes The primary end point was a composite measure representing improvement in the pro-
cess of cholesterol risk management. It consisted of measurement of a complete fasting
cholesterol panel by the primary care physician or prescription of a new cholesterol-
lowering medication or an increase in dosage of a cholesterol-lowering medication. As a
composite end point, only the first event attained in the cluster was counted
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Tsuyuki 2002 (Continued)
Notes Funding source: Supported by unrestricted grants from the University Hospital Foun-
dation (Edmonton), Merck Frosst Canada Ltd, The Alberta College of Pharmacists (Ed-
monton), and the Institute of Economics (Edmonton)
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was conducted via a computer- gener-
ated sequence using block randomization (block size of 4) with
stratification by study center (pharmacy)”
Allocation concealment (selection bias) Low risk Computer-generated block randomisation
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Non-blinded personnel and patients may have behaved differ-
ently on account of trial allocation
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Objective outcome measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Tsuyuki 2015
Methods Randomised trial
Participants 248 hypertensive patients (intervention 181; control 67)
23 pharmacies
Alberta, Canada
Year of study: July 2009 to May 2013.
Interventions Patients received enhanced pharmacist care, guided by national hypertension guidelines.
This included assessment, counselling about cardiovascular risk and blood pressure con-
trol, review of medications, drug therapy changes, lifestyle advice and written informa-
tion about hypertension. The patient’s general practitioner was aware of any changes
to medication and assessment results. Follow-up occurred monthly until target BP was
achieved for 2 visits, and then every 3 months for study period
Outcomes Systolic and diastolic BP
% achieving target BP
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Tsuyuki 2015 (Continued)
Notes Funding source: RxACTION was supported by grants from the Canadian Institutes of
Health Research, Alberta Innovates-Health Solutions, Merck, the Canadian Foundation
for Pharmacy, and the Cardiovascular Health and Stroke Strategic Clinical Network of
Alberta Health Services. The study was further supported by ManthaMed through the
in-kind provision of BpTRU devices. Dr Houle received funding as a graduate student
from the Canadian Institutes of Health Research, the Interdisciplinary Chronic Dis-
ease Collaboration (funded by Alberta Innovates-Health Solutions), and Hypertension
Canada. Dr McAlister was supported by a salary award from Alberta Innovates-Health
Solutions and the University of Alberta Chair in Cardiovascular Outcomes Research
Conflict of interest:DrTsuyuki has received research funds for investigator-initiated trials
from AstraZeneca, Sanofi, and Merck and has provided consulting for PharmaSmart
International and Boehringer Ingelheim. The other authors report no conflicts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted at the level of the patient and was
performed by a centralised secure website to ensure concealment
Allocation concealment (selection bias) Low risk Randomisation was conducted at the level of the patient and was
performed by a centralised secure website to ensure concealment
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Because of the nature of the intervention, blinding was not pos-
sible. Possibility that knowledge of allocation could alter partic-
ipant or personnel behaviour
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk All BP measurements performed by the pharmacist were made
with an automated device which takes 6 readings, discarding the
first and taking the average of the remainder. Home measure-
ments were performed with an automated home BP monitor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Unequal number of participants in control (n = 67), interven-
tion (n = 181), although intervention group was split in 2, but
outcomes reported as a whole
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Verret 2012
Methods Randomised trial
Participants 114 participants (intervention 58: control 56)
Specialised anticoagulation clinic of the Montreal Heart Institute
Montreal, Canada
Year of study: November 2009 to May 2010.
Interventions Self-management of anticoagulation control versus standard care as control
Instruction on self-management
Patients randomised to the self-management group immediately received training on
the use of an automated device and the self-management algorithm developed by the
investigators. This included instructions on the frequency of International Normalised
Ratio (INR) monitoring, specific recommendations on what to do in the case of high or
low INR, how and when to communicate with the pharmacists in the self-management
programme, how to use the device, and the patient’s responsibility in the programme.
The session concluded with clinical scenarios, during which patients had to apply their
knowledge. They returned 1 week later to validate their use of the device and the algo-
rithm. Patients who had difficulty using the device or algorithm at the second visit were
invited to an additional second or third visit. If difficulties persisted, the patient was not
allowed to undergo self-management. On a weekly basis, patients in the self-manage-
ment group monitored their INR and adjusted their dose of warfarin according to the
algorithm. Through a voicemail message, patients were required to communicate their
INR result and any adjustment performed. The patient was contacted if no telephone
call was received on the expected day, or if an error in management occurred. If the INR
was outside the algorithm limits, the dose was adjusted by the pharmacist
Number of Interventions: 2 - 3 visits over 2 - 3 weeks, then weekly telephone commu-
nication
Duration: 4 months
Outcomes Adverse events, Quality of Life (QoL) - general treatment satisfaction
Notes Funding source: Dr. de Denus was supported by the Fonds de la Recherche en Sante du
Quebec and the Universite de Montreal Beaulieu-Saucier Chair in Pharmacogenomics.
The Coaguchek XS devices and CoaguChek XS PT test strips were provided by Roche
Diagnostics Canada
Conflict of interest:Dr. deDenuswas supported by the Fonds de laRecherche enSante du
Quebec and the Universite de Montre al Beaulieu-Saucier Chair in Pharmacogenomics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation list was generated by using permuted ran-
dom blocks of sizes 4 and 6. This list was generated by theMon-
treal Heart Institute Co-ordinating Center Biostatistics Depart-
ment using statistical software
Allocation concealment (selection bias) Low risk Patients were then randomised to continue their management
at the anticoagulation clinic (control group) or to switch to self-
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Verret 2012 (Continued)
management (self-management group). Patients randomised to
the control group received no further training
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Intervention group received training on use of a device that the
control group did not receive
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk No objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Vivian 2002
Methods Randomised trial
Participants 56 hypertensive patients (group numbers not stated)
The study was conducted at the Veterans Affairs Medical Center
Philadelphia, Pennsylvania, USA
Year of study: Not stated.
Interventions Pharmacist-managed hypertension clinic
Patients in the intervention group were scheduled to see the clinical pharmacist once a
month at the pharmacist-managed hypertension clinic. A prescribing pharmacist made
appropriate drug therapy changes (in both drug selection and dosage) for blood pressure
control in accordance with guidelines. The pharmacist did not make any changes in
their patients’ other drugs that may adversely affect blood pressure. Drug counselling,
consisting of a discussion about side effects, recommended lifestyle changes, and an
assessment of compliance, was provided at each visit
Number of Interventions: 1 a month
Duration: 6 months
Outcomes Systolic BP
Diastolic BP
Health-related Quality of Life
Notes Funding source: Christian R. and Mary F. Lindback Foundation
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Vivian 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned to either the interven-
tion group or the control group”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP objective. Satisfaction possibly biased
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Unclear risk Quote: “Measurements were obtained by a clinical pharmacist
using an auscultatory sphygmomanometer.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk Main results presented
Other bias Low risk None
Volume 2001
Methods Randomised trial
Participants 363 elderly participants (group numbers not stated)
Ambulatory elderly (≥ 65 years of age) patients who were concurrently using 3+ medi-
cations according to pharmacy profile
16 community pharmacies
Alberta, Canada
Year of study: June 1997 to not stated.
Interventions Pharmaceutical care
Treatment pharmacists were enrolled in an intensive education programme designed to
give them the necessary skill sets to provide care to study patients
Treatment pharmacists used an initial interview and frequent follow-up communication
with the patient and other caregivers. In addition, pharmaceutical care interventions
were often due to an in-depth review of the information collected by establishing a
therapeutic relationship with the patient as opposed to being triggered by the receipt of
a prescription, as was the case in the control pharmacies
The frequency, number and duration of interventions was unclear
Duration of study: 16 months.
Outcomes None available
Notes Funding source: Hoechst Marion Roussel provided an unconditional grant
Conflict of interest: None stated
Risk of bias
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Volume 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study statistician did not know the identity of the pharma-
cies and randomly assigned pharmacies from 6 of the 8 pairs to
either the treatment or the control group
Allocation concealment (selection bias) Low risk The study statistician did not know the identity of the pharma-
cies and randomly assigned pharmacies from 6 of the 8 pairs to
either the treatment or the control group
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Unclear risk Quote: “Treatment pharmacists were enrolled in an intensive
education program designed to give them the necessary skills...
”
Personnel were not blinded.
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
High risk Quote: “It was not possible to blind patients to the intervention”
and adherence to medication regimens and patient satisfaction
were measured with “self-report measures”
Hence unblinded assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 5 of 8 intervention pharmacists and 7 of 8 control pharma-
cists provided data. Reasons for lack of data provision included
lack of owner commitment
Selective reporting (reporting bias) Unclear risk Outcomes unavailable
Other bias Unclear risk Unclear
Wal 2013
Methods Randomised trial
Participants 142 hypertensive patients (intervention 72: control 70)
The study was conducted in the outpatient unit of the medicine department in Lakshmi
Pat Singhania. Institute of Cardiology
Kanpur, India.
Year of study: July 2010 to August 2011
Interventions Pharmaceutical care
Intervention group patients received pharmaceutical care including written, validated
health education material. Patients were counselled on the names, indications, adverse
effects and specific administration instruction for their antihypertensive medications.
Physical activity or exercise performed by patients was assessed by interviewing the pa-
tients. A study-specific patient counselling documentation form was used. Blood pres-
sure readings were noted in the data collection form at baseline and first and second
follow-up. Potential problems were also discussed with physicians and documented. The
control group did not receive any pharmaceutical care
Number and frequency of interventions unclear.
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Wal 2013 (Continued)
Duration: 13 months
Outcomes Systolic BP
Diastolic BP
Quality of Life (SF-36)
Notes Funding source: Supported by intervention cardiologists and Medical Superintendent
of LPS institute of Cardiology Kanpu
Conflict of interest: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Enrolled patients were randomised by the block randomisation
method into 2 groups, control and intervention
Allocation concealment (selection bias) Unclear risk Unclear if concealment occurred
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk BP is an objective measure
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk BP is an objective measure
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10% however, high overall attrition
54/72 in intervention group and 48/70 in control group com-
pleted the trial
Selective reporting (reporting bias) Low risk Main results reported
Other bias Low risk None
Weinberger 2002
Methods Randomised trial by practice: 36 drugstores divided into 12 clusters of 3 geographically-
proximal drugstores
Participants 1113 patients with chronic obstructive pulmonary disease (COPD) and asthma
Asthma - 660 (pharmaceutical care programme 262, peak flow monitoring control 233,
usual care control 165)
COPD - 453 (pharmaceutical care programme 185, peak flow monitoring control 130,
usual care control 138)
Health professional (delivering intervention): Unclear
Practice: 36
Community pharmacies
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Weinberger 2002 (Continued)
Indianapolis, USA
Year of study:July 1998 to not stated.
Interventions Pharmaceutical care: patients received peak flow monitor + instructions for use, written
educational materials, and monthly telephone calls from research personnel to collect
Peak Expiratory Flow Rate (PEFR) results; pharmacist assessed PEFR results and other
relevant medical information (medications, refill history, Emergency Department visits
and hospitalisations) and implemented pharmaceutical care activities) vs
Peak flow monitoring: patients received peak flow monitors and instructions for use
and monthly telephone calls from research personnel to collect peak flow PEFR results
(results were not seen by the pharmacist) vs
Usual care: patients did not receive peak flow monitors but received monthly follow-up
phone calls from research personnel.
Number of interventions: mean 19.4 in asthma, 22.4 in COPD patients over 12 months
Outcomes PEFR (combined for asthma and COPD patients) at 12 months
Health-related quality of life (HRQOL) for asthma patients at 12 months
HRQOL for COPD patients at 12 months
Notes Funding source: Department of Veterans Affairs
Conflict of interest: Newell and Collins were employed by CVS throughout the project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a random number chart”
Allocation concealment (selection bias) Low risk Not stated but unlikely due to nature of
intervention
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Both baseline and follow-up interviewers
blind
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Both baseline and follow-up interviewers
blind for PEFR
Incomplete outcome data (attrition bias)
All outcomes
High risk Between group attrition < 10%, however,
high attrition overall
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
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Wu 2006
Methods Randomised trial
Participants 442 participants (general medicine patients) (intervention 219: control 223)
Specialist medical clinics of the Prince of Wales Hospital
Hong Kong (catchment population of 1.2 million)
Year of study: Not stated.
Interventions Telephone intervention
Intervention group patients received a 10- to 15-minute telephone call from a pharmacist
between clinic visits throughout the study period. The pharmacist asked about the pa-
tient’s treatment regimens; clarified any misconceptions; explained the nature of any side
effects; reminded patients of their next clinic appointment; reinforced the importance of
treatment compliance and discussed relevant aspects of self-care, such as diet, exercise,
and self-monitoring. Due to frequent changes of attending doctors, information was not
fed back to the clinic staff, although patients were encouraged to report all side effects,
self-initiated changes in regimen, or concerns to their doctors at their next visit. Control
group patients received no interventions
Number of Interventions: 10 - 15 minutes, every 2 to 4 months
Duration: 2 years
Outcomes Mortality
Notes Funding source: Hong Kong Government Health Care and Promotion Fund (HSRC/
HCPF grant 226103) and MSD international grant
Conflict of interest: :JCNC and PCYT are investigators in clinical trials and research
programmes sponsored by MSD. JCNC is also a member of the MSD Worldwide
Diabetes Advisory Board
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk At the enrolment visit, eligible patients were reassessed for com-
pliance. The pharmacistwas blinded to the randomisation codes,
which were computer-generated by a statistician and sealed in
envelopes labelled with consecutive numbers. The envelopes
were opened by the clinic nurse in an ascending manner, and
patients were allocated to the intervention or control group
Allocation concealment (selection bias) Low risk At the enrolment visit, eligible patients were reassessed for com-
pliance. The pharmacistwas blinded to the randomisation codes,
which were computer-generated by a statistician and sealed in
envelopes labelled with consecutive numbers. The envelopes
were opened by the clinic nurse in an ascending manner, and
patients were allocated to the intervention or control group
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
Low risk Quote: ”blinding was not possible because the intervention was
complex and caregivers were involved
Personnel were not blinded, but with this telephone intervention
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Wu 2006 (Continued)
it is unlikely that knowledge of allocation undermined protocol
delivery
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Deaths: objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%.
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk None
Zermansky 2001
Methods Randomised trial
Participants 1188 elderly patients (intervention 608; control 580)
4 general practices
1 pharmacist
Leeds, United Kingdom
Year of study: June 1999 to June 2000.
Interventions Patients had 1 consultation with pharmacists to identify drugs, assess adherence, iden-
tify issues. Review active medical problems. Pharmacists could offer minor changes to
treatment or could refer to general practitioner if recommendations were more major
Outcomes Number of repeat prescriptions
Hospital admissions at 12 months
Notes Funding source: NHS Research and Development National Coordinating Centre for
Health Technology Assessment
Conflict of interest: None declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Those who consented were randomised to an inter-
vention group (clinical review by pharmacist) or control group
(normal care) by computer-generated random numbers.”
Allocation concealment (selection bias) Low risk Computer-generated random numbers
Blinding of participants and personnel
(performance bias)
All Outcomes/Outcome 1
High risk Non-blinded
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Zermansky 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All Outcomes/Outcome 1
Low risk Changes to prescriptions seems unlikely to be biased.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Between group attrition < 10%. Overall completion rate > 80%
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bayraktar-Ekincioglu 2013 Insufficient information provided
Gangwar 2014 Insufficient information provided
Varma 1999 Included hospitalised and non-hospitalised patients; data not presented separately
Characteristics of studies awaiting assessment [ordered by study ID]
Aguiar 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Al Hamarneh 2018
Methods Not yet assessed
Participants
Interventions
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Al Hamarneh 2018 (Continued)
Outcomes
Notes
Al-Tameemi 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Aljumah 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Almomani 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Anderegg 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Avery 2012
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Basger 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Basheti 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Batta 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Boudreau 2002
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Butt 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Cani 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Cantrill 2010
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Carter 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Choi 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Chow 2014
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Chow 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Chow 2015a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Clyne 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Cooney 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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De Azevedo 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Dischinger 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Elhatab 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Erku 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Erku 2017a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Garcia 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Geurts 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Goldfien 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Grainger-Rousseau 1996
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Haag 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Hedegaard 2014
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Hedegaard 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Hedegaard 2015a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Hedegaard 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Houle 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Iqbal 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Isetts 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
ISRCTN10671625 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Kandasamy 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Korcegez 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Lainscak 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Lalonde 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Lim 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Loganadan 2012
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Lowrie 2012
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Lyons 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Manfrin 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Mansell 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Margolis 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Marra 2011
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Marra 2011a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Martin 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Martin 2017a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Mateti 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
McNamara 2011
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Mendes 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Mikuls 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Nguyen 2011
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Obarcanin 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Obarcanin 2015a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Ojieabu 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Ojieabu 2017a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Okada 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Olivera 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Omran 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Periasamy 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Pevnick 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Pistja 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Renuga 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Rubio-Valera 2009
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Scala 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Schmiedel 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Schneiderhan 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Shao 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Siaw 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Smith 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Souter 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tahaineh 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tan 2011
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tierney 2005
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Tsuyuki 2015a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tsuyuki 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tsuyuki 2016a
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Tsuyuki 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Tuttle 2018
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Ummavathy 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Van Der Meer 2016
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Verret 2011
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Vinluan 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Wishah 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Wongpakaran 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Yang 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
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Yang 2017
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Zhao 2015
Methods Not yet assessed
Participants
Interventions
Outcomes
Notes
Characteristics of ongoing studies [ordered by study ID]
Da Silva 2012
Trial name or title da Silva 2012
Methods Randomised trial. Impact of pharmaceutical care on the quality of life of patients with Chagas disease and
heart failure
Participants 88 adult patients with Chagas heart disease complicated by heart failure
Conducted at the Evandro Chagas Clinical Research Institute (IPEC), Rio de Janeiro, Brazil
Interventions Quote “All patients from both groups will take part in medical consultations every month. After each medical
consultation, a pharmacist blinded to the patient’s assignmentwill interview all patients, to identify compliance
to treatment and any drug-related problems (DRPs). After this, all patients will interact with the clinical
pharmacist. Those randomised to the control group will receive all prescription medications, while those
patients randomised to the intervention group will not only receive all prescription medications but will
also undergo pharmaceutical care, to solve DRPs, confirm, and reinforce their compliance to the medical
prescription. Whenever the pharmacist identifies a DRP in the intervention group, s/he will interact with
the physician, to solve the DRP. All patients will take part in a pharmaceutical consultation at the end of the
follow-up, to identify DRPs, complete quality-of-life questionnaires, and perform six-minute-walk tests.”
Outcomes Quality of Life - evaluated using the 36-item short-form (SF-36) and the Minnesota Living with HF Ques-
tionnaire (MLHFQ)
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Da Silva 2012 (Continued)
Starting date December 2012
Contact information Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Av.
Brasil 4365, Rio de Janeiro, RJ 21040-900, Brazil
Notes Results not yet published
Forster 2015
Trial name or title Forster 2015
Methods Randomised trial. Effectiveness of a computerized drug-monitoring programme to detect and prevent adverse
drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized
controlled trial
Participants 2200 adult ambulatory patients in the province of Québec, Canada, who have been prescribed an incident
medication for the management or prevention of a chronic health condition
Interventions Quote “The use of the ISTOP-ADE system, which consists of an interactive voice response system (IVRS)
paired with pharmacist support. The IVRS will call patients at 3 and 17 days post-prescription to determine
if they are experiencing any problems and connect them with a pharmacist when required or desired by the
patient.”
Outcomes Medication persistence at 180 days
Starting date October 2015
Contact information Clinical Epidemiology Program, Ottawa Hospital Research Institute, 1053
Carling Avenue, Ottawa, ON K1Y 4E9, Canada
Notes Results not yet published
Kuhmmer 2015
Trial name or title Kuhmmer 2015
Methods Randomised trial
Participants Participants with hypertension and diabetes
Recruited from a public emergency department, Southern Brazil
Interventions Quote “Immediately post-discharge, intervention group received a structured 30-minute adherence-focused
intervention including: discussion on hypertension and/or diabetes, risk of complications, prescribed drug
therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, sched-
ule of administration, correct storage and any necessary lifestyle modifications. Printed educational material,
with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions
(for example, reduce salt and sugar intake, practice regular physical activity, smoking cessation, reducing
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Kuhmmer 2015 (Continued)
alcohol consumption, monitor stress levels in day-to-day and reduce weight and keep it within the normal
range) was handed to patients”
Outcomes Not applicable
Starting date Unknown
Contact information
Notes Results not yet published
Porteous 2013
Trial name or title Porteous 2013
Methods Randomised trial
Participants Participants with allergic rhinitis
Community pharmacies in NHS Grampian and NHS Greater Glasgow & Clyde, United Kingdom
Interventions Community pharmacy-delivered goal-focused approach
The intervention was developed to enhance replicability of the intervention by applying a reliable and valid
taxonomy of behaviour change techniques (BCTs). The core BCTs identified in the intervention are captured
by 4 of the taxonomy’s 16 clusters: Goals and planning (specific BCTs: goal-setting (outcome); goal-setting
(behaviour); problem-solving; action-planning), Natural consequences (specific BCT: information about
health consequences), Regulation (specific BCT: pharmacological support), and Feedback and Monitoring
(specific BCTs: self-monitoring of behaviour; self-monitoring of outcome(s) of behaviour). The BCTs were
operationalised in theHelp for Hay Fever intervention. Community pharmacy staff were trained. 1 pharmacist
and at least 1 pharmacy assistant from each of the 6 intervention pharmacies attended a 3-hour training
workshop. The workshop included training in self-management theory, the use of goal-setting as a behaviour
change technique, participant recruitment (including taking consent) and a role-play scenario
Outcomes
Starting date
Contact information
Notes Results not yet published. Protocol paper only
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 % outside blood pressure range 18 4107 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.29, 0.55]
2 % outside HbA1c range 5 558 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.04, 2.22]
3 Hospital attendance/admission 14 3631 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.11]
4 Adverse drug effects 3 590 Odds Ratio (M-H, Random, 95% CI) 1.65 [0.84, 3.24]
5 SF-36 Physical Functioning 7 1329 Mean Difference (IV, Random, 95% CI) 5.84 [1.21, 10.48]
6 Mortality 9 1980 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.56, 1.12]
7 HbA1c (%) 15 2298 Mean Difference (IV, Random, 95% CI) -0.77 [-0.97, -0.58]
8 Fasting blood glucose (mmol/l) 8 1349 Mean Difference (IV, Random, 95% CI) -1.17 [-1.71, -0.63]
9 Diastolic blood pressure
(mmHg)
31 5939 Mean Difference (IV, Random, 95% CI) -3.50 [-5.44, -1.56]
10 Systolic blood pressure
(mmHg)
32 6003 Mean Difference (IV, Random, 95% CI) -5.96 [-7.35, -4.57]
11 Total cholesterol (mmol/l) 7 1592 Mean Difference (IV, Random, 95% CI) -0.35 [-0.56, -0.13]
12 LDL Cholesterol (mmol/l) 6 854 Mean Difference (IV, Random, 95% CI) -0.14 [-0.30, 0.02]
13 FEV1 3 291 Mean Difference (IV, Random, 95% CI) 0.11 [-0.01, 0.23]
14 Peak Flow (%) 2 460 Mean Difference (IV, Random, 95% CI) 3.36 [-0.36, 7.09]
15 Dyspnoea 2 820 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.68, 1.20]
Comparison 2. Pharmacist services targeted at patients versus services delivered by other health professionals
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure (mmHg) 3 1238 Mean Difference (IV, Random, 95% CI) 1.31 [-6.22, 8.84]
2 Diastolic blood pressure
(mmHg)
2 959 Mean Difference (IV, Random, 95% CI) -1.36 [-4.30, 1.59]
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Analysis 1.1. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 1 % outside blood pressure range.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 1 % outside blood pressure range
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albsoul-Younes 2011 27/131 42/122 6.1 % 0.49 [ 0.28, 0.87 ]
Bogden 1998 22/49 37/46 4.7 % 0.20 [ 0.08, 0.50 ]
Borenstein 2003a 39/98 57/99 6.1 % 0.49 [ 0.28, 0.86 ]
Carter 2008 3/31 11/24 3.0 % 0.13 [ 0.03, 0.53 ]
Di Donato 2014 75/192 28/96 6.2 % 1.56 [ 0.92, 2.64 ]
Gar o 2002 7/31 26/29 3.0 % 0.03 [ 0.01, 0.15 ]
Green 2008 104/237 274/493 7.0 % 0.62 [ 0.46, 0.85 ]
Hirsch 2014 30/100 48/100 6.0 % 0.46 [ 0.26, 0.83 ]
Ho 2013 41/99 48/94 6.1 % 0.68 [ 0.38, 1.20 ]
Hunt 2008 105/230 136/233 6.8 % 0.60 [ 0.41, 0.87 ]
Magid 2013 74/162 106/164 6.5 % 0.46 [ 0.29, 0.72 ]
Margolis 2013 75/129 73/112 6.3 % 0.74 [ 0.44, 1.25 ]
Obreli-Neto 2015 13/97 67/97 5.4 % 0.07 [ 0.03, 0.14 ]
Reid 2005 18/92 41/68 5.5 % 0.16 [ 0.08, 0.33 ]
Simpson 2011 23/77 28/72 5.6 % 0.67 [ 0.34, 1.32 ]
Sookaneknun 2004 40/118 50/117 6.2 % 0.69 [ 0.41, 1.17 ]
Tsuyuki 2015 65/154 38/61 5.9 % 0.44 [ 0.24, 0.81 ]
Vivian 2002 5/26 19/27 3.5 % 0.10 [ 0.03, 0.36 ]
Total (95% CI) 2053 2054 100.0 % 0.40 [ 0.29, 0.55 ]
Total events: 766 (Pharmacist), 1129 (Usual care)
Heterogeneity: Tau2 = 0.37; Chi2 = 91.54, df = 17 (P<0.00001); I2 =81%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Pharmacist Favours Usual Care
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Analysis 1.2. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 2 % outside HbA1c range.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 2 % outside HbA1c range
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castejon 2013 17/21 10/23 19.7 % 5.53 [ 1.41, 21.66 ]
Farsaei 2011 33/59 83/86 20.0 % 0.05 [ 0.01, 0.16 ]
Obreli-Neto 2015 36/97 94/97 20.1 % 0.02 [ 0.01, 0.06 ]
Schneiderhan 2014 7/44 5/45 20.0 % 1.51 [ 0.44, 5.19 ]
Taveira 2011 31/44 37/42 20.3 % 0.32 [ 0.10, 1.00 ]
Total (95% CI) 265 293 100.0 % 0.29 [ 0.04, 2.22 ]
Total events: 124 (Pharmacist), 229 (Usual care)
Heterogeneity: Tau2 = 4.89; Chi2 = 52.96, df = 4 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Pharmacist Favours Usual Care
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Analysis 1.3. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 3 Hospital attendance/admission.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 3 Hospital attendance/admission
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernsten 2001 86/240 77/190 14.4 % 0.82 [ 0.55, 1.21 ]
Bond 2000 7/111 10/172 5.4 % 1.09 [ 0.40, 2.95 ]
Charrois 2006 6/36 6/32 3.8 % 0.87 [ 0.25, 3.02 ]
Hawes 2013 0/24 12/37 0.8 % 0.04 [ 0.00, 0.74 ]
Ho 2013 8/122 5/119 4.4 % 1.60 [ 0.51, 5.04 ]
Jackson 2004 13/59 19/68 7.2 % 0.73 [ 0.32, 1.64 ]
Jarab 2012 3/66 11/67 3.5 % 0.24 [ 0.06, 0.91 ]
Lopez 2006 23/70 31/64 8.7 % 0.52 [ 0.26, 1.05 ]
Mehuys 2008 1/80 5/70 1.4 % 0.16 [ 0.02, 1.44 ]
Naunton 2003 16/57 29/64 7.9 % 0.47 [ 0.22, 1.01 ]
Olesen 2014 77/253 73/264 14.7 % 1.14 [ 0.78, 1.67 ]
Verret 2012 9/58 6/56 4.7 % 1.53 [ 0.51, 4.62 ]
Weinberger 2002 15/64 11/59 6.6 % 1.34 [ 0.56, 3.20 ]
Zermansky 2001 110/579 92/550 16.4 % 1.17 [ 0.86, 1.58 ]
Total (95% CI) 1819 1812 100.0 % 0.85 [ 0.65, 1.11 ]
Total events: 374 (Pharmacist), 387 (Usual care)
Heterogeneity: Tau2 = 0.09; Chi2 = 23.16, df = 13 (P = 0.04); I2 =44%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Pharmacist Favours Usual Care
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Analysis 1.4. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 4 Adverse drug effects.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 4 Adverse drug effects
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2000 9/111 12/172 29.9 % 1.18 [ 0.48, 2.89 ]
Chrischilles 2014 27/98 10/95 34.0 % 3.23 [ 1.47, 7.13 ]
Verret 2012 26/58 23/56 36.0 % 1.17 [ 0.55, 2.45 ]
Total (95% CI) 267 323 100.0 % 1.65 [ 0.84, 3.24 ]
Total events: 62 (Pharmacist), 45 (Usual care)
Heterogeneity: Tau2 = 0.18; Chi2 = 4.17, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Pharmacist Favours Usual Care
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Analysis 1.5. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 5 SF-36 Physical Functioning.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 5 SF-36 Physical Functioning
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hunt 2008 142 44 (11) 130 42 (12) 22.8 % 2.00 [ -0.74, 4.74 ]
Mazroui 2009 117 62.4 (19.591) 117 48 (23.179) 18.4 % 14.40 [ 8.90, 19.90 ]
Mehos 2000 18 67.4 (27.69) 18 71.1 (27.69) 5.2 % -3.70 [ -21.79, 14.39 ]
Sadik 2005 104 63.1 (26.276) 104 52.8 (28.357) 15.2 % 10.30 [ 2.87, 17.73 ]
Sellors 2003 196 55 (3.476) 212 55 (2.064) 24.7 % 0.0 [ -0.56, 0.56 ]
Taylor 2003 33 68.2 (42.1) 36 52.8 (42.2) 4.4 % 15.40 [ -4.51, 35.31 ]
Wal 2013 54 58.33 (31.43) 48 50.93 (30.89) 9.2 % 7.40 [ -4.71, 19.51 ]
Total (95% CI) 664 665 100.0 % 5.84 [ 1.21, 10.48 ]
Heterogeneity: Tau2 = 22.52; Chi2 = 38.51, df = 6 (P<0.00001); I2 =84%
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 6 Mortality.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 6 Mortality
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Verret 2012 0/58 0/56 Not estimable
Lopez 2006 9/70 19/64 13.6 % 0.35 [ 0.14, 0.84 ]
Gattis 1999a 3/90 5/91 5.4 % 0.59 [ 0.14, 2.56 ]
Wu 2006 25/219 38/223 29.1 % 0.63 [ 0.36, 1.08 ]
Naunton 2003 3/57 5/64 5.3 % 0.66 [ 0.15, 2.87 ]
Jackson 2004 4/59 5/68 6.2 % 0.92 [ 0.23, 3.58 ]
Lenaghan 2007 49/56 41/47 8.3 % 1.02 [ 0.32, 3.29 ]
Ho 2013 11/122 9/119 12.7 % 1.21 [ 0.48, 3.04 ]
Olesen 2014 19/253 14/264 19.4 % 1.45 [ 0.71, 2.96 ]
Total (95% CI) 984 996 100.0 % 0.79 [ 0.56, 1.12 ]
Total events: 123 (Pharmacist), 136 (Usual care)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.04, df = 7 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 7 HbA1c (%).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 7 HbA1c (%)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Andres 2007 56 -0.5 (1.2) 56 0.7 (0.9) 7.4 % -1.20 [ -1.59, -0.81 ]
Castejon 2013 19 7.3 (0.3) 24 8 (0.2) 9.9 % -0.70 [ -0.86, -0.54 ]
Choe 2005 36 8 (1.4) 29 9.3 (2.1) 3.3 % -1.30 [ -2.19, -0.41 ]
Clifford 2005 92 -0.5 (1.05) 88 0 (1.05) 8.4 % -0.50 [ -0.81, -0.19 ]
Doucette 2009 36 7.72 (1.45) 42 8.03 (1.91) 4.1 % -0.31 [ -1.06, 0.44 ]
Farsaei 2011 59 7.5 (1.6) 86 9 (1.2) 6.4 % -1.50 [ -1.98, -1.02 ]
Jahangard-Rafsanjani 2014 45 6.6 (1.5) 40 7 (1.7) 4.6 % -0.40 [ -1.09, 0.29 ]
Krass 2007 100 7.9 (1.2) 85 8 (1.2) 7.9 % -0.10 [ -0.45, 0.25 ]
Mahwi 2013 62 9.2 (2) 61 9.5 (2.1) 4.3 % -0.30 [ -1.02, 0.42 ]
Mazroui 2009 117 6.9 (1.104) 117 8.3 (1.104) 8.6 % -1.40 [ -1.68, -1.12 ]
Obreli-Neto 2015 97 -0.7 (0.754) 97 0 (0.502) 9.7 % -0.70 [ -0.88, -0.52 ]
Samtia 2013 174 7.5 (1.26) 168 8.08 (1.49) 8.5 % -0.58 [ -0.87, -0.29 ]
Sarkadi 2004 33 6.09 (1.744) 31 6.59 (1.69) 3.6 % -0.50 [ -1.34, 0.34 ]
Suppapitiporn 2005 180 7.91 (1.27) 180 8.8 (1.36) 8.8 % -0.89 [ -1.16, -0.62 ]
Taveira 2011 44 7.4 (1.2) 44 8.4 (2) 4.6 % -1.00 [ -1.69, -0.31 ]
Total (95% CI) 1150 1148 100.0 % -0.77 [ -0.97, -0.58 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 59.80, df = 14 (P<0.00001); I2 =77%
Test for overall effect: Z = 7.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 8 Fasting blood glucose (mmol/l).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 8 Fasting blood glucose (mmol/l)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ali 2012 23 6.88 (1.05) 23 9.04 (1.93) 12.4 % -2.16 [ -3.06, -1.26 ]
Farsaei 2011 86 8.1 (2.78) 86 9.22 (3.04) 12.6 % -1.12 [ -1.99, -0.25 ]
Hammad 2011 110 5.93 (2.64) 89 6.2 (2.42) 14.2 % -0.27 [ -0.97, 0.43 ]
Jaber 1996 17 8.5 (2.3) 22 11 (4) 5.3 % -2.50 [ -4.50, -0.50 ]
Mahwi 2013 62 10.91 (4.12) 61 10.86 (3.47) 8.7 % 0.05 [ -1.30, 1.40 ]
Mazroui 2009 117 7.78 (1.545) 117 9.48 (2.401) 16.0 % -1.70 [ -2.22, -1.18 ]
Obreli-Neto 2015 97 -1.51 (2.39) 97 0.06 (1.2) 15.9 % -1.57 [ -2.10, -1.04 ]
Samtia 2013 174 8.86 (3.01) 168 9.34 (2.97) 14.9 % -0.48 [ -1.11, 0.15 ]
Total (95% CI) 686 663 100.0 % -1.17 [ -1.71, -0.63 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 26.45, df = 7 (P = 0.00042); I2 =74%
Test for overall effect: Z = 4.23 (P = 0.000023)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 9 Diastolic blood pressure (mmHg).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 9 Diastolic blood pressure (mmHg)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Albsoul-Younes 2011 130 -10.5 (12.9) 123 -7.17 (13.11) 3.3 % -3.33 [ -6.54, -0.12 ]
Amariles 2012 317 79 (8.6) 323 80.1 (9.8) 3.6 % -1.10 [ -2.53, 0.33 ]
Bogden 1998 49 -14 (11) 46 -2 (11) 3.1 % -12.00 [ -16.43, -7.57 ]
Carter 2008 31 74.7 (9.6) 24 78.5 (10.9) 2.8 % -3.80 [ -9.32, 1.72 ]
Chisholm 2002 13 77 (10.2) 10 91.8 (12) 2.0 % -14.80 [ -24.08, -5.52 ]
De Castro 2006 30 77 (10) 34 78 (11) 2.9 % -1.00 [ -6.15, 4.15 ]
Di Donato 2014 181 76.53 (9.41) 94 76 (9.42) 3.5 % 0.53 [ -1.82, 2.88 ]
Doucette 2009 36 67.8 (8.9) 42 67.4 (8.32) 3.2 % 0.40 [ -3.44, 4.24 ]
Gar o 2002 41 73.32 (8.2) 41 78.59 (8.55) 3.3 % -5.27 [ -8.90, -1.64 ]
Green 2008 483 83.08 (9.81) 247 85.7 (9.62) 3.6 % -2.62 [ -4.10, -1.14 ]
Hammad 2011 110 76.6 (10.7) 89 78.8 (7.6) 3.5 % -2.20 [ -4.75, 0.35 ]
Hirsch 2014 71 -2.5 (10.2) 89 -0.3 (13.8) 3.2 % -2.20 [ -5.92, 1.52 ]
Ho 2013 122 76 (12) 119 75 (12) 3.4 % 1.00 [ -2.03, 4.03 ]
Hunt 2008 142 77 (10) 130 80 (12) 3.4 % -3.00 [ -5.64, -0.36 ]
Jahangard-Rafsanjani 2014 45 82.2 (9.7) 40 82 (11.8) 3.0 % 0.20 [ -4.43, 4.83 ]
Krass 2007 69 77 (8) 73 76 (9) 3.4 % 1.00 [ -1.80, 3.80 ]
Lee 2006 83 67.5 (9.9) 76 68.6 (10.5) 3.3 % -1.10 [ -4.28, 2.08 ]
Magid 2013 162 -20.7 (3.5) 164 -8.2 (4.5) 3.6 % -12.50 [ -13.37, -11.63 ]
Margolis 2013 75 75.1 (16.47) 73 80.8 (16.57) 2.9 % -5.70 [ -11.02, -0.38 ]
Mazroui 2009 117 76.3 (7.726) 117 84.1 (9.328) 3.5 % -7.80 [ -9.99, -5.61 ]
Mehos 2000 18 -10.5 (7.212) 18 -3.8 (9.164) 2.9 % -6.70 [ -12.09, -1.31 ]
Obreli-Neto 2015 97 -14.8 (14.572) 97 -1.9 (9.296) 3.3 % -12.90 [ -16.34, -9.46 ]
Park 1996 23 83.2 (8) 26 83.7 (10.9) 2.9 % -0.50 [ -5.81, 4.81 ]
Rothman 2005 99 78 (9.42) 95 81 (9.42) 3.4 % -3.00 [ -5.65, -0.35 ]
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(. . . Continued)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Simpson 2011 110 -2.3 (10.435) 113 0.6 (10.847) 3.4 % -2.90 [ -5.69, -0.11 ]
Solomon 1998 63 80.2 (9.6) 70 83.2 (11.5) 3.3 % -3.00 [ -6.59, 0.59 ]
Sookaneknun 2004 118 71.55 (10.8) 117 74.23 (11.87) 3.4 % -2.68 [ -5.58, 0.22 ]
Stewart 2014 122 80.2 (13.6) 122 78.8 (13.8) 3.3 % 1.40 [ -2.04, 4.84 ]
Tsuyuki 2015 154 76 (12) 61 78.1 (10) 3.3 % -2.10 [ -5.24, 1.04 ]
Vivian 2002 26 77.5 (10.7) 27 80.4 (11.4) 2.7 % -2.90 [ -8.85, 3.05 ]
Wal 2013 54 84.42 (5.16) 48 86.72 (5.1) 3.5 % -2.30 [ -4.29, -0.31 ]
Total (95% CI) 3191 2748 100.0 % -3.50 [ -5.44, -1.56 ]
Heterogeneity: Tau2 = 26.78; Chi2 = 480.46, df = 30 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.53 (P = 0.00042)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Pharmacist Favours Usual Care
198Pharmacist services for non-hospitalised patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 10 Systolic blood pressure (mmHg).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 10 Systolic blood pressure (mmHg)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Albsoul-Younes 2011 130 -16.1 (14.6) 123 -10.6 (13.5) 4.2 % -5.50 [ -8.96, -2.04 ]
Amariles 2012 317 134.2 (13.8) 323 138.2 (15.7) 4.9 % -4.00 [ -6.29, -1.71 ]
Bogden 1998 49 -23 (22) 46 -11 (23) 1.7 % -12.00 [ -21.06, -2.94 ]
Carter 2008 31 124.2 (9.7) 24 133 (14.2) 2.5 % -8.80 [ -15.43, -2.17 ]
Chisholm 2002 13 145.3 (16.8) 10 175.8 (33.9) 0.3 % -30.50 [ -53.41, -7.59 ]
De Castro 2006 30 134 (11) 34 135 (15) 2.6 % -1.00 [ -7.40, 5.40 ]
Di Donato 2014 181 131.1 (16.8) 94 128 (16.73) 3.8 % 3.10 [ -1.07, 7.27 ]
Doucette 2009 36 125.3 (11.67) 42 124.3 (17.62) 2.5 % 1.00 [ -5.55, 7.55 ]
Gar o 2002 41 128.54 (15.06) 41 142.9 (20.42) 2.1 % -14.36 [ -22.13, -6.59 ]
Green 2008 483 140.91 (15.14) 247 146.3 (14.83) 4.9 % -5.39 [ -7.68, -3.10 ]
Hammad 2011 110 122.66 (13.2) 89 127.2 (15.2) 3.9 % -4.54 [ -8.55, -0.53 ]
Hirsch 2014 71 -5.2 (16.9) 89 -1.7 (17.7) 3.1 % -3.50 [ -8.88, 1.88 ]
Ho 2013 122 130 (20) 119 132 (21) 3.2 % -2.00 [ -7.18, 3.18 ]
Hunt 2008 142 142 (19) 130 148 (22) 3.3 % -6.00 [ -10.91, -1.09 ]
Jahangard-Rafsanjani 2014 45 132.8 (17.6) 40 134.2 (18.7) 2.1 % -1.40 [ -9.15, 6.35 ]
Krass 2007 69 133 (15) 73 135 (15) 3.3 % -2.00 [ -6.94, 2.94 ]
Lee 2006 73 124.4 (14) 62 133.3 (21.5) 2.7 % -8.90 [ -15.14, -2.66 ]
Magid 2013 162 -10.5 (2) 164 -4.8 (2.5) 5.7 % -5.70 [ -6.19, -5.21 ]
Margolis 2013 75 125.7 (16.47) 73 134.8 (16.57) 3.1 % -9.10 [ -14.42, -3.78 ]
Mazroui 2009 117 127.2 (15.728) 117 132.1 (11.865) 4.1 % -4.90 [ -8.47, -1.33 ]
Mehos 2000 18 -17.1 (13.576) 18 -7 (18.668) 1.3 % -10.10 [ -20.76, 0.56 ]
Obreli-Neto 2015 97 -23 (17.085) 97 -0.4 (13.567) 3.7 % -22.60 [ -26.94, -18.26 ]
Park 1996 23 143.2 (11.5) 26 148.6 (20.1) 1.7 % -5.40 [ -14.44, 3.64 ]
Rothman 2005 99 133 (16.73) 95 139 (16.73) 3.4 % -6.00 [ -10.71, -1.29 ]
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(. . . Continued)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Simpson 2011 110 -7.4 (14.983) 113 -2.5 (14.372) 4.0 % -4.90 [ -8.76, -1.04 ]
Solomon 1998 63 138.9 (13.9) 70 144.9 (21.3) 2.7 % -6.00 [ -12.06, 0.06 ]
Sookaneknun 2004 118 121.47 (14.9) 117 124.77 (17.97) 3.7 % -3.30 [ -7.52, 0.92 ]
Stewart 2014 122 131.7 (22) 122 135.3 (22.3) 3.0 % -3.60 [ -9.16, 1.96 ]
Taveira 2011 44 123.4 (12.3) 44 127 (17.3) 2.6 % -3.60 [ -9.87, 2.67 ]
Tsuyuki 2015 154 130.7 (14) 61 139.7 (11) 4.2 % -9.00 [ -12.54, -5.46 ]
Vivian 2002 26 130.5 (13.2) 27 148.4 (21) 1.6 % -17.90 [ -27.31, -8.49 ]
Wal 2013 54 132.8 (9.03) 48 139.43 (9.47) 4.1 % -6.63 [ -10.23, -3.03 ]
Total (95% CI) 3225 2778 100.0 % -5.96 [ -7.35, -4.57 ]
Heterogeneity: Tau2 = 8.80; Chi2 = 117.72, df = 31 (P<0.00001); I2 =74%
Test for overall effect: Z = 8.41 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 11 Total cholesterol (mmol/l).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 11 Total cholesterol (mmol/l)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Faulkner 2000 15 5.77 (1.26) 15 6.67 (1.95) 2.9 % -0.90 [ -2.07, 0.27 ]
Paulos 2005 23 4.57 (0.8) 19 5.11 (0.95) 9.2 % -0.54 [ -1.08, 0.00 ]
Peterson 2004 39 4.4 (0.6) 42 4.6 (0.8) 15.1 % -0.20 [ -0.51, 0.11 ]
Mazroui 2009 117 4.47 (0.773) 117 5.32 (1.104) 17.1 % -0.85 [ -1.09, -0.61 ]
Simpson 2011 110 -0.23 (0.963) 113 -0.09 (0.868) 17.2 % -0.14 [ -0.38, 0.10 ]
Malone 2001 162 4.92 (1.06) 180 5.04 (1.01) 17.8 % -0.12 [ -0.34, 0.10 ]
Amariles 2012 317 4.62 (0.68) 323 4.87 (0.79) 20.6 % -0.25 [ -0.36, -0.14 ]
Total (95% CI) 783 809 100.0 % -0.35 [ -0.56, -0.13 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 26.64, df = 6 (P = 0.00017); I2 =77%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 12 LDL Cholesterol (mmol/l).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 12 LDL Cholesterol (mmol/l)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Doucette 2009 36 2.08 (0.72) 42 2.39 (0.94) 12.2 % -0.31 [ -0.68, 0.06 ]
Faulkner 2000 15 3.67 (1.03) 15 4.18 (1.21) 3.6 % -0.51 [ -1.31, 0.29 ]
Ho 2013 122 2.05 (0.82) 119 1.95 (0.64) 23.1 % 0.10 [ -0.09, 0.29 ]
Obreli-Neto 2015 97 -0.27 (1.07) 97 0.07 (0.29) 20.5 % -0.34 [ -0.56, -0.12 ]
Simpson 2011 110 -0.23 (0.38) 113 -0.1 (0.786) 24.9 % -0.13 [ -0.29, 0.03 ]
Taveira 2011 44 2.37 (0.62) 44 2.41 (0.78) 15.8 % -0.04 [ -0.33, 0.25 ]
Total (95% CI) 424 430 100.0 % -0.14 [ -0.30, 0.02 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 11.44, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 13 FEV1.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 13 FEV1
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gonz lez-Martin 2003 11 2.48 (0.89) 10 2.51 (0.27) 4.6 % -0.03 [ -0.58, 0.52 ]
Jarab 2012 63 1.15 (0.425) 64 1.06 (0.551) 48.4 % 0.09 [ -0.08, 0.26 ]
Khdour 2009 71 1.19 (0.559) 72 1.05 (0.498) 47.0 % 0.14 [ -0.03, 0.31 ]
Total (95% CI) 145 146 100.0 % 0.11 [ -0.01, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 14 Peak Flow (%).
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 14 Peak Flow (%)
Study or subgroup Pharmacist Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Weinberger 2002 123 65.5 (19.5) 187 63.02 (22.024) 63.4 % 2.48 [ -2.19, 7.15 ]
Mehuys 2008 80 84 (19.4) 70 79.1 (19) 36.6 % 4.90 [ -1.25, 11.05 ]
Total (95% CI) 203 257 100.0 % 3.36 [ -0.36, 7.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Pharmacist services targeted at patients versus the delivery of no comparable
service, Outcome 15 Dyspnoea.
Review: Pharmacist services for non-hospitalised patients
Comparison: 1 Pharmacist services targeted at patients versus the delivery of no comparable service
Outcome: 15 Dyspnoea
Study or subgroup Pharmacist Usual care Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Solomon 1998 12/43 20/55 11.1 % 0.68 [ 0.29, 1.61 ]
Tommelein 2013 130/376 125/346 88.9 % 0.93 [ 0.69, 1.27 ]
Total (95% CI) 419 401 100.0 % 0.90 [ 0.68, 1.20 ]
Total events: 142 (Pharmacist), 145 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Pharmacist services targeted at patients versus services delivered by other
health professionals, Outcome 1 Systolic blood pressure (mmHg).
Review: Pharmacist services for non-hospitalised patients
Comparison: 2 Pharmacist services targeted at patients versus services delivered by other health professionals
Outcome: 1 Systolic blood pressure (mmHg)
Study or subgroup Pharmacist
Other
Health
Professional
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hawkins 1979 349 147 (18) 280 141 (13) 34.3 % 6.00 [ 3.57, 8.43 ]
McAlister 2014 143 126.5 (17.9) 136 122.2 (13) 32.8 % 4.30 [ 0.64, 7.96 ]
Okamoto 2001 164 135.1 (15.3) 166 141.66 (17.9) 32.9 % -6.56 [ -10.15, -2.97 ]
Total (95% CI) 656 582 100.0 % 1.31 [ -6.22, 8.84 ]
Heterogeneity: Tau2 = 41.54; Chi2 = 33.37, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Pharmacist services targeted at patients versus services delivered by other
health professionals, Outcome 2 Diastolic blood pressure (mmHg).
Review: Pharmacist services for non-hospitalised patients
Comparison: 2 Pharmacist services targeted at patients versus services delivered by other health professionals
Outcome: 2 Diastolic blood pressure (mmHg)
Study or subgroup Pharmacist
Other
Health
Professional
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hawkins 1979 349 84 (6) 280 84 (4) 55.1 % 0.0 [ -0.78, 0.78 ]
Okamoto 2001 164 77.65 (8.7) 166 80.67 (10.2) 44.9 % -3.02 [ -5.06, -0.98 ]
Total (95% CI) 513 446 100.0 % -1.36 [ -4.30, 1.59 ]
Heterogeneity: Tau2 = 3.94; Chi2 = 7.30, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses
Author/Year Clinical condition Outcome measures used for meta-analyses
Adibe 2013a Diabetes (Type 2) -
Adler 2004 Major depression and/or dysthymia -
Albsoul-Younes 2011 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Ali 2012 Diabetes (Type 2) Fasting blood glucose (mmol/l)
Amariles 2012 Cardiovascular disease Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg); Total cholesterol (mmol/L)
Andres 2007 Diabetes (Type 2) HbA1c (%)
Armour 2007 Asthma -
Barbanel 2003- Asthma -
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
Bernsten 2001 Older Patients (aged > 65) Hospital attendance/admission
Blalock 2010 At-risk patients (Older patients (aged >65) receiv-
ing medication that increases their risk of falling)
-
Bogden 1998 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Bond 2000 Repeat prescribing Hospital attendance/admission; Adverse drug ef-
fects
Borenstein 2003a Hypertension % outside blood pressure range
Bosnic-Anticevich 2010 Asthma/Chronic Obstructive Pulmonary Disease
(COPD)
-
Boyd 2013 Non-adherence in chronic conditions -
Brook 2003 Depression -
Bruhn 2013 Pain (Chronic) -
Capoccia 2004 Depression -
Castejon 2013 Diabetes % outside HbA1c range; HbA1c (%)
Carter 2008 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Charrois 2006 Asthma Hospital attendance/admission
Chisholm 2002 Transplant patients (renal with focus on BP con-
trol)
Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Choe 2005 Diabetes (Type 2) HbA1c (%)
Chrischilles 2014 Adults with disability Adverse drug effects
Clifford 2005 Diabetes (Type 2) (vascular risk factors) HbA1c (%)
Cody 1998 Health Related Quality of Life (Short Form Sur-
vey 36)
-
Cordina 2001 Asthma -
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
De Castro 2006 Hypertension Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Di Donato 2014 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Doucette 2009 Diabetes HbA1c (%); Diastolic blood pressure (mmHg);
Systolic blood pressure (mmHg); LDL Choles-
terol (mmol/L)
Edwards 2014 Chemotherapy -
Farsaei 2011 Diabetes (Type 2) % outside HbA1c range; HbA1c (%); Fasting
blood glucose (mmol/l)
Faulkner 2000 Hypercholesterolaemic patients receiving combi-
nation drug therapy
Total cholesterol (mmol/L); LDL Cholesterol
(mmol/L)
Finley 2003 Depression -
Garção 2002 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
García-Cárdenas 2013 Asthma -
Gattis 1999a Heart failure Mortality
González-Martin 2003 Asthma Forced expiratory volume (FEV1)
Goodyer 1995 Heart failure -
Green 2008 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Hammad 2011 Metabolic syndrome Fasting blood glucose (mmol/l); Diastolic blood
pressure (mmHg); Systolic blood pressure
(mmHg)
Hawes 2013 Patients at risk of rehospitalisation Hospital attendance/admission
Hawkins 1979 Hypertension and Diabetes Diastolic blood pressure (mmHg) (Comparison
2)
Hay 2006 Knee pain -
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
Hendrie 2014 Type 2 Diabetes -
Hirsch 2014 Blood pressure % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Ho 2013 Acute Coronary Syndrome % outside blood pressure range;Hospital at-
tendance/admission; Diastolic blood pressure
(mmHg); Systolic blood pressure (mmHg); LDL
Cholesterol (mmol/L); Mortality
Holland 2005 Multiple conditions -
Hunt 2008 Hypertension % outside blood pressure range; SF-36 physical
functioning; Diastolic blood pressure (mmHg);
Systolic blood pressure (mmHg)
Jaber 1996 Diabetes Fasting blood glucose (mmol/l)
Jackson 2004 Anticoagulation (Warfarin) Hospital attendance/admission; Mortality
Jahangard-Rafsanjani 2014 Diabetes HbA1c (%); Diastolic blood pressure (mmHg);
Systolic blood pressure (mmHg)
Jarab 2012 Chronic Obstructive Pulmonary Disease Hospital attendance/admission; Forced expira-
tory volume (FEV1)
Khdour 2009 Chronic Obstructive Pulmonary Disease Forced expiratory volume (FEV1)
Krass 2007 Diabetes HbA1c (%); Diastolic blood pressure (mmHg);
Systolic blood pressure (mmHg)
Kritikos 2007 Asthma -
Krska 2001 Multiple conditions -
Lai 2013 Osteoporosis (postmenopausal) -
Lee 2006 Elderly with coronary risk factors Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Lenaghan 2007 Multiple conditions Mortality
Lenander 2014 Polypharmacy (> 5 medications) -
Li 2014 Chronic Obstructive Pulmonary Disease -
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
Lopez 2006 Heart failure Hospital attendance/admission; Mortality
Losada-Camacho 2014 Epilepsy -
Magid 2013 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Mahwi 2013 Diabetes (Type 2) HbA1c (%); Fasting blood glucose (mmol/l)
Malone 2001 At-risk patients (high risk of drug related prob-
lems (DRPs))
Total cholesterol (mmol/L)
Margolis 2013 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg);
Marques 2013 Depression -
Marra 2012 Osteoarthritis (Knee) -
Mazroui 2009 Type 2 diabetes SF-36 physical functioning; HbA1c (%); Fasting
blood glucose (mmol/l); Diastolic blood pressure
(mmHg); Systolic blood pressure (mmHg);Total
cholesterol (mmol/L)
McAlister 2014 Cerebrovascular Accident (BP/lipid levels after
stroke)
Systolic blood pressure (mmHg) (Comparison 2)
Mehos 2000 Hypertension SF-36 physical functioning; Diastolic blood pres-
sure (mmHg); Systolic blood pressure (mmHg)
Mehuys 2008 Asthma Hospital attendance/admission; Peak Flow (%)
Milos 2013 Multiple conditions -
Murray 2007 Heart failure -
Naunton 2003 Multiple conditions Hospital attendance/admission; Mortality
Obreli-Neto 2015 Older patients (with diabetes and hypertension) % outside blood pressure range;% outside
HbA1c range; HbA1c (%); Fasting blood glucose
(mmol/l); Diastolic blood pressure (mmHg); Sys-
tolic blood pressure (mmHg); LDL Cholesterol
(mmol/L)
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
Okamoto 2001 Hypertension Systolic blood pressure (mmHg) (Comparison 2)
; Diastolic blood pressure (mmHg) (Comparison
2)
Olesen 2014 Polypharmacy (older patients) Hospital attendance/admission; Mortality
Park 1996 Hypertension Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Paulos 2005 Dyslipidaemia Total cholesterol (mmol/L)
Peterson 2004 Dyslipidaemia Total cholesterol (mmol/L)
Reid 2005 Hypertension % outside blood pressure range
Rickles 2005 Depression -
Rothman 2005 Diabetes (Type 2) Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Rubio-Valera 2012 Depression -
Sadik 2005 Heart failure SF-36 physical functioning
Salazar-Ospina 2017 Bipolar Diseases -
Samtia 2013 Diabetes (Type 2) HbA1c (%); Fasting blood glucose (mmol/l)
Sarkadi 2004 Diabetes (Type 2) HbA1c (%)
Schneider 1982 Hypertension and Congestive Heart Failure -
Schneiderhan 2014 Metabolic Syndrome % outside HbA1c range
Sellors 2003 Multiple conditions SF-36 physical functioning
Sidel 1990 Multiple conditions -
Silveira 2014 HIV -
Simpson 2011 Diabetes (Type 2) % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pres-
sure (mmHg);Total cholesterol (mmol/L); LDL
Cholesterol (mmol/L)
Solomon 1998 Chronic Obstructive Pulmonary Disease Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg); Dyspnoea
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Table 1. Included studies (N = 116) and outcome measures presented in meta-analyses (Continued)
Sookaneknun 2004 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Stewart 2014 Hypertension (primary) Diastolic blood pressure (mmHg); Systolic blood
pressure (mmHg)
Suppapitiporn 2005 Type 2 diabetes HbA1c (%)
Tang 2014 Epilepsy -
Tannenbaum 2014 Benzodiazepine users -
Taveira 2011 Cardiovascular risk % outside HbA1c range; HbA1c (%); Sys-
tolic blood pressure (mmHg); LDL Cholesterol
(mmol/L)
Taveira 2014 Cardiovascular risk -
Taylor 2003 Multiple conditions SF-36 physical functioning
Tommelein 2013 Chronic Obstructive Pulmonary Disease Dyspnoea
Tsuyuki 2002 Cardiacovascular risk; atherosclerotic disease or
diabetes
-
Tsuyuki 2015 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Verret 2012 Anticoagulant patients/stroke risk Hospital attendance/admission; Adverse drug ef-
fects; Mortality
Vivian 2002 Hypertension % outside blood pressure range; Diastolic
blood pressure (mmHg); Systolic blood pressure
(mmHg)
Volume 2001 Polypharmacy (older patients > 3 medications) -
Wal 2013 Hypertension SF-36 physical functioning; Diastolic blood pres-
sure (mmHg); Systolic blood pressure (mmHg)
Weinberger 2002 Chronic Obstructive Pulmonary Disease Hospital attendance/admission; Peak Flow (%)
Wu 2006 Various Mortality
Zermansky 2001 Multiple conditions Hospital attendance/admission
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A P P E N D I C E S
Appendix 1. Search strategies
Medline (OVID)
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Date: March 2, 2015
1. Pharmacists/ or Pharmacists’ Aides/ (11431)
2. Pharmaceutical Services/ (4317)
3. pharmacist?.ti,ab. (20403)
4. ((pharmaceutical or pharmacotherapy or pharmacotherapies or pharmacotherapeutic or prescribing or prescriber? or dosing or
dosage) adj2 (advice or care or management or recommendation? or service or services)).ti,ab. (4872)
5. (pharmacist? adj2 (managed or comanag$ or co-manag$ or case manag$)).ti,ab. (357)
6. Drug Information Services/ (3640)
7. ((drug or prescription?) adj2 (information adj2 (service or services or advice or recommendat$ or education$))).ti,ab. (367)
8. drug educator?.ti,ab. (5)
9. or/1-8 (32751)
10. Outpatient Clinics, Hospital/ or Pain Clinics/ or Outpatients/ (24657)
11. (outpatient? or out-patient?).ti. or ((outpatient? or out-patient?) adj2 (care or clinic? or drug therapy or management or pharma-
ceutical or prescription? or visit?)).ab. (54319)
12. Ambulatory care/ or exp Ambulatory Care Facilities/ (78057)
13. (ambulatory or outpatient? or out-patient?).ti. (49572)
14. ((ambulatory or outpatient? or out-patient?) adj2 (care or facility or facilities or patient? or clinic?)).ab. (51236)
15. Home Care Agencies/ or Hospitals, Community/ (11643)
16. (home care or patient? home? or homecare or community hospital?).ti,ab. (26408)
17. (community adj3 (health$ adj (centre or centres or center? or clinic?))).ti,ab. (4932)
18. exp Community Health Services/ (500019)
19. Community Health Nursing/ (18483)
20. (community adj2 (care or healthcare or health care or patient? care or (health$ adj2 service?))).ti,ab. (11488)
21. (community adj3 (health$ adj (centre or centres or center? or clinic? or unit or units))).ti,ab. (4968)
22. exp Primary Prevention/ or Patient Education as Topic/ (184041)
23. ((immuni?ation? or vaccination?) adj2 (clinic or clinics or service or services)).ti,ab. (1301)
24. (mobile adj (clinic? or healthcare or care)).ti,ab. (448)
25. (((early intervention or preventive or preventative or prevention) adj2 service?) or anonymous testing).ti,ab. (6926)
26. ((consumer or patient?) adj2 education$).ti,ab. (16496)
27. Self Care/ or Blood Glucose Self-Monitoring/ or Self Administration/ (37116)
28. (self care or self manag$ or self administration).ti,ab. (26649)
29. or/10-28 (805009)
30. Physicians, Primary Care/ or General Practitioners/ or Physicians, Family/ (18329)
31. General practice/ or Family Practice/ or Primary Care Nursing/ (64545)
32. ((general or family) adj3 (practice? or practitioner? or Physician? or doctor?)).ti,ab. (96029)
33. Primary health care/ (55449)
34. (primary adj2 (care or healthcare)).ti,ab. (90606)
35. or/30-34 (217858)
36. Patient Compliance/ or Medication Adherence/ (55541)
37. Patient Care/ or Patient Care Management/ or Patient-Centered care/ (21135)
38. Disease Management/ or Case Management/ (20765)
39. professional-patient relations/ (22010)
40. “Continuity of Patient Care”/ (14812)
41. or/36-40 (129007)
42. clinical clerkship/ or education, medical, continuing/ or education, nursing, continuing/ (45982)
43. (continuing adj2 (doctor? or medical or nurse or nursing or nurses or physician? or practitioner? or family physician? or GP) adj2
education$).ti,ab. (4983)
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44. (detailing or detailer?).ti,ab. (3988)
45. or/42-43 (47805)
46. 9 and 29 (7830)
47. 9 and 35 (2895)
48. 9 and 41 (2851)
49. 9 and 45 (329)
50. (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti. (936569)
51. exp animals/ not humans.sh. (3987626)
52. 50 not 51 (863695)
53. clinical trial/ or multicenter study/ (619543)
54. random$.ti,ab. or controlled.ti. (793429)
55. (control adj2 (group or groups or patient? or cohort?)).ti,ab. (354151)
56. evaluation studies as topic/ (119788)
57. (comparative study or evaluation studies or “research support American recovery and reinvestment act” or research support NIH
extramural or research support NIH intramural or research support non us govt or research support us govt non phs or research support
us govt phs).pt. (8454230)
58. (evaluation or change or effect or effectiveness).ti. or (quality adj2 improv$).ti,ab. or impact?.ti,ab. or patient outcomes.ti,ab.
(1779157)
59. ((or/53-55) or ((or/56-57) and 58)) not 51 (1798844)
60. (or/46-49) and 52 (1218)
61. ((or/46-49) and 59) not 60 (1393)
62. remove duplicates from 60 (1196
63. remove duplicates from 61 (1374)
Embase (OVID)
Embase Classic+Embase <1947 to 2015 February 27>
Search Date: March 2, 2015
1. *Pharmacist/ 17634
2. pharmacist?.ti,ab. 44766
3. ((pharmaceutical or pharmacotherapy or pharmacotherapies or pharmacotherapeutic or prescribing or prescriber? or dosing or
dosage) adj2 (advice or care or management or recommendation? or service or services)).ti,ab. 8765
4. (pharmacist? adj2 (managed or comanag$ or co-manag$ or case manag$)).ti,ab. 638
5. ((drug or prescription?) adj2 (information adj2 (service or services or advice or recommendat$ or education$))).ti,ab. 557
6. drug educator?.ti,ab. 15
7. or/1-6 56864
8. *outpatient department/ or *outpatient/ or *outpatient care/ or *ambulatory care/ 37977
9. (outpatient? or out-patient?).ti. or ((outpatient? or out-patient?) adj2 (care or clinic? or drug therapy ormanagement or pharmaceutical
or prescription? or visit?)).ab. 82015
10. *ambulatory care/ 11976
11. (ambulatory or outpatient? or out-patient?).ti. 65057
12. ((ambulatory or outpatient? or out-patient?) adj2 (care or facility or facilities or patient? or clinic?)).ab. 81470
13. *community hospital/ or *community mental health center/ 6877
14. *community health nursing/ or *community psychiatric nursing/ or *community care/ or *community mental health/ or *com-
munity medicine/ 42037
15. *home care/ or *home health agency/ or *home mental health care/ or *home rehabilitation/ or *home respiratory care/ or *visiting
nursing service/ 28185
16. (home care or patient? home? or homecare or community hospital?).ti,ab. 33559
17. (community adj3 (health$ adj (centre or centres or center? or clinic?))).ti,ab. 6125
18. *community health nursing/ or *community psychiatric nursing/ or *community care/ or *community mental health/ or *com-
munity medicine/ 42037
19. (community adj2 (care or healthcare or health care or patient? care or (health$ adj2 service?))).ti,ab. 14526
20. (community adj3 (health$ adj (centre or centres or center? or clinic? or unit or units))).ti,ab. 6170
21. *primary prevention/ or *patient education/ 30335
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22. exp *vaccination/ or *immunization/ 87274
23. ((immuni?ation? or vaccination?) adj2 (clinic or clinics or service or services)).ti,ab. 1482
24. (mobile adj (clinic? or healthcare or care)).ti,ab. 504
25. (((early intervention or preventive or preventative or prevention) adj2 service?) or anonymous testing).ti,ab. 8454
26. ((consumer or patient?) adj2 education$).ti,ab. 23686
27. *self care/ or *self help/ or *self monitoring/ 17507
28. (self care or self manag$ or self administration).ti,ab. 36132
29. *home health agency/ 26
30. *community program/ 469
31. or/8-30 441848
32. *primary medical care/ or *primary health care/ or family medicine/ 49741
33. *general practice/ or *general practitioner/ 54750
34. ((general or family) adj3 (practice? or practitioner? or Physician? or doctor?)).ti,ab. 124919
35. (primary adj2 (care or healthcare)).ti,ab. 114224
36. or/32-35 250478
37. *patient compliance/ 18355
38. *patient care/ or *patient care planning/ 56343
39. *case management/ or *disease management/ 7750
40. *patient assessment/ 723
41. *medical assessment/ or *“evaluation and follow up”/ 1880
42. *eye care/ or *foot care/ or *blood glucose monitoring/ 4815
43. or/37-42 88885
44. *continuing education/ or *residency education/ 17150
45. (continuing adj2 (doctor? or medical or nurse or nursing or nurses or physician? or practitioner? or family physician? or GP) adj2
education$).ti,ab. 6436
46. (detailing or detailer?).ti,ab. 5388
47. or/44-45 22694
48. clinical trial/ or multicenter study/ 889647
49. random$.ti,ab. or controlled.ti. 1022116
50. (control adj2 (group or groups or patient? or cohort?)).ti,ab. 495154
51. multicenter study/ 115967
52. 7 and 31 6253
53. (7 and 36) not 52 3652
54. (7 and 43) not (or/52-53) 1330
55. (7 and 47) not (or/52-54) 302
56. (random$ or placebo$ or double-blind$).tw. 1072053
57. multicenter study/ or controlled clinical trial/ or clinical trial/ or controlled study/ or randomized controlled trial/ 5045905
58. exp animals/ or exp Invertebrates/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ 21731421
59. human/ or normal human/ or human cell/ 15790114
60. 58 and 59 15743053
61. 58 not 60 5988368
62. (or/56-57) not 61 3761811
63. 52 and 62 1228
64. 53 and 62 904
65. 54 and 62 187
66. 55 and 62 42
67. or/63-67 2361
68. remove duplicates from 67 2333
The Cochrane Library (OVID)
Search Date: March 4, 2015
1 non-dispensing.ti,ab. (18)
2 (pharmacist? adj2 (physician? or doctor?)).ti. (45)
3 (evaluation and pharmacist?).ti. (36)
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4 (pharmacist? adj2 (care or case manag$ or comanag$ or co-manag$ or delivered or directed or disease manag$ or educator? or led or
managed or outreach or prescriber? or prescribing)).ti,ab. (401)
5 ((community pharmacy or community pharmacies) adj4 (patient ? care or case manag$ or comanag$ or co-manag$ or delivered or
directed or disease manag$ or educator? or led or managed or outreach or prescriber? or prescribing)).ti,ab. (24)
6 (pharmacist? adj2 (advice or consultation? or consultant? or counsel$ or initiated or intervention? or participation)).ti,ab. (491)
7 (pharmacist? adj3 (role or roles) adj5 (change or changing or changes or new or increas$)).ti,ab. (5)
8 (pharmacy and care).ti. (40)
9 or/1-8 [Keyword] (832)
10 (community adj2 (pharmacist? or pharmacy)).ti,ab. (347)
11 (pharmacist? adj2 (managed or comanag$ or co-manag$ or case manag$)).ti,ab. (55)
12 ((pharmaceutical or pharmacotherapy or pharmacotherapies or pharmacotherapeutic or prescribing or prescriber? or dosing or
dosage) adj2 (advice or care or management or recommendation? or service or services)).ti,ab. (657)
13 (pharmacist? adj2 (managed or comanag$ or co-manag$ or case manag$)).ti,ab. (55)
14 ((drug or prescription?) adj2 (information adj2 (service or services or advice or recommendat$ or education$))).ti,ab. (10)
15 drug educator?.ti,ab. (1)
16 (outpatient? or out-patient?).ti. or ((outpatient? or out-patient?) adj2 (care or clinic? or drug therapy or management or pharma-
ceutical or prescription? or visit?)).ab. (175808)
17 (ambulatory or outpatient? or out-patient?).ti. (166725)
18 ((ambulatory or outpatient? or out-patient?) adj2 (care or facility or facilities or patient? or clinic?)).ab. (368619)
19 (home care or patient? home? or homecare or community hospital?).ti,ab. (1892)
20 (community adj3 (health$ adj (centre or centres or center? or clinic?))).ti,ab. (389)
21 (community adj2 (care or healthcare or health care or patient? care or (health$ adj2 service?))).ti,ab. (1061)
22 (community adj3 (health$ adj (centre or centres or center? or clinic? or unit or units))).ti,ab. (393)
23 ((immuni?ation? or vaccination?) adj2 (clinic or clinics or service or services)).ti,ab. (85)
24 (mobile adj (clinic? or healthcare or care)).ti,ab. (20)
25 (((early intervention or preventive or preventative or prevention) adj2 service?) or anonymous testing).ti,ab. (547)
26 ((consumer or patient?) adj2 education$).ti,ab. (2220)
27 (self care or self manag$ or self administration).ti,ab. (3865)
28 ((general or family) adj3 (practice? or practitioner? or Physician? or doctor?)).ti,ab. (7580)
29 (primary adj2 (care or healthcare)).ti,ab. (9565)
30 (continuing adj2 (doctor? or medical or nurse or nursing or nurses or physician? or practitioner? or family physician? or GP) adj2
education$).ti,ab. (238)
31 (detailing or detailer?).ti,ab. (283)
32 10 or 11 or 12 or 14 (1004)
33 32 not 9 (677)
34 pharmacist?.ti. and (or/16-31) (447)
35 34 or 33 or 9 (1570)
36 from 35 keep 1-21 [CDSR] (21)
37 from 35 keep 22-45 [ACP] (24)
38 from 35 keep 46-99 [DARE] (54)
39 from 35 keep 100-1479 [CENTRAL] (1380)
40 from 35 keep 100-1479 [CENTRAL] (1380)
41 from 35 keep 1480-1496 [MTH] (17)
42 from 35 keep 1497-1503 [HTA] (7)
43 from 35 keep 1504-1570 [NHS EED] (67)
Cinahl (EBSCO)
Search Date: March 1, 2015
S29 S19 AND S28 (291)
S28 S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 (144,381)
S27 TI controlled AND TI ( trial or trials or study or experiment* or intervention ) (16,915)
S26 AB ( (multicent* n2 design*) or (multicent* n2 study) or (multicent* n2 studies) or (multicent* n2 trial*) ) or AB ( (multi-cent*
n2 design*) or (multi-cent* n2 study) or (multi-cent* n2 studies) or (multi-cent* n2 trial*) ) (6,262)
S25 TI multicentre or multicenter or multi-centre or multi-center (4,202)
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S24 TI ( cluster N2 trial* or cluster N2 study or cluster N2 group or cluster N2 groups or cluster N2 cohort or cluster N2 design or
cluster N2 experiment* ) OR AB ( cluster N2 trial* or cluster N2 study or cluster N2 group or cluster N2 groups or cluster N2 cohort
or cluster N2 design or cluster N2 experiment* ) (1,569)
S23 TI ( control group or control groups OR control* experiment* or control* design or controlled study ) OR AB ( control group
OR control groups or control* cohort* or controlled experiment* controlled design or controlled study) (47,039)
S22 TI random* or AB random* (102,748)
S21 TI ( “clinical study” or “clinical studies” ) or AB ( “clinical study” or “clinical studies” ) (6,586)
S20 (MM “Clinical Trials+”) (7,876)
S19 S16 OR S18 (3,048)
S18 S7 AND s17 (1,849)
S17 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 (448,860)
S16 S1 OR S2 OR S3 OR S4 OR S5 OR S6 (2,069)
S15 (MH “Patient Care”) OR (MH “Continuity of Patient Care”) OR (MH “Multidisciplinary Care Team”) OR (MH “Disease
Management”) (40,058)
S14 TI ( detailing or detailer* or outreach ) OR AB ( detailing or detailer* or outreach ) (4,338)
S13 (MH “Education, Medical, Continuing”) OR (MH “Education, Nursing, Continuing”) (12,240)
S12 (MH “Primary Health Care”) OR (MH “Physicians, Family”) (33,768)
S11 (MH “Community Mental Health Services+”) OR (MH “Drug Information Services+”) OR (MH “Family Planning+”) OR (MH
“Home Health Care”) OR (MH “Maternal Health Services”) OR (MH “Preventive Health Care”) OR (MH “Diagnostic Services+”)
OR (MH “Health Education+”) OR (MH “Postnatal Care+”) OR (MH “Community Health Nursing+”) (160,946)
S10 (MH “Community Health Centers”) (2,458)
S9 (MH “Outpatients”) OR (MH “Outpatient Service”) OR (MH “Ambulatory Care Facilities+”) (38,658)
S8 TI ( (role or outpatient? or community or out-patient? or ambulatory) ) OR AB ( (role or outpatient? or community or out-patient?
or ambulatory) ) (227,897)
S7 (MH “Pharmacists”) OR TI Pharmacist* (4,841)
S6 TI (pharmacist* n2 role*) OR AB ( ((pharmacist* n2 role*) N3 (chang* or new or increas*)) ) (182)
S5 TI ( (pharmacist* n2 advice) or (pharmacist* n2 consult*) or (pharmacist* n2 counsel*) or (pharmacist* n2 initiated) or (pharmacist*
n2 intervention) ) OR AB ( (pharmacist* n2 advice) or (pharmacist* n2 consult*) or (pharmacist* n2 counsel*) or (pharmacist* n2
initiated) or (pharmacist* n2 intervention) ) (418)
S4 TI community pharma* (400)
S3AB (pharmacist* n2 evaluation) or (pharmacist* n2managed) or (pharmacist* n2 care) or (pharmacist* n2 comanag$) or (pharmacist*
n2 manag*) or (pharmacist* n2 delivered) or (pharmacist* n2 directed) or (pharmacist* n2 educator*) or (pharmacist* n2 led) or
(pharmacist* n2 outreach) or (pharmacist* n2 prescrib*) (465)
S2 TI ( evaluation or managed or care or comanag$ or management or delivered or directed or educator* or led or outreach or prescrib*
) AND TI pharmacist* (594)
S1TInon-dispensingORABnon-dispensingORTI ( (pharmacist* n2 physician*)OR (pharmacist* n2doctor*) )ORAB ( (pharmacist*
n2 physician*) OR (pharmacist* n2 doctor*) )
ProQuest Dissertations & Theses
(TI(pharmacy OR pharmacist) AND TI(community OR outpatient OR multidisciplinary OR delivery))
ClinicalTrials.gov
WHO International Clinical Trials Registry Platform (ICTRP)
Search terms:
Community pharmacy
Community Pharmacist
Outpatient pharmacy
Outpatient pharmacist
Out-patient pharmacy
Out-patient pharmacist
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Appendix 2. Outcome Measures by Clinical Condition
COPD:
1. Forced expiratory volume (FEV1)
2. Forced vital capacity
3. MRC Dyspnoea Score (or other validated COPD (chronic obstructive pulmonary disease) score)
4. BMI
5. Saturated oxygen (if severe disease)
6. Symptom control might be measured with some or all of the following:Breathlessness, Exacerbation frequency, Exercise tolerance
Depression
1. BDI
2. BAI
3. Patient satisfaction
Diabetes
1. Blood glucose
2. HbA1c mmol/mol
3. HbA1c %
4. Diabetes Quality of life
Hypertension
1. Systolic
2. Diastolic
Asthma
1. Validated asthma tool
2. Lung function: measured as FEV1 or PEF
3. Number of exacerbations
4. No daytime symptoms
5. No nighttime wakening
Polypharmacy
1. Adherence
2. Number of hospitalisations
3. Mortality
4. Drug related problems
5. Self rated health
6. Number of drugs
Posthospitalization care transitions
1. Hospital admissions
2. Emergency room attendance
3. Resolution of medicine discrepancies
4. Health care use (contacts and hospital care)
Bipolar disorder
1. Number of hospitalisations
2. Number of emergency consultations
3. Number of unscheduled outpatient visits
HIV
1. Adherence
2. Depressoin
3. Alcohol consumption
Mental illness
1. Metabolic risk
2. % Taking antipsychotics
3. Number of metabolic syndrome risk parameters
Anticoagulation
1. Therapeutic INR (anticoagulation) achieved
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2. Bleeding
3. Hospital readmission due to anticoagulation problem.
Anti-psychotics / metabolic syndrome
1. Number of metabolic syndrome risk parameters
Osteoporosis
1. Satisfaction
2. Knowledge
WH A T ’ S N E W
Last assessed as up-to-date: 31 March 2015.
Date Event Description
21 November 2017 New search has been performed This is an update of a review last published in 2010,
which in now split into two separate reviews. This re-
view focuses specifically on effects on patient outcomes
and includes a selected range of outcomes
7 November 2017 New citation required and conclusions have changed We introduced changes to comply with cur-
rent Cochrane methodological standards, including
GRADE and the ’Summary of findings’ table. This
review now includes 116 studies. We have added sev-
eral additional meta-analyses for a range of outcomes,
which demonstrate that pharmacist services have vary-
ing effects on patient outcomes compared with usual
care. There was little or no difference between the ef-
fectiveness of interventions that were pharmacist-led
compared with the same intervention being delivered
by other healthcare professionals
H I S T O R Y
Review first published: Issue 9, 2018
Date Event Description
4 April 2018 Feedback has been incorporated The feedback and queries from reviewers has been ad-
dressed and the review updated
21 March 2018 Amended The review was updated to address peer reviewers’
comments and suggestions and now contains 116
studies
21 March 2018 Amended The title for the review was amended
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(Continued)
18 November 2016 Amended text updated and validation report items addressed
1 December 2010 Amended Conflict of interest modified.
16 June 2010 New citation required but conclusions have not
changed
New search, criteria for included studies changed to
only include RCTs, new authors
16 June 2010 New search has been performed Reconciled old and new studies
21 August 2008 Amended Converted to new review format.
18 January 2000 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review was originally part of a broader review evaluating the effectiveness of outpatient pharmacists’ non-dispensing roles on
patient outcomes and prescribing patterns, first published under the title: Expanding the roles of outpatient pharmacists: effects on health
services utilisation, costs, and patient outcomes in Issue 2, 2000 of the Cochrane Library (Bero 1995, Beney 2000, Nkansah 2010). As
more data became available, the broader review was split, with this current version focusing solely upon the effect of pharmacists’ non-
dispensing services on non-hospitalised patient outcomes.
We tried to use a consistent strategy to deal with the large variety of outcomes reported in the studies. Where multiple outcomes were
reported we created a hierarchy of outcomes, both within each outcome category and when choosing a representative outcome for
the overall analysis. We applied the Cochrane ’Risk of bias’ tool rather than the EPOC ’Risk of bias’ tool. To comply with current
Methodological Expectations of Cochrane Intervention Reviews (MECIR) standards, we introduced GRADE and added ’Summary
of findings’ tables for the main comparisons.
MdBa, CS, NWS, MdBr, CM, AJW, PR, MJ and MCW are all new authors with this review.
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